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This review critically summarizes the literature on the spectrum of health effects of zinc status, ranging from symptoms of zinc deficiency to excess
exposure. Studies on zinc intake are reviewed in relation to optimum requirements as a function of age and sex. Current knowledge on the bio-
chemical properties of zinc which are critical to the essential role of this metal in biological systems is summarized. Dietary and physiological factors
influencing the bioavailability and utilization of zinc are considered with special attention to interactions with iron and copper status. The effects of
zinc deficiency and toxicity are reviewed with respect to specific organs, immunological and reproductive function, and genotoxicity and carcino-
genicity. Finally, key questions are identified where research is needed, such as the risks to human health of altered environmental distribution of
zinc, assessment of zinc status in humans, effects of zinc status in relation to other essential metals on immune function, reproduction, neurological
function, and the cardiovascular system, and mechanistic studies to further elucidate the biological effects of zinc at the molecular level. - Environ
Health Perspect 102(Suppl 2):5-46 (1994).
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The Spectrum of Health
Effects Related to Zinc Status:
From Deficiency to Excess
There is considerable evidence that zinc de-
ficiency in humans is a serious worldwide
problem and outweighs the potential prob-
lem ofaccidental, self-imposed, or environ-
mental exposure to zinc excess. Acute
deficiency (1) and chronic deficiency (2)
are well-known entities in human popula-
tions and are probably much more com-
mon than generally recognized. The
importance of zinc for human health was
first documented in 1963 (3). During the
past 25 years, deficiency ofzinc in humans
due to nutritional factors and several dis-
ease states has now been documented
throughout the world. Prevalence of zinc
deficiency is high in populations that con-
sume large quantities of cereal proteins
containing high amounts ofphytate, an or-
ganic phosphate compound. Alcoholism,
malabsorption, sickle cell anemia, chronic
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renal disease, and other chronically debil-
itating diseases are now known to be pre-
disposing factors for zinc deficiency in
humans (4).
Zinc deficiency is reflected in clinical
syndromes which affect men and women of
all ages and all socioeconomic and cultural
classes in the United States. It is neither
prevalent in any specific area ofthe United
States nor associated with any specific or
definitive biochemical marker, which can
make its identification difficult and confus-
ing. Its presence is manifested by a wide
spectrum of symptoms, from acute, life
threatening problems to mild subclinical or
marginal disorders which may only vaguely
disturb well being. The acute problems are
often seen in profoundly ill patients treated
in hospitals, whereas subclinical problems
may be so vague that patients seek assis-
tance outside traditional medical practice.
Based upon clinical data and using tra-
ditional, epidemiologic techniques, Henkin
and Aamodt (5) have reclassified zinc defi-
ciency into three syndromes; these are a)
acute, b) chronic, and c) subacute zinc defi-
ciency. Acute zinc deficiency is relatively
uncommon and follows parenteral hyperal-
imentation or oral L-histidine administra-
tion. Chronic zinc deficiency is more
common, usually resulting from chronic
dietary lack ofzinc. Subacute or latent zinc
deficiency is the most common of these
syndromes. It is estimated that there are 4
million people in the United States with
this syndrome, the initial symptom being
dysfunction of taste and olfaction; treat-
ment with exogenous zinc restores taste
and smell but this usually requires months
before these functions are returned to nor-
mal (6). Diagnosis of these disorders is
most efficacious following oral administra-
tion of zinc tracers such as 65Zn, 67Zn, or
70Zn with subsequent evaluation ofthe ki-
netics oftransfer ofthe isotope into various
body tissues, the formulation ofthe data by
compartmental analysis, and the integra-
tion of the data by a systematic model of
zinc metabolism. Obviously, these tech-
niques are complex and technically diffi-
cult, not a routine means readily applicable
to assessing zinc status in individuals. In
fact, there are no simple means for assess-
ing the status ofzinc in the human popula-
tion.
Clinical symptoms of human zinc-defi-
ciency states exhibit a spectrum ranging
from mild to severe and may even be fatal
ifunrecognized and not corrected (4). The
clinical manifestations ofseverely zinc defi-
cient subjects include bullous pustular der-
matitis, diarrhea, alopecia, mental
disturbances, and intercurrent infections
due to cell-mediated immune disorders.
These severe signs are seen in patients with
acrodermatitis enteropathica secondary to
an inborn error ofzinc absorption, patients
receiving total parenteral nutrition without
zinc, and patients receiving penicillamine
therapy. Growth retardation, male hypo-
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gonadism, skin changes, poor appetite,
mental lethargy, abnormal dark adaptation,
and delayed wound healing are usual mani-
festations of moderate deficiency of zinc.
Recent studies show that a mild or mar-
ginal deficiency of zinc in humans is char-
acterized by neurosensory changes,
oligospermia in males, decreased serum
testosterone in males, hyperammonemia,
decreased serum thymulin activity, de-
creased IL-2 production, decreased natural
killer cell activity, alterations in T cell sub-
populations (4), impaired neuropsycholog-
ical functions (7), and decreased ethanol
clearance (8). All the above manifestations
are correctable by zinc supplementation.
Zinc is generally considered a relatively
nontoxic metal (9). This classification is
based on several characteristics: a) zinc is a
metal essential to hundreds of biological
processes and must be consumed in the
diet for optimum health; b) zinc is rela-
tively abundant in the natural environ-
ment; c) the recommended daily allowance
(RDA) ofzinc in the human population is 8
to 15 mg higher than many other essential
metals; d) zinc does not appear to accumulate
in the body with age; e) there are no known
genetic abnormalities which result in excessive
accumulation ofzinc in the body, unlike met-
als such as copper (Wilson's disease) and iron
(hemochromatosis); f) homeostatic mecha-
nisms regulate the body burden ofzinc such
that increased intake is associated with de-
creased absorption and increased excretion; g)
zinc may have antioxidant effects and does
not participate in oxidation-reduction cycles
like iron and other transition elements; h) ad-
ministration of zinc for therapeutic purposes
in man at doses above the RDAhave not pro-
duced significant pathology; and i) adminis-
tration of zinc to experimental animals in
doses more that 100 times the RDAhave not
producedsignificantpathology.
Some zinc salts, such as zinc chloride, in
sufficient concentration can injure epithe-
lial tissue. Inhalation, exposure ofthe skin,
or ingestion can produce local pathological
effects. In addition, intake of excess zinc
has been reported in human studies to af-
fect levels of pancreatic enzymes (10) and
lipoproteins in serum (11,12), to alter the
metabolism of copper (13-15) and iron
(16), and to alter immunological function
(12).
The industrial use ofzinc affects the en-
vironmental distribution ofthis metal; zinc
is frequently found in industrial waste sites.
Currently, regulatory agencies in the
United States are concerned with the possi-
ble significance of increased exposure to
zinc through environmental sources such as
increases in drinking water, particularly
through leaching ofzinc into ground water
surrounding waste sites. Excess exposure to
zinc is also potentially a hazard for indus-
trial workers, especially through inhalation
ofwelding fumes and exposure in smelting
operations. Oral intake at levels above the
RDA is also ofconcern in individuals who
self medicate with dietary supplements of
zinc and those who are treated with these
preparations for therapeutic purposes.
The purposes of this paper are to a)
review data on the zinc status of the US
population, including critical dietary
and physiological determinants; b) sum-
marize current understanding ofthe role of
zinc in biochemical and physiologic
processes, as revealed in part by studies of
zinc deficiency; c) evaluate the available lit-
erature regarding effects of increased expo-
sure to zinc; and d) recommend areas of
investigation for enhancing understanding
of the health effects of zinc over the spec-
trum of zinc status from deficiency to ex-
cess.
Zinc Status in the US
Population
ZincIntake intheDiet
Zinc status of humans is generally deter-
mined by the quality and quantity of zinc
in the diet and the physiologic condition of
the individual. For persons with fully func-
tional homeostatic mechanisms, quality
and quantity of the diet are the major de-
terminants of zinc adequacy. Diet quality
and quantity are determined by the eco-
nomic resources of the person, the avail-
ability of foods in the market place and
individual food choices. Quality ofthe diet
determines the sources and bioavailability
ofdietary zinc.
The zinc content ofomnivorous North
American diets is about 10-15 mg daily
(17). A survey ofUS foods found 4.63 mg
Zn/1000 kcal (18). Some reported dietary
intakes of zinc are shown in Table 1
(19-30). The zinc contents of food prod-
ucts are altered by cooking, and zinc
bioavailability is dependent on other com-
ponents of the diet. Consequently, intakes
ofzinc based on calculations from food ta-
bles are estimates only.
Zinc is not evenly distributed in quan-
tity or availability among foods. Table 2 in-
dicates the total zinc content in ordinary
size portions offoods. The major source of
readily bioavailable zinc in the US diet is
beef (32,33). The second most important
source is pork (34). Current data suggest
that meat provides nearly 50% of the zinc
in the average US diet, that dairy products
provide about 20% and that cereals and
legumes provide the remainder (35) (Table
3). In contrast to omnivores, lacto-ovo-
vegetarians obtain the majority of zinc
from cereals (16%), beans and nuts (26%),
and milk and eggs (18%) (36).
The critical importance of the bioavail-
ability ofdietary zinc to zinc nutriture was
first shown in experimental animals
Table 1. Zinc intakes in diets of children, adults, and vegetarians.
Zinc intake, mg
Age Sex n Mean SD Population Reference
1 month M, F 35 1.90 0.20 Breast-fed, Canada (19)a
1 month M, F 25 3.60 0.60 Bottle-fed, Canada (19)a
6 months M, F 16 2.70 0.50 Breast-fed, Canada (19)a
6 months M, F 23 4.60 0.70 Bottle-fed, Canada (19)a
2-7 years M, F 96 6.30 0.44 Middle income, USA (20)b
2-6 years M, F 85 5.00 _m Low income, USA (21)c
3-5 years M, F 5 6.36 0.83 Norwegian children (22)d
10-13 years M, F 6 10.16 1.42 Norwegian preteens (22)d
14-16 years F 15 12.00 5.00 High school, USA (23)e
16-30 years F 21 13.80 7.27 College women, USA (23)e
14-64 years M, F 22 8.60 0.52 Middle income, USA (24)f
30 years F 100 10.10 3.30 Canadians, omnivorous (25)9
Adult F 5 6.40 1.69 Vegetarians, USA (26)h
Adult M 5 20.30 8.80 Military, USA (27)i
81.7 years M, F 21 5.53 m Geriatric hospital (28)i
85.5 years M, F 24 8.90 2.53 Healthy elderly at home (29)k
25-48 years M, F 112 8.5 4.5 Vegetarians(Punjabi), Canada (30)1
a3-day records taken at homevisits. b24-hr recall and food checklist. C24-hr recall and food checklist. d2-week food
records. eWeighed 24-hr diets with duplicate food composite. f14-day food record and 132 diet composites. 93-day
food records and 24-hr food composite. h3-day food records. 16 days of duplicate chemical diet composites. Dupli-
cate chemical diet composites. kDuplicate chemical dietcomposites. 13-dayweighed records and thirty 1-day dupli-
cate composites. mValue not reported.
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Table 2. Zinc content of common household portions of selected foods'
Food Portions Zinc, mg
Fish, light poultry meat, shell fish 3 oz <2.0
(except crab and oyster)
Poultry liver, dark chicken meat 3 oz 2.0/3.0
Pork, veal, crab, dark turkey meat, 3 oz 3.0/4.0
ground beef, 77% lean
Beef liver, beef 3 oz 4.0/5.0
Oyster 3oz > 5.0
Egg, whole 1 0.5
Peanut butter 2 Tbsp 0.9
Mature dried beans, lentils, chickpeas, 1/2 cup 0.9/1.0
split peas (boiled, drained)
Cow peas, black eyed peas (boiled, drained) 1/2 cup 1.5
Milk: Whole, fluid 1 cup 0.9
Canned, evaporated 1/2 cup 1.0
Dried, nonfat, instant 1/3 cup 1.0
Ice cream 1 1/2 cup 1.0
Cheddar cheese 3 slices (1 1/2 oz) 1.6
Cooked oatmeal 1 cup 1.2
Cooked whole wheat cereal 1 cup 1.2
Wheat flakes 1 oz 0.6
Bran flakes, 40% 1 oz 1.0
Wheat germ, toasted 1 Tbsp 0.9
Corn flakes 1 oz 0.08
Cooked corn meal 1 cup 0.3
White wheat bread 1 slice 0.2
Whole wheat bread 1 slice 0.5
Cooked brown rice, hot 1 cup 1.2
Cooked white rice, hot 1 cup 0.8
Precooked white rice, hot 1 cup 0.4
From Sandstead (31); reprinted with permission.
(37,38). Phytate, present in grain and veg-
etable components of the diet, was shown
to inhibit zinc absorption. Subsequent re-
search showed that zinc absorption in hu-
mans was also impaired by phytate
(39-42). Zinc forms insoluble complexes
with phytate at alkaline pH, which are even
more insoluble as a calcium-phytate-zinc
complex (43). Other dietary inhibitors of
zinc absorption include lignin, certain
hemicelluloses, products of nonenzymatic
Maillard browning, calcium phosphopep-
tides from the digestion of casein, and cal-
cium (43-46).
The availability of zinc from diets rich
in foods prepared from unrefined cereals
tends to be poor. This was first illustrated
by balance studies on Iranian subjects fed
diets rich in bread prepared from whole
grain wheat flour (39,40,47). Subse-
quently, others used analysis ofplasma zinc
to show that foods rich in phytate, fiber,
and lignin reduce apparent absorption of
zinc (44,48). Ofparticular interest was the
effect of tortilla on the increase in plasma
zinc that occurs after ingestion of 120 g of
oyster (44). The increase was completely
prevented by simultaneous consumption of
120 g of tortilla. Other studies found that
as little as 26 g daily of wheat bran incor-
porated into 180 g of bread in a mixed
western diet reduced the net retention of
zinc (49). The importance of the inhibi-
tion ofzinc retention by high cereal diets is
illustrated by the Prasad-Halsted syn-
drome, a condition of growth retardation
and delayed sexual maturation among ado-
lescents in Egypt and Iran who subsist on
diets that are based on whole wheat unleav-
ened bread and little or no meat
(3,50-52). More recent findings in East
African children, among whom short
stature is common, support the concept
that diets high in phytate can cause serious
impairment in zinc nutriture of popula-
tions. The principle finding was an inverse
relation of phytate-zinc and calcium-phy-
tate-zinc molar ratios to the concentration
of zinc in hair from the children (53). Al-
though hair zinc is a relatively insensitive
indicator ofzinc status, it is a useful index
because it may be low while plasma levels
are within the normal range (54-56).
The binding of zinc by calcium phos-
phopeptides derived from the peptic diges-
tion of casein (45) may affect the
bioavailability of zinc to humans and thus
affect zinc nutriture. This suggestion is
supported by the finding of lower zinc re-
tentions in 18 men fed diets that provided
15% of energy from protein, of which
about 40% was from dairy products, as
compared to zinc retention when the di-
etary protein was 8% of energy and the
dairy products were not added (49). A
nearly 50% reduction in zinc retention in
postmenopausal women fed cow's milk
compared to water also indicates that cow's
milk can decrease zinc bioavailability (57).
Others have found that dairy products
added to a meal that contained turkey meat
lowered zinc retention (58). Zinc-tolerance
tests in humans fed milk or cheese also in-
dicate impaired zinc absorption (48,59).
Zinc Intake in DrinkingWater
Under usual conditions, drinking water is a
minor source ofzinc intake. According to a
review by the National Research Council
of the National Academy of Sciences
(NAS/NRC), the highest observed concen-
trations ofzinc in drinking water are 1.3 to
Table 3. Contribution offoods to dietary intake of zinc.
Zinc content Zinc consumed/ Percent oftotal
as purchased, person/day, food intake
Food group mg/kg mg
Milk, cheese, ice cream 4.3' 2.5 20
Meat, poultry, fish 18.6 5.5 43
Dry beans, peas, nuts 24.7 0.5 4
Eggs 12.7 0.6 5
Dark green and deepyellowvegetables 2.8 0.1 1
Citrus fruit, tomatoes 1.8 0.3 2
Potatoes 2.4 0.3 2
Othervegetables, fruit 2.0 0.7 6
Cereal, pasta 16.3 0.8 7
Flour, mixes 2.8 0.1 1
Bread 7.2 0.6 5
Other bakery products 6.0 0.4 3
Fats, oils 1.8 0.1 1
Sugar, sweets 0.6 0 0
Total food 12.5 100
From Sandstead (31); reprinted with permission.
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Table 4. Recommended dietary allowances (RDA) forzinca
Lactating
Infant Children Males Females Pregnant 1st 2nd
Age,years 0-0.5 0.5-1.0 1-10 11-51 + 11-51 + 6mo 6mo
ZincRDA, mg 5 5 10 15 12 15 19 16
From National Research Council (62).
1.5 mg/l (9). Thus a person drinking 2 1
daily would consume a maximum of 3
mg/day from this source. The usual dietary
intake of most adults does not exceed 12
mg daily. Therefore, consumption of
drinking water containing the maximum
observed zinc concentration would result
in a total intake of 15 mg/day, which is the
current RDA for adult men. The US Envi-
ronmental Protection Agency standard for
maximum zinc concentration in drinking
water is 5 mg/l (60), which is based on the
aversive taste associated with higher zinc
concentrations in water (61).
Zinc DietaryRequirements
It is difficult to precisely determine the re-
quirement of zinc in various populations,
inasmuch as many dietary factors affect the
bioavailability of zinc and environmental
and physiological factors alter the require-
ments of zinc in different age groups.
Nonetheless, the current US guidelines for
RDAs ofzinc (Table 4) appear reasonable.
A substantial fraction of the population
may consume less zinc than recommended
(31,63,64).
Growing infants, children, adolescents
and pregnant mothers require more zinc
per kilogram than mature adults. In early
lactation human milk provides about 2 to
3 mg zinc daily. The amount gradually de-
creases to about 0.6 mg/day at 6 months
(65). During lactation, the zinc content of
milk remained constant in spite of 60 mg
zinc supplementation per day for 2 weeks
(66,67).
Zinc is less available from cow's milk
formula than from human milk. Growth of
infants fed zinc-enriched (5.8 mg/I) cow's
milk formula was better than that of in-
fants fed an unenriched formula that con-
tained an amount ofzinc (1.8 mg/l) similar
to human milk (68). Since that report was
published, formulas have been supple-
mented to provide 5 mg zinc daily, assum-
ing consumption of 750 ml of formula
(17). Because of the phytate content, zinc
availability from soy-based formulas is
lower than from cow's milk or human milk
(69).
Provisional factorial estimates of zinc
requirements ofinfants (Table 5) are 1.1 to
1.25 mg daily up to 1 year (70). The US
NAS/NRC RDA of zinc infants is 5 mg
daily, assuming 20% bioavailability (17).
The minimal requirement of dietary zinc
for premature infants weighing 670 to
2420 g during the period from 36 to 40
weeks postconceptional age was deter-
mined to be 0.8 mg/kg/day (71). The cur-
rent recommendation for zinc
administration in infants receiving total
parenteral nutrition is 97.5 pg/kg/day. This
amount ofzinc may not be adequate for in-
fants who have excessive gastrointestinal
fluid losses, such as those who have re-
cently undergone surgery and had excessive
gastrointestinal drainage (72).
Factorial estimates (Table 5) suggest
that preadolescent children require about
1.6 mg of absorbed zinc daily for growth
and maintenance (70). The mean dietary
requirement is therefore about 8.0 mg daily
for diets containing 20% bioavailable zinc.
If one assumes a 15% coefficient of varia-
tion and an allowance of 30% above the
mean requirement, the recommended in-
take for preadolescent children is 10.4 mg
daily. Based on different data and calcula-
tions, the RDA committee recommended
10 mg daily (17). Average zinc intakes of
US children ages ito 3 years are about
75% of the RDA, or 7.5 mg daily (35).
Data in Table 1 are consistent with the US
Department of Agriculture report. One
early study showed that with dietary in-
takes of 4 to 6 mg/day, zinc balance was
negative in preschool children (73). Ifone
assumes the RDA is 30% above the average
dietary requirement, the probability ap-
proach for evaluating dietary data indicates
that more than 50% ofUS children are at
risk ofzinc deficiency (74).
It is evident from the above that quanti-
tative knowledge of the zinc requirements
of children is limited. One suspects that
children from poor families, such as those
cited in Table 1, who were from poor His-
panic families in Denver and displayed im-
proved growth when supplemented with
zinc (21), are at substantial significant risk
ofzinc deficiency. Studies in Middle East-
ern schoolboys have also demonstrated re-
tardation of growth and maturation
(75,76), ameliorated by zinc supplementa-
tion (77).
Because of accelerated growth, the zinc
requirement ofadolescents, as noted above,
is greater than that of preadolescents. For
this reason the RDA for this age group is
the same as that for adults (12 mg for
women and 15 mg for men) (17). Factor-
ial estimates (Table 5) of requirement are
14 mg daily for males ages 11 to 17 years
and 13.3 mg daily for females ages 10 to 13
years, with 20% bioavailability of dietary
zinc (70). Assuming a 15% coefficient of
variation in requirement, the recom-
mended intake from the factorial estimates
is 18.2 mg for boys, and 17.3 mg daily for
girls. At present it is unknown how close
Table 5. Provisional dietary requirements forzinc in relation to estimates of retention, losses, and availability.
Peak Milligrams necessary in
daily Urinary Sweat Total dailydiet ifcontent
retention, excretion, excretion, required, ofavailable zinc is
Age mg mg mg mg 10% 20% 40%
Infants
0-4months 0.35 0.4 0.5 1.25 12.5 6.3 3.1
5-12 months 0.2 0.4 0.5 1.1 11.0 5.5 2.8
Males
1-10 years 0.2 0.4 1.0 1.6 16.0 8.0 4.0
11-17years 0.8 0.5 1.5 2.8 28.0 14.0 7.0
18+years 0.2 0.5 1.5 2.2 22.0 11.0 5.5
Females
1-9years 0.15 0.4 1.0 1.55 15.5 7.8 3.9
10-13 years 0.65 0.5 1.5 2.65 26.5 13.3 6.6
14-16years 0.2 0.5 1.5 2.2 22.0 11.0 5.5
17+years 0.2 0.5 1.5 2.2 22.0 11.0 5.5
Pregnantwomen
0-20 weeks 0.55 0.5 1.5 2.55 25.5 12.8 6.4
20-30 weeks 0.9 0.5 1.5 2.9 29.0 14.5 7.3
30-40weeks 1.0 0.5 1.5 3.0 30.0 15.0 7.5
Lactating women 3.45 0.5 1.5 5.45 54.5 27.3 13.7
From Sandstead (31) based on WHO Report(70); reprinted with permission.
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the factorial estimates (70) are to the true
requirement. If one assumes that dietary
zinc intakes of adolescents are similar to
those reported for adults (Table 1), the
great majority consume less zinc than is
recommended by the RDA or that is calcu-
lated as needed from the factorial estimates
of requirement. Information is insufficient
to resolve these issues. As a practical appli-
cation of this knowledge, one suspects the
observation on low-income adolescents of
improved pregnancy outcome subsequent
to zinc supplementation was related to in-
sufficient zinc in their habitual diets (78).
With secession of growth the zinc re-
quirements of adults decrease to amounts
required for tissue repair and general main-
tenance (Table 5). At 20% bioavailability
the factorial estimate of need is 11.0 mg
daily for both men and women (70). The
RDA is slightly higher, consumption of 15
mg/day by adult males (Table 4). Other
government advisory bodies have set differ-
ent recommendations for zinc intake. The
Canadian Bureau of Nutritional Sciences
has recommended that a lower zinc intake
(9 mg/day for adult males and 8 mg/day
for females) is safe and adequate.
The effects of dietary composition on
the requirement for zinc are illustrated by
data from 30-day balance studies carried
out in healthy men fed omnivorous diets
(79). In these studies the relationship be-
tween dietary intake of zinc (y) and zinc
balance (x) was examined to determine the
intake required to maintain equilibrium (y
intercept). The diets provided 8% of en-
ergy as protein and were low in fiber and
phytate. An intake of7.18 ± 0.09 (SE) mg
zinc daily was sufficient for equilibrium,
which suggests the dietary zinc was more
than 30% bioavailable. When 26 g ofvari-
ous cereal brans were added to the diet in
30 balance studies, the zinc requirement for
equilibrium increased to 9.13 ± 0.37 (SE)
mg daily. When the protein intake was in-
creased to 15% of energy by adding dairy
products to the diet, equilibrium intake
was 12.17 ± 0.40 (SE) mg zinc on a diet
without fiber and phytate and 14.74 ± 0.33
(SE) mg zinc (p<0.01) with a diet contain-
ing 26 g of cereal. Estimates of zinc re-
quirements in relation to protein and
phosphorus intake, based on data from the
above metabolic studies, are indicated in
Table 6.
The factorial estimate (70) of zinc re-
quirement at 20% bioavailability suggests a
recommended intake of 14.3 mg for both
men and women, assuming a 15% coeffi-
cient ofvariation. The RDA for men is 15
mg daily and for women is 12 mg daily.
Reported self-selected adult intakes ofzinc
are listed in Table 1. According to US De-
partment of Agriculture data, 60% of
women ages 19 to 50 years consume <9.0
mg zinc daily (35), or 75% of the RDA.
This suggests that more than 50% ofthese
women are at risk ofzinc deficiency (74).
Among the elderly, zinc intakes are
about 9 mg daily with a wide range (80).
Because the capacity to absorb zinc from
the intestine is reduced with aging (81), it
seems likely that the elderly are at increased
risk of zinc deficiency, an impression that
appears supported by data (80). The cur-
rent zinc RDA for the elderly is the same as
for younger adults. Relatively few elderly
consume those amounts ofzinc. Bunker et
al. (82) have recently published a study il-
lustrating these points. Five-day metabolic
balance studies for zinc were carried out in
20 housebound elderly 70- to 85-year-old
subjects who ate self-selected diets. The
mean daily intake for zinc was significantly
lower than the RDA for this age group.
Zinc balances were negative; leukocyte zinc
levels (but not plasma zinc) were decreased
compared to controls and correlated with
zinc balance.
In conclusion, evaluation of the risk of
zinc deficiency by the probability approach,
using estimates of zinc requirements from
factorial calculations and balance studies,
the 1989 RDA, and reported intakes of
zinc suggest that many Americans are at
risk ofzinc deficiency (31,63,64). Zinc de-
ficiency has been documented in low-in-
come children who participated in a
Head-Start program (83), in poor children
in the Southeastern United States
(63,64,84), in elderly persons from the
United States (4,85), and in so-called
"normal healthy subjects" from the United
States who showed zinc-related immuno-
logical abnormalities (86,87). In the
United States, although severe dietary defi-
ciency of zinc in the absence of other fac-
tors is unlikely, mild and marginal
deficiency of zinc is likely in subjects who
consume diets rich in phytate, dietary fiber,
and calcium phosphopeptides from dairy
products, and low in red meat. The risk of
zinc deficiency (moderate or severe) is sub-
stantially increased by conditioning factors
such as intestinal malabsorption, catabolic
illness, alchoholism, cirrhosis, hemolytic
anemias, renal failure, certain medications
(diuretics, steroids and acetylcholinesterase
inhibitors), blood loss by parasitic infesta-
tions, geophagia, and an excessive loss of
zinc due to sweating (3,4,50,88,89).
Biochemical Properties of Zinc
ChemistryofElementalandSaltForms
ofZinc
Zinc, an element with an atomic weight of
65, is classified as a Group IIB post-transi-
tion member of the periodic table. The
Group IIB metals below zinc in the peri-
odic table are cadmium and mercury,
nonessential metals ofgreater toxicity. Key
chemical characteristics ofzinc are a) a ten-
dency to lose two electrons and as the +2
cation form salts of varying solubility in
aqueous solution and b) a tendency to form
relatively stable coordinate bonds with elec-
tronegative ligands such as nitrogen, oxy-
gen, and sulfur. Zinc, unlike other
transition elements, is relatively stable in
the divalent state and does not undergo
redox changes.
Reactions inAqueousSolution
Zinc in aqueous solution as the +2 cation
becomes hydrated at low pH and at high
pH forms zincate anions, possibly
Zn(OH)42 . Various zinc compounds dif-
fer significantly in their aqueous solubility.
Table 6. Relationship of dietary zinc requirements to dietary phosphorus and protein intakes of men fed fixed
American diets.a
Dietaryzinc requirements, mga
Protein intake,g 40 60 80 100
1000 5.27 6.91 8.54 10.17
(2.48-8.07)1 (4.11-9.70) (5.74-11.33) (7.38-12.96)
1500 9.11 10.27 11.42 12.57
(6.32-11.91) (7.47-13.06) (8.62-14.21) (9.78-15.36)
2000 12.95 13.63 14.30 14.97
(10.16-15.75) (10.83-16.42) (11.50-17.09) (12.18-17.76)
2500 16.79 16.99 17.18 17.37
(14.00-19.59) (14.19-19.78) (14.38-19.97) (14.58-20.16)
aThese data are exclusive ofthe zinc loss in sweat, which was 0.50 ± 0.38 mg for 88 twenty-four-hour collections
on 13 men under temperate conditions. bEstimated 95% confidence interval. Table from Sandstead (31); reprinted
with permission.
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For example, the solubility ofzinc chloride
(mw 136) in water at 25'C is 432 g/100
ml whereas that of zinc oxide (mw 81) at
29°C is 0.00016 g/100 ml (90).
Interactions with Proteins
Cellular Binding Ligand-Metallothionein.
Metallothionein, found in most mam-
malian tissues, is a significant macromolec-
ular ligand for zinc. This small protein
(mw 6700) is primarily an intracellular cy-
tosolic molecule, although the protein is
detectable in extracellular fluids such as
plasma and urine. Metallothionein, unique
in its high cysteine content, binds 7 moles of
zinc per mole ofprotein. The zinc atoms are
now known to be distributed in 2 clusters, 1
containing 3 zinc atoms and 9 cysteine mole-
cules and the other 4 zinc and 11 cysteines
(91). The normal function of this protein is
not clear but may include a role as a free-radi-
cal scavenger (92). In vitrostudies have shown
metallothionein to be a potent binder ofhy-
droxyl radicals (93)
. Whether it also plays a role in the provi-
sion ofzinc to apometalloenzymes is as yet
unconfirmed. It does play a prominent role
in the tissue localization of zinc, as the
major intracellular binding site, and possi-
bly in the gastrointestinal absorption of
zinc. Metallothionein is also important in
the "detoxification" of certain nonessential
metals such as cadmium. Factors which
promote increased expression of metallo-
thionein, such as stress, infection, heat
shock proteins, glucocorticoids, and
nonessential metals such as cadmium and
mercury, may increase zinc content of the
liver and decrease its plasma concentration
(92).
Enzymes. Zinc is required for the opti-
mum function of as many as 300 enzymes
(91). The role of zinc in these metallo-
enzymes includes participation in catalytic
functions, maintenance ofstructural stabil-
ity, and regulatory functions (94). Zinc
metalloenzymes are involved in the forma-
tion or hydrolysis of each of the major
classes of endogenous compounds (pro-
teins, lipids, carbohydrates, etc.) and in-
cludes representatives from each of the six
categories of enzymes of the International
Union ofBiochemistry. The crystal structure
has been identified for 12 zinc enzymes (91),
including alcohol dehydrogenase, car-
boxypeptidases A and B, alkaline phos-
phatase and carbonic anhydrases I and II.
Current evidence indicates that the zinc
binding sites vital to catalysis include three
amino acid residues and an "activated"
water molecule. The amino acids can in-
clude combinations ofhistidine, glutamine,
aspartate, or cysteine. Histidine is the most
frequently observed and is often coordi-
nated with an oxygen group of a nearby
amino acid, most notably the carboxylate
in aspartate (95). Analysis ofthe coordina-
tion sites of zinc in enzymes where its role
is structural indicates bonding to sulfur lig-
ands in cysteines to form a tetradentate
complex. Vallee and Auld (91) have re-
cently proposed, based on analysis of ma-
trix zinc enzymes such as procollagenase,
that one mechanism of enzyme activation
may entail proteolytic cleavage of a seg-
ment with a cysteine zincbinding site. The
residual protein would contain a zinc with
only tridentate binding characteristics, thus
rendering a fourth site available to act in a
catalytic role.
DNA-binding Proteins. The interaction
ofzinc with proteins helps explain another
critical function of zinc in biological sys-
tems, the regulation of DNA and RNA
synthesis (96-99). By coordination with
cysteine and histidine residues in certain
proteins, zinc confers on the complex a ter-
tiary structure which has affinity for unique
stretches of DNA in promoter gene re-
gions. The configurations include the zinc
finger, the most common zinc motif, and
the more recently characterized zinc thio-
late cluster, seen in GAL4 (two zinc, six
cysteine). A model ofthe 3-dimensional in-
teraction of a zinc-finger binding protein
with DNA, based on X-ray crystallographic
analysis, has recently been published (100).
The a-helix of the finger loops was found
to sit in the major groove of [-DNA, one
loop per groove, with the primary contact
at a three base-pair subside. Binding at
these sites enhances DNA transcription
and increases synthesis ofthe protein prod-
uct for that messenger RNA sequence.
Quantitative analysis for zinc content has
definitively established the presence ofzinc
in the DNA binding proteins, TFIIA, the
glucocorticoid receptor, GAL4, and g32P.
The amino acid sequences of niany other
DNA binding proteins, estimated at more
than 150 (91), contain homologous cys-
teine- and/or histidine-containing sites,
suggestive of a critical structural role of
zinc.
Hormone-Receptor Interactions. Zinc is
also required for the optimum activity of
growth hormone. Recently, Cunningham
et al. (101) demonstrated that zinc
markedly enhances the affinity of human
growth hormone for the extracellular bind-
ing domain of the human prolactin recep-
tor. The KD value of zinc (0.4 pM) is in
the range of free zinc in serum which sup-
ports the physiological significance of this
observation. Analysis of binding constants
for mutants suggests that zinc forms a
tetradentate complex through coordination
with two histidine sites and one glutamine
site on growth hormone and one histidine
on the prolactin receptor. Remarkably, zinc
does not play a role in the interaction of
human growth hormone with the human
growth hormone receptor. Cunningham et
al. (101) have suggested the importance of
examining the role ofzinc in binding inter-
actions of hormones with receptors of the
cytokine superfamily which are homolo-
gous to the prolactin receptor.
Neurotransmitter Receptors. Recent evi-
dence indicates that zinc plays a modulat-
ing role in synaptic transmission by
interacting with specific sites on ionotropic
neurotransmitter receptor proteins. Celen-
tano et al. (102) have demonstrated in
spinal cord neurons that extracellular zinc
inhibits y-aminobutyric acid (GABA) re-
ceptor function by an allosteric mecha-
nism. The zinc interaction site differs from
that for other known modulatory sub-
stances but is recognized by certain divalent
cations like cadmium. Zinc has also been
shown to interact with the N-methyl-D-as-
partate (NMDA) receptor at a unique ex-
tracellular site distinct from other
modulators like magnesium or glycine. In
cultured hippocampal neurons, zinc, in mi-
cromolar concentrations, acts as a noncom-
petitive antagonist of NMDA-induced
increased membrane conductance (103).
Zinc in normal physiological conditions is
believed to affect synaptic transmission in
certain areas ofthe central nervous system,
such as the hippocampus where it is con-
centrated in presynaptic vesicles and on re-
lease inhibits GABAB receptor activation
(104). The normal role ofzinc in the brain
is clearly complex, since it acts as an in-
hibitory modulator at receptors for both




nase C Several investigators have reported
interactions of zinc with protein kinase C,
a critical enzyme in the signal transduction
pathway elicited by membrane receptor ac-
tivation followed by enhanced phospho-
inositol turnover. The literature is at
present not consistent with respect to the
effects of zinc. Murakami et al. (105) re-
ported that zinc activated and then inhib-
ited the catalytic activity ofthis enzyme, as
the concentration increased. Other investi-
gators demonstrate only an inhibitory ef-
fect of zinc and argue that the activation
observed by others is an artifact ofcalcium
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release in the experimental model (106).
The site and mechanism of zinc-induced
inhibition has not been thoroughly estab-
lished; data from the work of Speizer sug-
gest that zinc does not interact with the
cation (Ca, Mg) or diacylglycerol regula-
tory sites but may impair stimulation ofthe
enzyme by fatty acids (106). Other work
has focused on the translocation ofprotein
kinase C which is involved in its activation
(107). These studies suggest that zinc en-
hances interaction of the enzyme with
"phospholipid and membrane cytoskeletal
protein," which may play a role in a spe-
cific functional response in human B lym-
phocytes.
Antioxidant Activity. Under in vitro
conditions in biological systems, zinc can
act as an antioxidant by interacting with
sulfhydryl groups of macromolecules,
thereby inhibiting their oxidation and by
competing for binding sites on membranes
with metals such as copper and iron,
thereby decreasing the electron transfer ca-
pabilities ofthe latter (108). In vivo at least
one mechanism of zinc-induced antioxi-
dant effect is the induction of metalloth-
ionein which is an effective free-radical
quencher. Zinc administration can inhibit
the toxicity of agents such as carbon tetra-
chloride, ethanol and ionizing radiation,
which act in part through oxidative injury.
These effects ofzinc, however, may not be
directly linked to an antioxidant effect and
may be attributable to other mechanisms.
Membrane Interactions. Another prop-
erty ofzinc which has been hypothesized to
play a role in normal physiological function
of zinc is its capacity to "stabilize mem-
branes" (109,110). This phenomenon is
presumably a consequence of the binding
of zinc to ligands in membranes which are
essential for maintenance of the normal
structural geometry ofthe protein and lipid
components. Experimental systems where
this property ofzinc has been observed in-
clude erythrocytes where zinc decreases os-
motic fragility and protects against various
inducers ofhemolysis such as osmotic gra-
dients and bacterial toxins, and hepatic
lysosomes where zinc elevated in vitro or in
vivo enhances their stability as indicated by




DermalAbsorption. There is a paucity of
literature on the dermal absorption ofzinc.
Information is lacking on the rate and ex-
tent oftransport ofdifferent zinc salts and
on the various factors likely to influence
this process such as zinc-binding proteins
in the skin. Published studies have limited
applicability because they are of limited
scope. Keen and Hurley (111) observed
that 8- or 24-hr application of zinc chlo-
ride in corn oil to the skin ofpregnant rats
on a zinc-deficient diet increased the
plasma concentration ofzinc to normal or
slightly above normal levels, respectively.
The fraction ofthe applied dose which was
absorbed was not determined. A study by
Hallmans (112) suggested that serum and
urine zinc levels increased following appli-
cation of adhesive tape containing zinc
oxide onto second and third degree burn
wounds. These data do not permit estima-
tion ofthe magnitude or rate ofdermal ab-
sorption ofzinc. Skog and Wahlberg (113)
have reported estimates of the percuta-
neous uptake of zinc chloride following
topical application to the dorsal skin ofthe
guinea pig. Their data were based on moni-
toring the decline of radioactivity emitted
by 65Zn in at least 10 trials for each con-
centration. Concentrations of0.08 to 4.87
M ZnCl2 with pH ranging from 1.8 to
6.1, were tested. Their method ofdata pre-
sentation makes interpretation difficult. It
appeared that in most trials the loss of ra-
dioactivity after 5 hr was less than 1%, ex-
cept for the trial with the lowest pH where
the mean may have been between 1 and
2%. Kapur et al. (114) examined radioac-
tivity remaining after 6 or 24 hr in the
block of rabbit skin to which one of four
zinc compounds in a glycerin:propylene
glycol vehicle had been applied. This study
entailed two animals sacrificed at different
times, so the data are extremely limited.
Gastrointestinal Absorption. Zinc up-
take by high molecular weight proteins in
the intestinal mucosa is an active process
requiring ATP (115). Under conditions of
normal dietary zinc uptake, the initial up-
take ofzinc by the brush-border membrane
of the mucosal cell appears to depend on
its net availability for uptake to, and trans-
fer by, a membrane associated carrier. The
uptake increases significantly with zinc de-
pletion. The net availability ofzinc for up-
take into the mucosal cell depends on the
relative zinc binding affinity of zinc-bind-
ing ligands in the intestinal lumen and the
membrane carrier.
Recently, the intestinal site of zinc ab-
sorption in humans has been determined
with the triple-lumen steady state perfusion
technique (116). Seventeen healthy sub-
jects participated in the study. During in-
testinal perfusion of a balanced electrolyte
solution containing 0.1 mM of zinc ac-
etate, zinc absorption occurred throughout
the entire small intestine. However, the je-
junum had the highest rate of absorption
(357 ± 14 nM/min/40 cm) compared to
the duodenum (230 ± 33 nM/min/40 cm)
and ileum (84 ± 10 nM/min/40 cm). A
linear increase in the rate ofzinc absorption
was observed when the concentration of
zinc infused into the jejunum varied from
0.1 to 1.8 mM. Intestinal absorption of
zinc was significantly stimulated by the ad-
dition of glucose (20 mM). Conversely,
zinc (0.9 mM) also enhanced the absorp-
tion of glucose. The enhanced absorption
ofzinc in glucose was not accompanied by
any increase in absorption of water and
sodium. In contrast, increasing the concen-
tration of zinc in the perfusate resulted in
decreased absorption of sodium and water
in a dose-related manner. Thus, these stud-
ies demonstrated that zinc absorption is
concentration-dependent, occurs through-
out the small intestine with a maximum
rate in the jejunum, and is probably car-
rier-mediated.
Factors known to influence the net gas-
trointestinal absorption ofzinc are listed in
Table 7 and include: a) ligands (zinc may
be bound to one or more ligands, some of
which will impede and others enhance ab-
sorption); b) zinc status (absorption is in-
creased during zinc deficiency); c)
intracellular transport (the active transport
mechanism of zinc appears to be under
metabolic control); and d) endogenous zinc
secretion (a significant amount ofzinc is se-
creted into the intestinal lumen via the ep-
ithelial cells, bile, and pancreatic secretion.
LIGANDS. Most ofthe information con-
cerning zinc absorption is limited to experi-
mental animal model studies. During
digestion, zinc is released from its dietary
ligands (mostly proteins) and becomes as-
sociated with intestinal low molecular
weight ligands which make zinc available
to the intestinal microvilli. Some of these
ligands such as histidine and other amino
acids are of dietary origin but others such
as metallothionein may be of endogenous
origin. Wapnir et al. (117) observed that
amino acids increased zinc absorption in
the colon, a site not considered as impor-
tant for absorption ofzinc in humans.
Putative ligands in milk include citric
acid, picolinic acid, immunoglobulins and
lactoferrins. Whether picolinic acid or cit-
ric acid is the predominant low molecular
weight zinc ligand in human milk has not
been settled (119-121). The possibility
also exists that the association of zinc with
citric or picolinic acid is an artifact ofisola-
tion procedures. Although both citric acid
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and picolinic acid enhance zinc absorption,
their physiological relevance is not clear.
Although human milk contains less zinc
than cow's milk, the availablility ofzinc in
human milk is significantly higher (122).
Some investigators have suggested that
human milk contains a specific protein lig-
and for zinc, which is not present in signifi-
cant quantity in cow's milk (123,124). In
one study, a human milk protein was iso-
lated which enhanced zinc absorption
(123). Other compounds in milk which
may or may not be ligands per se also facili-
tate zinc absorption. These include histi-
dine, D-penicillamine, essential fatty acids
and prostaglandins (118).
Prostaglandin E has been reported to
increase zinc absorption. In zinc-deficient
rats, a positive correlation between zinc and
prostaglandin E content of the gut has
been observed (125). Cottonseed oil im-
proved the clinical condition ofthree cases
of patients with acrodermatitis enteropath-
ica, a fatal disease prior to the advent of
zinc therapy (126). Linoleic acid and 'y-
linolenic acid increased the phospholipids
ofthe intestinal mucosa from zinc-deficient
rats. Although zinc is not bound to
prostaglandins or essential fatty acids, they
may facilitate its absorption by unknown
mechanisms.
Zinc absorption was measured in 37
children with malnutrition using the oral
zinc tolerance test (22 mg elemental zinc)
and the data were compared with those ofa
group of healthy control subjects (127).
The increase in plasma zinc was signifi-
cantly lower in patients with marasmic
kwashiorkor than in the control group
which may reflect decreased absorption.
The zinc tolerance test was, however, nor-
mal in marasmic patients.
Plant proteins, such as soy, increase zinc
requirement in comparison to proteins of
animal origin in experimental animals. Ex-
cessive intake of phytate, a component of
plant protein (myoinositol 1,2,3,4,5,6-
hexakisdihydrogen phosphate), has been
implicated as an important factor responsi-
ble for zinc deficiency in Middle Eastern
dwarfs (128). Negative zinc balance as a re-
sult of fiber supplementation has been
demonstrated (129). This effect may have
been secondary to phytate and lignin in the
diet. However, the effect has not been con-
sistently observed in humans or in animals
which may be due to different effects of
soluble and insoluble fiber (26,36,130). In
vegetarians, phytate and fiber intake is sig-
nificantly higher than in individuals eating
an omnivorous diet, and it is likely that
their combined effect on zinc absorption is
clinically more important.
Alcohol is known to decrease zinc ab-
sorption in the rat (131,132). In humans,
the effect of alcohol on zinc absorption is
not well defined. Sullivan et al. (133,134),
by using a zinc tolerance test, showed that
zinc absorption was decreased by concur-
rent alcohol intake. Absorption of65Zn has
been shown to be lowered in patients with
alcoholic cirrhosis in comparison to con-
trols (135). In alcoholics consuming a
standard meal, absorption of 50 mg but
not 25 mg ofzinc was decreased (136). Al-
coholics exhibit low levels of plasma zinc
and also hyperzincuria, which might be an
important factor in the pathogenesis of
zinc deficiency (134).
Zinc absorption has also been examined
in nonalcoholic cirrhotic patients with the
oral zinc (22.5 mg elemental zinc) toler-
ance test (137). The increase in plasma
zinc was significantly lower in cirrhotic pa-
tients compared to the control group in the
first, second, and fourth hour post inges-
tion. Zinc malabsorption may in part be
the result ofpathological changes in the in-
testinal mucosa and lamina propria, docu-
mented in biopsies
EDTA, which is used during the pro-
cessing ofvegetables, has been shown to re-
duce zinc absorption in humans (44,138).
EDTA appears to have two effects, one to
decrease dietary zinc content and the other
to decrease its absorption. Thus, depending
upon the frequency and quantity ofEDTA
being used, one may observe a negative ef-
fect on zinc homeostasis in humans.
ZINC STATUS. Zinc absorption is in-
creased in zinc-deficient rats and decreased
in rats fed excess zinc (118,139,140). Zinc
absorption is also increased in pregnant rats
and reverts to normal after parturition. In
humans an 11-fold increase in zinc inges-
tion, from a normal dietary intake of 8 to
13 mg daily to diet plus a 100 mg zinc sup-
plement daily (as ZnSO4), produced only a
37% increase in plasma zinc (141). These
results could be explained in part by a drop
in absorption from 43 to 9% of the in-
gested zinc load.
INTRACELLULAR TRANSPORT. The
mechanism by which zinc is transferred to
or across the mucosal surface of the mi-
crovilli is not known. Once in the intesti-
nal cell, zinc becomes associated with
metallothionein and perhaps other proteins
(142). This process appears to be depen-
dent on protein synthesis, since cyclohex-
imide and actinomycin D inhibit mucosal
zinc uptake (143,144). The complexing of
zinc with the intracellular metalloprotein is
an energy-dependent process. The precise
role of intestinal metallothionein in zinc
absorption is not well understood.
Transport studies using pig small in-
testinal brush-border membrane vesicles
showed that zinc uptake was augmented by
highly permeable anions such as thio-
cyanates, suggesting that movement ofzinc
involved complex formation with negative
species (145). The imposition of an out-
wardly directed K+ gradient (negative in-
side) did not affect the maximum value
(Jmax) of saturable zinc uptake but in-
creased the concentration for halfmaximal
uptake (Km) significantly. This suggests
that at least a portion ofzinc which crosses
the membrane does not do so in a cationic
form. The presence of calcium had no ef-
fect on zinc entry into the vesicles (145).
In one study (146), the addition of an
excess offolate, histidine or glucose had no
effect on zinc (5 iM) uptake by porcine in-
testinal brush-border membrane vesicles,
whereas addition of picolinate, citrate and
phytate to the incubation medium signifi-
cantly reduced zinc uptake. The inhibitory
effects of these ligands may have been due
to the formation of zinc ligand complexes
which are either insoluble, or which reduce
the binding ofzinc to its mucosal receptor.
Although this model is useful for compar-
ing the effects ofpotential zinc binding lig-
ands in the diet, these data do not provide
an insight into the effects ofvarious ligands
on zinc absorption.
Zinc uptake was investigated in mem-
branes derived from small intestines of rats
fed zinc-adequate and zinc-deficient diets
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Table 8. Zinc concentrations in body fluids, hair, and
blood cells of humans.
Fluid Zinc concentration Reference
Plasma 110.7 ± 14.8 jtg/dL (148)
Erythrocytes 40.67 ± 3.60,ug/9 Hb (148)
Lymphocytes 50.9 ± 5.9 lag/101 cells (154)
Granulocytes 45.9 ± 6.4 pug/1010 cells (154)
Platelets 3.3 ± 0.3gg/101h cells (154)
Hair 193 18jg/g (155)
Urine 643 198 ug/d (155)
Milkb 1.2 3.6gg/ml (156)
Bile 171 106 gg/ml (157)
Whole sweat 115+30tg/dl (88)
Cell-free sweat 93 ± 26 ig/dl (88)
Seminal plasma 692 + 24 jig/ml (158)
Cerebrospinal fluid 0.03 ± 0.02 jig/ml (159)
aMean ± SD.bDuring lactation.
(147). Zinc uptake into basolateral mem-
brane vesicles exhibited a saturable phase
within the zinc concentration range of5 to
625 pM. Zinc uptake also showed a non-
saturable (diffusion) phase. Kinetic analysis
ofthe saturable component showed a K; at
1 min of 24 pM zinc and Jmax of 17
nmoles/mg protein/min. These studies
demonstrated that the basolateral mem-
brane zinc transport system proceeds prin-
cipally by a carrier-mediated mechanism.
These studies also suggest that zinc trans-
port by the basolateral membrane may be
ATP dependent.
Zinc in Plasma and Tissues. Values for
the plasma zinc in normal subjects ob-
tained by different investigators using vari-
ous techniques are with few exceptions in
reasonably good agreement. Better meth-
ods ofavoiding sample contamination and
more precise analytical tools now provide
accurate data for plasma zinc. The plasma
zinc concentration (mean ± SD) in normal
subjects has been reported as 110.7 ± 14.8
ig/dl (148) (Table 8).
Plasma zinc levels in the newborn are in
the same range as in adults (65). The levels
fall to just below adult level within the first
week oflife and continue to decline until 3
months; the adult level is reachieved at
about 4 months ofage. Some investigators
have shown decreasing plasma zinc values
with increasing age over 60 years
(150,151), which may reflect lower dietary
intake and decreased absorption. Whether
or not this decrease implies an increased re-
quirement for zinc in elderly subjects re-
mains to be established.
Transferrin, albumin, and cx-2-macro-
globulin have been proposed as likely
serum proteins involved in the transport of
zinc in blood subsequent to its absorption
(152). The binding ofzinc to amino acids
and serum protein has been studied in vitro
by Prasad and Oberleas (152). Following
incubation of 65Zn with pooled native
human serum, ultrafilterable zinc was de-
termined to be 2 to 8% ofthe total serum
zinc, when the zinc/albumin molar ratio
was varied from 0.33 to 2.5. Under similar
conditions, 0.2 to 1.2% ofzinc was ultrafil-
trable when predialyzed serum was used. In
physiological concentrations, addition of
amino acids to predialyzed serum increased
ultrafilterable 65Zn severalfold. Histidine,
glutamine, threonine, cystine, and lysine
showed the most marked effect in this re-
gard. It was suggested that the amino-acid-
bound fraction of zinc may have an
important role in biological transport of
this element. In predialyzed serum, the en-
dogenous zinc content was determined to
be highest in the albumin fraction with
smaller concentrations in a-, -, and y-
globulins. The results obtained by using
65Zn-incubated predialyzed serum, how-
ever, indicated a difference in the behavior
ofexogenous zinc as compared with the en-
dogenous zinc bound to various serum pro-
teins. In vitro studies using predialyzed
albumin, haptoglobin, ceruloplasmin, a-2-
macroglobin, transferrin, and IgG, incu-
bated with 65Zn, revealed that zinc was
bound to all these proteins, and that the
binding of zinc to IgG was electrostatic in
nature. Whereas amino acids competed ef-
fectively with albumin, haptoglobin, trans-
ferrin and IgG for binding ofzinc, a similar
phenomenon was not observed with re-
spect to ceruloplasmin and a-2-macroglob-
ulin, suggesting that the latter two proteins
exhibited a specific binding property for
zinc.
The uptake of transferrin-bound zinc
by human lymphocytes is stimulated in
vitro by several agents such as
prostaglandin E1, epinephrine, glucagon,
histamine, and serotonin (153).
Prostaglandin F2a however, is inhibitory.
The mechanism is not known.
Body fluid, hair, and blood cell levels of
zinc in humans are shown in Table 8. Zinc
in lymphocytes, granulocytes, and platelets
appear to be a sensitive indicator of zinc
status in humans. Table 9 shows the con-
centrations of zinc in various human and
animal tissues.
Peripheral Utilization. Apart from
studies of zinc uptake by the liver
(160-162), very little is known about the
utilization of zinc by peripheral tissues.
65Zn uptake by isolated rat hepatocytes in
culture showed a rapid initial phase which
was not carrier-mediated, and a slower sec-
ond phase. Neither phase was affected by
cyanide, prostaglandins or sex steroids, sug-
gesting that active transport was not in-
volved (160,163). High (65,000) and low
(metallothionein, about 6000) molecular
weight proteins were involved in zinc up-
take by hepatocytes. When excess zinc was
available, the lower weight proteins played
a greater role.
A kinetic analysis ofzinc uptake by iso-
lated rat liver parenchymal cells defined
two intracellular pools (161,162). In 1
pool zinc was bound relatively weakly and
equilibrated rapidly with the medium at
370C (labile pool). ln the other pool zinc
appeared to be bound tightly and equili-
brated slowly. Zinc uptake was temperature
dependent and was inhibited by both N-
ethylmaleimide and iodoacetamide, sug-
gesting that sulfhydryl groups may be
involved in one or more steps in the
translocation/binding process. In contrast
Table 9. Zinc concentrations in human and animal tissues (mg/kg dryweight)
Tissue Human Rat Calf Pig
Liver 141-245 101± 13 101 150.8± 12
Kidney 184-230 91 ± 3 73 97.8± 3.0
Lung 67-86 81 ± 3 81
Muscle 197-226 45± 5 86
Pancreas 115-135 139.5± 4.0
Heart 100 73± 16









Testis 176± 12 79 54 ± 2.0
Esophagus 108± 17 88.1 ± 3.0
aMean ± SD.bFrom Prasad(155); reprintedwith permission.
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to earlier studies, metabolic inhibitors such
as azide, cyanide, and oligomycin inhibited
uptake ofzinc. The factors that augmented
the uptake/exchange ofzinc, namely gluco-
corticoids, glucagon, epinephrine, and
dibutyryl cyclic AMP, were also those that
stimulated metallothionein gene expression
in hepatocytes. Changes in zinc flux into
intracellular pools were directly related to
the metallothionein content ofhepatocytes.
In vitro 65Zn uptake by human retinal
pigment epithelium has also been studied
(164). The data were consistent with a fa-
cilitated type of transport and demon-
strated the ability of human retinal
pigment epithelium to accumulate and re-
tain zinc.
It has been suggested that the peripheral
utilization of zinc is abnormal in patients
with myotonic dystrophy, thereby causing
localized zinc depletion in cardiac and
skeletal muscle (165). Muscle catabolism is
also an important mechanism by which
zinc can be released to maintain fetal
growth in zinc-deficient pregnant rats
(166). In pregnancy, there is reduced ma-
ternal fecal zinc excretion suggesting that
peripheral utilization ofzinc by the fetopla-
cental unit may be increased (167).
Excretion. Zinc excretion is primarily
via the feces (168). Daily fecal excretion
ranges from 5 to 10 mg/day and depends
upon the dietary zinc. In pathological con-
ditions accompanied by diarrhea and mal-
absorption excessive fecal loss of zinc may
rapidly result in negative zinc balance.
Fecal zinc is comprised of unabsorbed di-
etary zinc and endogenous zinc loss from
bile, pancreatic fluid and cells of the in-
testinal mucosa. In man studies of65Zn ad-
ministered intravenously indicate that
secretion of zinc into the intestine is as
high as 18% of the administered tracer
(169,170). The pancreatic secretion ofzinc
into the intestinal lumen has been studied
in animals (171,172). Mateseche et al.
(173) have demonstrated that even under
"normal" conditions nearly as much zinc
could be secreted from the pancreas as was
absorbed from the intestine. The secretion
of endogenous zinc is increased when the
dietary protein is of plant origin in com-
parison to when the protein source is ofan-
imal origin.
Basal and cholecystokinin-stimulated
pancreaticobiliary secretion of zinc has
been studied in normal subjects on zinc-ad-
equate and zinc-deficient diets and in pa-
tients with Wilson's disease before and
after zinc therapy (153). Following intra-
venous infusion of cholecystokinin
(CCK8) (40 ng/kg/hr), the pancreaticobil-
iary secretion ofzinc increased from a basal
of 283 ± 76 nM/min to a peak of 717 ±
175 nM/min in normal subjects on a zinc
adequate diet. Normal subjects on a zinc
deficient diet had both lower basal (67 ± 16
nM/min) and stimulated (560 ± 31
nM/min) pancreaticobiliary secretion of
zinc. In contrast to the markedly reduced
pancreaticobiliary secretion of copper, pa-
tients with Wilson's disease, not treated
with zinc, had normal basal (227 ± 126
nM/min) and stimulated (729 + 196
nM/min) zinc secretion. These studies
demonstrate that a considerable amount of
zinc is being secreted in pancreaticobiliary
fluid in healthy subjects and in patients
with Wilson's disease. These data also indi-
cate that pancreaticobiliary secretion of
zinc is dependent on zinc status and may
therefore play a role in zinc homeostasis.
Zinc is also excreted in the urine. In hu-
mans approximately 200 to 600 pg zinc is
lost per day in the urine, generally less than
10% of the amount consumed in the diet.
Urinary zinc excretion appears to be sensi-
tive to alterations in zinc status (4,141). An
11-fold increase in zinc ingestion in hu-
mans, by supplementation with ZnSO4,
has been shown to produce a 37% increase
in plasma zinc, but a 188% increase in
daily zinc excretion in the urine (141).
These results indicated enhanced renal
clearance in response to an increase in
plasma levels, possibly due to increased fil-
tration and/or decreased reabsorption.
Zinc clearance studies in anesthetized
dogs have been performed during hydrope-
nia, mannitol infusion, and infusion of
mannitol plus ZnSO4, ZnCl2, or cysteine
(174). Under control conditions the clear-
ance of ultrafiltrable endogenous zinc was
about one-quarter that ofinulin, indicating
substantial net reabsorption. ZnSO4 infu-
sion increased filtered zinc 13-fold and zinc
excretion only 6-fold, indicating increased
net zinc reabsorption. Stop-flow studies lo-
calized zinc reabsorption to the distal
nephron during infusion of mannitol and
mannitol plus ZnSO4 or ZnCl2. Cysteine
infusion increased urinary zinc excretion
86-fold, indicating net tubular zinc secre-
tion, some of which derived from non-
plasma sources. Zinc secretion was shown
to occur in the proximal tubule with rever-
sal of the distal reabsorption pattern seen
during ZnSO4 and ZnCl2 infusion. These
experiments demonstrate that the nephron
under these experimental conditions is ca-
pable ofboth proximal secretion and distal
reabsorption of zinc. There is no known
capacity in mammals to store zinc with the
possible exception of zinc stored in the
bone. Homeostasis of zinc thus depends
upon the balance between absorption and
excretion. Zinc excretion is decreased when
animals or humans are zinc deficient
(175-177). Zinc excretion in both urine
and feces may be extremely low in zinc-de-
ficient rats. In addition, zinc redistribution
from bone into muscle may occur
(178,179). Conversely, in zinc-supple-
mented animals, endogenous secretion of
zinc is increased which helps maintain zinc
homeostasis.
Interactionswith OtherMetals
Zinc and Copper. The interaction between
zinc and copper may be considered to be
mutually antagonistic. In zinc-deficient ex-
perimental animals levels ofcopper in liver
and bone have been observed to increase
(180-184). In zinc deficient dairy cows
copper excretion in milk is increased
(185). In contrast, excessive dietary zinc in
experimental animals produces copper defi-
ciency, as manifested by reduced copper
concentrations in liver, heart, and serum,
and decreased activities of copper metal-
loenzymes such as ceruloplasmin, cy-
tochrome oxidase, and superoxide
dismutase (186-190). The effective dose
level of zinc varies over a wide range from
about 100 to more than 1000 mg/kg di-
etary dry matter, because various dietary
constituents influence the availability ofthe
dietary zinc and, thereby, the effects on
copper metabolism. In humans chronic, el-
evated intake of zinc, 100 mg or more per
day prescribed or self-administered, has
been shown to induce copper deficiency
(15,191).
Changes in copper status are reversed
by raising dietary copper in oraer to nar-
row the zinc:copper ratio. Similarly, the
zinc supply may be raised as a protective
measure against copper toxicity in livestock
(192-194).
Imbalances between zinc and copper
may occur because ofeither deficient or ex-
cessive copper intake, or excessive intake of
zinc relative to copper. When the copper
supply is low and zinc intake is adequate,
zinc will be present at a relatively high level
compared to copper and, in this situation,
the zinc status is not affected, but copper
status may be impaired (190,195). Only a
slight increase in zinc concentration in the
liver and bone may be noted in copper-de-
ficient animals (196). The effects of high
copper intake when the zinc intake is nor-
mal are not well defined.
Mode ofZinc-Copper Interactions.
Zinc and copper inhibit each other's in-
testinal absorption under certain condi-
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tions. In rats excess copper decreases zinc
absorption in zinc-adequate, but not in
zinc-deficient, rats (197-200). In zinc defi-
ciency, absorption ofboth zinc and copper
is increased. In contrast, in copper defi-
ciency, copper absorption is increased but
zinc absorption is not.
A completely satisfactory explanation
for the zinc-copper interactions at the site
of absorption is not available. Intestinal
metallothionein level may play an impor-
tant role. The level of metallothionein in
the intestine is directly related to zinc sta-
tus; zinc induces the synthesis ofmetalloth-
ionein in intestinal cells (201). Inasmuch as
metallothionein has a higher affinity for
copper than zinc, copper absorbed by the
intestinal mucosal cells is bound to metal-
lothionein, does not enter the body and is
returned to the intestinal lumen with the
turnover of the intestinal mucosal cells
(143). No such relationship between met-
allothionein and reduced zinc absorption
after excess copper exposure has been re-
ported (202).
Zinc and Copper Interactions in Hu-
mans. Copper deficiency is rare in human
adults and is manifested by leukopenia and
anemia (15). In infants and children, nu-
tritional copper deficiency resulting in
hypochromic microcytic anemia and neu-
tropenia has been reported (203). Occa-
sionally, total parenteral nutrition without
copper supplementation has resulted in
copper deficiency in adults (204,205).
Hypocupremia and hypoceruloplas-
minemia were observed in an adult with
sickle cell anemia who received zinc (25 mg
elemental zinc every 4 hr for 2 years) as an
antisickling agent (15). The hypocupremia
was associated with microcytosis and rela-
tive neutropenia. Administration ofcopper
corrected these abnormalities. Hypocerulo-
plasminemia of varying degrees in several
other sickle cell anemia patients who were
receiving oral zinc therapy has been ob-
served (15).
These observations prompted Brewer et
al. (206) to treat patients with Wilson's
disease by oral administration ofzinc. Wil-
son's disease is an autosomal, recessively in-
herited, inborn error which causes low
excretion of copper by the liver and toxic
accumulation in the liver, brain, and other
tissues. Conventional therapy with the
chelator penicillamine can cause a variety
ofside effects so severe as to prevent its use
in about 10% ofpatients (207). The need
for alternative therapies led to trials with
zinc by Brewer. Supportive ofhis approach
were reports of Hoogenraad (208) which
suggested that zinc might be efficacious in
this disease.
Brewer et al. have studied a large series
of patients since their original report
(206,209-211). Their findings demon-
strate the efficacy of zinc (50 mg, 3 times
daily) in the treatment ofWilson's disease.
Use of the copper tracer 64Cu acetate in
cow's milk has documented that zinc ther-
apy markedly reduces copper absorption
from the intestine into blood from about
6% to <1% (212). Further studies have re-
vealed a decline to normal levels in 24-hr
urinary copper excretion and in noncerulo-
plasmin plasma copper in zinc-treated pa-
tients with Wilson's disease (209). Liver
biopsies suggested that zinc therapy also
prevented further hepatic accumulation of
copper (210).
Interactions ofZinc and Copper in
Other Clinical Conditions. A reciprocal re-
lationship between plasma levels of zinc
and copper has been observed in various
clinical conditions. A decreased plasma zinc
level and an increased plasma copper level
have been reported in pregnancy, women
on oral contraceptives, acute infection, ma-
lignancy, cardiovascular disease, renal dis-
ease, schizophrenia, and certain endocrine
diseases such as acromegaly and Addison's
disease.
The interference ofzinc with copper re-
tention in humans is illustrated by clinical
reports and investigations ofsubjects taking
zinc supplements. Anemia and neutropenia
developed in a man who took excess
amounts ofnonprescribed zinc gluconate for
2 years (13). Hyperzincemia, hypocupremia,
low serum ceruloplasmin, and ringed sider-
oblasts in normoblasts in the bone marrow
were observed. All the above manifestations
were reversed following withdrawal ofzinc.
Presumably, these manifestations were
caused by copper deficiency induced by ex-
cessive ingestion of zinc. Patterson et al.
(213) also reported sideroblastic anemia
and leukopenia associated with copper defi-
ciency in a young man who had ingested
more than 50 mg elemental zinc orally for
2 years. A woman studied by Hoffman et
al. (14) who took 440 to 660 mg of zinc
sulfate (110-165 mg elemental zinc) daily
for 10 months for aphthous ulcers of her
mouth and tongue developed copper defi-
ciency with anemia and neutropenia. Sam-
man and Roberts (214), using a
double-blind crossover design, compared
similar amounts of zinc supplementation,
150 mg zinc/day for 6 weeks, to placebo in
healthy men and women. Plasma copper
levels and hematocrits were not altered.
However, in a subsequent report, these in-
vestigators (215) indicated that in females,
but not males, the zinc treatment signifi-
cantly reduced ferroxidase activity ofserum
ceruloplasmin, antioxidant activity of ery-
throcyte superoxide dismutase and cop-
per-zinc erythrocyte superoxide dismutase.
Plasma zinc levels were higher in females
than in males, which possibly could explain
the sex-dependent effect ofzinc on copper
status.
Fischer et al. (216) studied the effects
of a lower leveJ of zinc supplementation
(25 mg twice daily) on copper metabolism
in 26 healthy adult men, also over a 6-week
interval. Plasma zinc was significantly in-
creased by week 2. No change occurred in
plasma copper. However, by 6 weeks Cu,
Zn-superoxide dismutase in red blood cells
was decreased about 10% in the zinc-
treated group, suggestive ofdecreased cop-
per status. Whether enzyme levels were
altered in other tissues was not tested, al-
though studies with rats by the same group
(189) have shown decreases in liver super-
oxide dismutase as zinc intake increased.
Balance studies in humans also suggest that
copper requirements for equilibrium are in-
creased as dietary zinc is elevated (217)
In summary, several studies indicate
that zinc may reduce the activity of ery-
throcyte superoxide dismutase, probably
in response to a change in copper status.
The physiological significance of this ef-
fect has not been established, either in pri-
mary copper deficiency or secondary to
elevated zinc levels. This enzyme converts
superoxide to hydrogen peroxide and oxy-
gen and therefore modulates the cellular
toxicity of superoxide generated in xeno-
biotic biotransformation or oxidant and
nonoxidant stress (218). Various factors
such as nonlethal stress have been shown
to induce increased synthesis of this en-
zyme (219). Implications of the protec-
tive effect of this enzyme against
chemically induced cancer are offered in
studies such as that by Werts and Gould
(220) who demonstrated higher enzyme
activity in mammary gland tissues from
aged, pregnant or multiparous
Sprague-Dawley rats, physiological states
with decreased susceptibility to dimethyl-
benzanthracene-induced mammary can-
cer. Other factors, however, may be more
critical determinants. To date there is no
evidence that excess intake ofzinc is asso-
ciated with mutagenicity or carcinogenic-
ity. Consequently, it is not clear that
pathological significance can be attributed
to the zinc-induced decrease in Cu,Zn-su-
peroxide dismutase, secondary to copper
deficiency.
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Iron Impairment ofZinc Absorption.
Recently, a concern has been raised that an
antagonistic effect of iron on zinc absorp-
tion may have a deleterious effect on zinc
nutrition, particularly in population groups
that are routinely supplemented with iron
(16,221). Both iron and zinc appear in the
first transition series of the periodic table,
and they share an identical outer electronic
configuration with manganese, cobalt and
nickel. Zinc and iron are essential for nor-
mal growth and development and are simi-
lar in amounts normally ingested.
In rodents, the capacity ofthe intestine
to absorb iron is greatly increased by feed-
ing a low iron diet. In iron-deficient rats
and mice, the oral absorption ofzinc is also
greatly increased, suggesting a shared trans-
port pathway (222-224). Hill and Ma-
trone (225) have proposed that ions with
similar electronic configuration might
compete for binding ligands that mediate
their intestinal absorption and subsequent
transport into the blood. Numerous stud-
ies, with only one exception (226), have
subsequently demonstrated that iron in-
hibits zinc absorption into plasma when
aqueous solutions ofthe minerals are tested
(227-234). Consistent with the electronic
configuration hypothesis, ferrous iron pro-
duces greater inhibition ofzinc uptake than
ferric iron (225).
The mechanisms of zinc and iron ab-
sorption are not completely similar. Iron
absorption is restricted to the duodenum,
whereas zinc is absorbed throughout the
small intestine and colon (140,223,229).
Zinc appears to be a less effective inhibitor
of iron absorption than iron is of zinc ab-
sorption. Although the capacity to absorb
iron is increased equally by either bleeding
or by feeding a low-iron diet, the absorp-
tion of zinc is increased only in rats and
mice fed low-iron diets (222). Finally, in
mice with sex-linked anemia (sla), the ge-
netic lesion affects the absorption of iron
but not zinc (235).
In human studies, it has been ob-
served that inorganic iron added to test
solutions of zinc salts in Fe/Zn ratios of
2.25 significantly lowered zinc absorp-
tion (229, 231,232,234). In contrast to
rodents, human subjects with an in-
creased capacity to absorb iron do not
absorb increased amounts of zinc given
as zinc chloride (234). This observation
suggests that zinc and iron probably do
not interact in humans to the same ex-
tent as observed in rodents and could ex-
plain why higher Fe/Zn ratios were
required to inhibit zinc absorption in
the human studies (221).
In contrast to the above results in hu-
mans, in three studies where iron was given
with food, no effect on zinc absorption was
observed. When oysters, providing about
54 mg "organic" zinc, were consumed with
100 mg of ferrous iron, plasma uptake of
zinc was not altered (231). When turkey
meat containing 4 mg of zinc was con-
sumed with either 17 mg or 34 mg offerric
iron, zinc absorption was unchanged
(234). Finally, when ferrous iron at a
Fe/Zn ratio of 25 was added to a compos-
ite meal containing 2.6 mg ofzinc, the ab-
sorption of zinc was not significantly
changed (229).
It appears, therefore, that under usual
conditions human zinc absorption is deter-
mined largely by the nature and extent of
zinc complex formation with food in the
intestinal tract, and normally the influence
of iron on zinc absorption may not be sig-
nificant. Under unusual circumstances,
however, if large iron supplements are in-
gested in the absence of food, it is likely
that iron could impair zinc absorption. A
number of clinical studies support this
point (16). For one, the study ofPrasad et
al. (175) followed four human volunteers
for several months on a semisynthetic soy
protein-based zinc-deficient diet containing
3.5 mg ofzinc per day. The fall in plasma
zinc was more pronounced in the first two
subjects who received 130 mg of iron per
day (Fe/Zn ratio of37:1), in comparison to
the other two who received 20.3 mg of
iron per day (Fe/Zn ratio of8:1). These re-
sults suggested that the iron excess en-
hanced the zinc deficiency.
A second study measured growth rates
of healthy middle-class white infants re-
ceiving zinc, 1.8 mg/I cow's milk formula,
vs those receiving zinc, 5.8 mg/I, plus iron,
12 mg/I. The results suggested that more
zinc was required in the presence of iron
for achieving optimal growth in the infants
(16). However, in another study of
healthy infants who were zinc sufficient,
iron supplementation (up to 30 mg/day)
did not appear to affect zinc nutriture
(236). This observation needs further con-
firmation.
In healthy nonpregnant women, a ratio
of iron to zinc increasing from 0.1 to 3.1
given in aqueous solution (zinc kept con-
stant at 25 mg) caused a progressive de-
crease in the plasma response to the
ingested zinc (231). In pregnant women,
zinc absorption is decreased by oral iron
supplements (167,237). Hambidge et al.
(167) reported an inverse relationship be-
tween the level of daily iron supplement
and the plasma zinc level in the first and
third trimester of pregnancy. Campbell-
Brown et al. (238) also observed that three
women who supplemented 100 mg or
more of iron daily had the lowest plasma
zinc levels in comparison to other pregnant
women who supplemented less iron daily.
Breskin et al. (239) showed that prenatal
supplements of 30 mg or more iron were
associated with significantly lower plasma
zinc levels in women in comparison to
those who received no iron supplement or
less than 30 mg per day. In contrast to the
above observations, other investigators
found no effect of iron supplementation
(160 mg ofiron daily) on plasma zinc level
in pregnant women (16).
Iron, 300 mg administered with 25 mg
ofzinc, decreased the peak plasma concen-
tration ofzinc in uremic subjects (25% de-
crease vs 40% decrease in controls). The
apparently decreased zinc absorption was
associated with lower fasting plasma zinc
and was exacerbated with aluminum intake
(240). Inasmuch as high aluminum intake
is common in hemodialyzed patients, the
above interactions are important for long-
term management ofthese cases.
Effect ofZinc on Iron Nutriture. A re-
cent study has shown that zinc impaired
the intestinal absorption ofiron in humans
(241). Mahloudji et al. (242) reported that
growth ofiron-deficient Iranian schoolboys
was greater when supplementation was 20
mg ofiron daily, rather than a combination
of20 mg ofiron and 20 mg ofzinc. These
results suggested that oral zinc may have
decreased the absorption of iron in these
children. The 59Fe absorption studies of
Aggett et al. (228) lend support to this
view.
A high level of zinc supplementation
may also affect iron storage. Toxic levels of
zinc in the diet may shorten the life-span of
red blood cells and cause anemia because of
the faster iron turnover (243). Zinc is
known to interfere with iron uptake by the
liver so that there is a decrease in the stor-
age of iron as ferritin (244). Decreased
iron levels in the liver and kidneys in re-
sponse to excessive zinc supplementation
has been observed (188,245-247). Inas-
much as transferrin in plasma is known to
transport both iron and zinc, the interac-
tion ofiron and zinc may be due in part to
competition at the transport level.
In women supplemental zinc, 50 mg
daily for 10 weeks, has been shown to alter
indices of iron status. Yardick et al. (190)
measured the effects of50 mg zinc daily or
50 mg zinc and 50 mg iron daily on zinc,
iron and copper indices in 18 women, 25
to 40 years ofage, over a 10-week interval.
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Zinc lowered serum ferritin, hematocrit,
and erythrocyte superoxide dismutase after
10 weeks compared to baseline. Zinc treat-
ment increased serum zinc but had no ef-
fect on hemoglobin, ceruloplasmin, or
salivary zinc. In the zinc-iron treatment
group, superoxide dismutase and salivary
zinc decreased. Serum ferritin and serum
zinc increased significantly, but other in-
dices did not. These data suggest that sup-
plemental zinc at a level of 50 mg daily
impairs both iron and copper status. Si-
multaneous iron supplementation pro-
tected iron status.
Iron absorption and distribution is al-
tered as well by zinc deficiency. A marked
increase in iron and a decrease in zinc con-
centration in various organs such as liver,
bone, pancreas, and testes has been ob-
served in zinc-deficient animals in compari-
son to pair fed controls (180,181,
248,249). These changes are reversed fol-
lowing zinc supplementation. Absorption
ofiron is enhanced in animals fed zinc-de-
ficient diets, which may explain in part the
increased organ levels ofiron (250).
Health Effects of Zinc
Deficiency and Excess
Effects on Organ Systems
Gastrointestinal Tract. HUMAN STUDIES.
Gastrointestinal effects ofhigher than nor-
mal levels oforal intake ofzinc compounds
have been described in a number ofcases of
accidental or self-administered exposures
and in prospective studies. Some of these
reports will be described in this section.
Chobanian (251) related the case of a
man who accidentally ingested about 3 oz
ofliquid zinc chloride solution. There were
local caustic effects including erosive
pharyngitis and esophagitis; in addition,
there was burning pain in the mouth and
throat along with nausea, vomiting, and
abdominal cramps. Chelation therapy was
instituted and within a few days the clinical
and biochemical effects of overdose were
reversed. The patient was discharged after
5 days. Since the ingested material was a
solution, exact dosage of zinc chloride
could not be established.
Burkhart et al. (252) reported the case
ofa 16-year-old boy who ingested approxi-
mately 50 zinc sulfate tablets (500 mg).
Following ipecac-induced emesis and oro-
gastric lavage, an abdominal radiograph
performed 4 hr after ingestion still demon-
strated most ofthe tablets within the stom-
ach but with three pills within the colon.
Whole-bowel irrigation with a polyethyl-
ene glycol savage solution administered
through a nasogastric tube produced a rec-
tal effluent that contained pills. Signifi-
cantly, the patient remained asymptomatic
throughout the whole bowel irrigation.
Stool guaiac tests were negative, but serum
chloride increased from 105 to 127 mEq/l.
Follow-up radiographic assessment revealed
complete clearance ofthe zinc tablets from
the gastrointestinal tract during the next 24
hr.
Murphy (253) has also reported on a
single oral dose ofzinc in a 16-year-old boy
who ingested 12 g of elemental zinc in an
attempt to hasten healing ofa minor lacer-
ation. Lethargy occurred for several days
after the ingestion, accompanied by an ele-
vated zinc concentration in whole blood.
Chelation therapy promoted dramatic clin-
ical improvement, and a fall in blood zinc
levels. Gastrointestinal disturbance was not
reported in this case.
In a prospective study, Henkin et al.
(6) gave 80 volunteers zinc sulfate, 100
mg as zinc ion, in four divided doses daily
for 3 to 6 months. Only one patient expe-
rienced a mild degree of diarrhea as the
only gastrointestinal disturbance. In con-
trast, Samman and Roberts (214) observed
gastrointestinal symptoms in 26 of 47
healthy volunteers who ingested 150 mg of
zinc sulfate in three divided doses daily for
6 weeks. Symptoms in the latter cases in-
cluded headache, nausea, stomach cramps,
and diarrhea. The form ofthe zinc salt, the
sulfate per se, similar to iron sulfate, may
have had a direct effect on the gastrointesti-
nal mucosa, but exact mechanisms are un-
known. Zinc gluconate and zinc acetate are
reported to be less irritating to the gastroin-
testinal tract than other forms, but this has
not been clearly confirmed (16).
ANIMAL STUDIES. Maita et al. (254) re-
ported ulcers of the forestomach in mice
fed zinc sulfate at levels from 1500 to 3900
mg/kg/day for 13 weeks. However, there
were no observed adverse effects in mice
exposed to 150 to 390 mg/kg/day (3000
ppm) for 13 weeks. Some mice given
30,000 ppm dietary zinc sulfate exhibited
other gastrointestinal lesions including ul-
cers at the junction ofthe forestomach and
the glandular portion, and increased mucus
secretion in the upper small intestine near
the glandular pyloric region. The study by
Straube et al. (255) wherein ferrets reacted
adversely with intestinal hemorrhages and
death is difficult to evaluate. There were
only three or four animals per group, the
diet may have been inadequate, and no
dose-response studies were reported.
The overall impression of reported
studies ofhigher than normal oral exposure
to zinc compounds is that most are subject
to criticism and questioning with respect to
human risk. In some cases the numbers of
experimental animals were exceedingly
small. Furthermore the levels of exposure
were far in excess ofthat to be expected in
human situations; ferrets received 4.25 mg
zinc oxide/kg/day for 3 weeks. In some
cases levels of exposures (e.g., sheep study
detailed below in the lung section) were
not clear, since some of the sources were
environmental (256). The reported ulcera-
tions in mice (254) exposed to zinc sulfate
stands alone and is difficult to interpret in
view oflack ofconfirming studies. It must
be recognized, however, that a potential ex-
ists for gastrointestinal toxicity from acci-
dental or intended intake oflarge amounts
ofzinc compounds.
Pancreas. NORMAL ROLE OF ZINC AND
EFFECTS OF DEFICIENCY. Zinc is a required
element for the normal exocrine and en-
docrine function of the pancreas. Its con-
centration in this tissue is many fold higher
than that of plasma, and in some species
pancreatic secretion into the gut may be an
important elimination route for this metal
(171,257). A key determinant of its accu-
mulation in this site appears to be the level
ofmetallothionein, the binding site for 70
to 80% of pancreatic zinc in the chick
(258). In rats 24 hr after injection ofa sin-
gle sc dose of zinc (20 mg Zn/kg as
ZnSO4), levels of the metal and of metal-
lothionein and its mRNA were higher in
the pancreas than in liver and kidney
(259). The increased expression of this
protein occurred in both endocrine and ex-
ocrine cells ofthis organ (260).
In the pancreas zinc is found in high-
est concentrations within the secretary
granules of islet ,8-cells, a distribution
pattern similar to that of numerous se-
cretory cells and neurons (110). Zinc in
these granules and vesicles is believed to
facilitate the stabilization of the struc-
ture of intravesicular proteins. In the
case of insulin, the crystalline precipitate
contains two zinc atoms within the hexa-
meric structure, bound to histidines in
each monomer, with an additional 10 to
12 zinc atoms more loosely associated
with the complex. Removal of zinc from
these sites by certain zinc-chelating
agents may explain their ability to cause
diabetes. Model studies with liposomes
indicate that the chelation of zinc pro-
duces acidification of intravesicular con-
tents and solubilization of insulin (261).
These phenomena lead to an increase in
vesicular osmotic pressure that results in
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rupture of vesicles, loss of insulin, and
possible damage to P-cells.
The glucose-stimulated secretion of in-
sulin is markedly decreased from in vitro
perfused pancreas of rats fed a zinc-defi-
cient diet; the degree of inhibition ap-
peared to increase with a greater degree of
zinc deficiency (1 ppm vs 5 ppm vs 30
ppm zinc in diet). The level of insulin
mRNA was unchanged, leading the authors
to speculate that either translation was im-
paired or more likely the degradation ofin-
sulin was enhanced (262). Another
possible explanation was an inhibition of
insulin release; Huber and Gershoff (263)
have reported a decrease in glucose-induced
insulin release from pancreatic slices of
zinc-deficient rats but no change in the
pancreatic content ofinsulin. A decrease in
plasma insulin levels in response to in-
traperitoneal injection of glucose has been
observed in obese rats fed a zinc-deficient
diet (<1 ppm); the degree of impairment
increased over the 8 weeks of the study
(264). No change, however, was reported in
lean animals of the same strain (LA/N-cp).
This importance of phenotype may explain
in part the fact that other investigators have
found a decrease or no change in glucose tol-
erance tests in zinc-deficient animals.
A markedly zinc-deficient diet in rats
has been shown to significantly reduce the
total pancreatic content of zinc within 2
days. This loss of zinc is associated with
more than a 50% decrease in the activity
of y-glutamyl hydrolase in pancreatic tis-
sue (265). Rapid loss in activity of pan-
creatic carboxypeptidase, a zinc
metalloenzyme, has been demonstrated
under similar conditions (266). It has
been suggested that the amount of apoen-
zyme is diminished (267), based on data
provided by Kirchgesser et al. (268).
Studies have not been reported on
whether the loss of activity results from a
decrease in the synthesis of the enzyme,
increased degradation or reduction in cat-
alytic activity due to perturbation in
structure or cofactor function associated
with insufficient zinc. In rats the decrease
in pancreatic activity ofY-glutamyl hydro-
lase is of physiological significance; hy-
drolysis of pteroylpolyglutamates in the
gut lumen is decreased and therefore the
absorption of monoglutamylfolate also is
decreased, since the pancreas is the source
ofthe enzyme. In man, this enzyme is as-
sociated with the intestinal brush border,
is a zinc-activated protein as well, and is
decreased in experimentally induced zinc
deficiency in humans (269)
EFFECT OF ZINC EXCESS. Changes in the
structure, biochemistry and function ofthe
pancreas have also been observed in ani-
mals and in man following increased intake
of zinc under experimental conditions or
inadvertent exposures. In a chronic study
in mice, Aughey et al. (270) administered
zinc sulfate in the drinking water (0.5 g
Zn/l) for 14 months. Plasma levels ofzinc
increased to a plateau about 1.5- to 2-fold
over controls within the first 30 days. Lev-
els ofzinc in liver, spleen and skin were un-
changed. The investigators concluded that
pancreatic islet cells in zinc-treated animals
were hypertrophied and contained an in-
creased number ofsecretary granules. Their
speculation as to mechanism was an in-
crease in pituitary release of GH and
ACTH, which could also explain the hy-
pertrophy observed in the adrenal cortex.
Their conclusions are difficult to confirm
from their paper based on subjective evalu-
ation ofhistology with no attempt at quan-
titation. Furthermore, no functional
consequences were found, in that insulin
and glucose levels in plasma were not dif-
ferent from controls. Only one concentra-
tion of zinc supplementation was tested.
No other literature has been found which
reports histological changes in islet cells in
zinc excess. Even diets containing 30,000
ppm of zinc sulfate fed for 13 weeks to
mice and rats did not reportedly alter the
morphology ofpancreatic islets and caused
no change in blood glucose levels (254).
The more frequently reported response
to marked elevation in zinc intake is an
increase in the serum levels of the pancre-
atic enzymes, amylase and lipase, and al-
terations in the histology of pancreatic
acinar cells. There are several studies in
humans which report an increase in serum
amylase. In patients with Wilson's disease
treated with zinc acetate (25-50 mg ele-
mental zinc 3 times a day chronically, or
200 mg 4 times a day for 10 days), serum
levels ofamylase and lipase increased with
a significantly greater response in the high
dose group (271). The values were normal
before the initiation of zinc therapy, in-
creased to slightly above normal after a
few weeks of therapy, and later stabilized
at the high normal range after 1 year of
zinc therapy. Very large doses ofzinc (800
mg/day) caused even greater elevation of
serum amylase and lipase. These changes,
however, were not associated with symp-
toms suggestive of pancreatitis such as
pain or diarrhea. The relevance of these
findings to subjects with normal copper
levels, i.e., without Wilson's disease in
which copper levels are elevated, is un-
clear. Copper deficiency which can be in-
duced by excess zinc is known by itself to
produce pancreatic atrophy with disorga-
nization ofacini (272).
Several case reports ofexcessive zinc in-
take in humans indicate possible effects on
the pancreas. In a patient who ingested 3
oz ofzinc chloride solution, serum zinc was
146 pg/dl and serum amylase and fasting
blood sugar were elevated to 183 and 221
mg/dl, respectively (251). The zinc solu-
tion had a corrosive effect on the pharynx
and esophagus, and the patient experienced
persistent nausea and vomiting. In another
patient ingestion of 12 g (150 mg/kg) ofel-
emental zinc over a 2-day period produced
an increase in serum lipase and amylase,
measured 8 days later; this patient did not
experience "gastrointestinal distress" (253).
An approximately 10-fold increased intake
ofzinc (estimated 25 mg zinc/l TPN solu-
tion as sulfate, dose not indicated) through
26 to 60 days of total parenteral nutrition
elevated serum zinc from 140 to 490 pg/dl
in seven patients and increased serum amy-
lase from the normal range of 130 to 310
to peaks of 557 to 1850 Klein units; re-
portedly, none of these patients exhibited
clinical signs of pancreatitis. It should be
noted that all ofthese patients had preexist-
ing gastrointestinal abnormalities which
necessitated TPN (10).
Studies ofthe effect ofexcessive zinc ex-
posure on exocrine function of the pan-
creas have been carried out in several
animal models. More detailed mechanistic
studies have been carried out in avian than
mammalian species. In the chick, a 7-fold
increment in the zinc content of a purified
diet to 500 mg/kg (500 ppm), added as
zinc oxide, resulted in an increase in
plasma and pancreatic zinc, to about 2 and
10 times that of control, respectively
(258). After 9 days, the pancreas appeared
firmer and paler with changes in acinar
structure, decreased zymogen granule den-
sity, some evidence of "periacinar fibrotic
infiltration," and no change in islet cells
(258). The plasma amylase activity rose
precipitously in the first day and then
dropped to a level which remained above
normal. The time-course of this drop re-
flected a substantial decrease in pancreatic
content of amylase to 20% of control on
day 2. Studies with radiolabeled leucine in-
dicated that this decline was associated
with a significant decrease in the rate of
synthesis ofamylase in the pancreas. Amy-
lase levels in the duodenal lumen were de-
creased, which was of functional
significance as indicated by the decreased
breakdown of starch in the large intestinal
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contents (273). Similar dose-response
curves were observed for decreases in pan-
creatic trypsinogen, chymotrypsinogen,
and lipase with detectable effects at the
lowest dose tested, 100 mg/kg. In contrast,
either no change or an increase was ob-
served in pancreatic content of procar-
boxypeptidase A and B and RNase. The
authors noted that only the latter are zinc-
containing enzymes, and that zinc may dif-
ferentially influence various steps of gene
expression for these proteins (258).
With respect to the environmental sig-
nificance ofthese zinc exposures, it is criti-
cal to note that in chicks fed a purified diet
(based on corn and soybean meal) de-
creases in the three pancreatic enzymes
tested were observed only with the highest
dose, 2000 mg/kg. The level of effect was
about equivalent to that of the 100 mg/kg
zinc dose administered in a purified diet
(273). Zinc is therefore about 20-fold less
potent in altering pancreatic enzymes when
administered in a nonpurified diet and
must be fed in extremely high doses. The
basis for this difference is not known, but it
illustrates the important influence of di-
etary compostion on dose-response rela-
tionships for this metal.
More extensive studies on histological
changes in the pancreas following zinc
exposure have recently been reported by
Kazacos and Van Vleet (274). Their ex-
periments entailed feeding 2500 ppm
zinc (as ZnSO4.H20) to male ducklings
from 1 to 56 days of age. This level of
zinc reduced food intake, so a control
group on a restricted diet was included.
Histological analysis was carried out
every 2 to 7 days. Altered acinar cell
structure was evident after 3 days of zinc
supplementation. The major early change
appeared to be the development of cyto-
plasmic vacuoles containing zymogenlike
material, altered mitochondria, intracis-
ternal sequestration of rough endoplas-
mic reticulum, autophagocytosis, and
apoptosis as the major form ofacinar cell
death. With time, atrophy of the pan-
creas occurred primarily because of de-
creased number and size of acinar cells.
Ductlike structures appeared which the
authors suggested may develop from "at-
rophic, dedifferentiated" acinar cells.
Several hypotheses as to the mechanism
of this effect were presented including
zinc-induced copper deficiency, and ex-
cessive pancreatic stimulation through
zinc-induced cholecystokinin or gluco-
corticoid release, all of which have been
observed to produce similar histological
changes in the pancreas.
The histological changes observed in
the pancreas of avian species following ex-
cess zinc exposure have been observed in
mammals as well. In mice and rats changes
in acinar cells of the pancreas were only
found after 13 weeks offeeding diets sup-
plemented with 30,000 ppm of ZnSO4
(25). The report implies but does not ex-
plicity state that the 10- and 100-fold
lower levels of zinc supplementation did
not alter pancreatic morphology. At the
highest dose (30,000 ppm), the changes in-
cluded degeneration and necrosis of acinar
cells, ductlike metaplasia and in rats inter-
stitial fibrosis. There were no reports of
physiological changes associated with this
effect, i.e., no diarrhea, and no reference to
islet cell abnormality. At the highest dose
blood glucose levels were decreased in mice
but not in rats. At this high-dose food in-
take was also decreased in all groups; the
magnitude and time dependence was
species and sex dependent. Body weight
was decreased in males ofboth species and
in female mice. There were no food-de-
prived controls in this study. The basal
content of zinc in the diet, a pulverized
chow, was not reported. The daily intake
ofthis highest dose was about 2-fold higher
in mice than in rats, consistent with the de-
gree of effect, and about equivalent to 3.9
and 1.5 g Zn/kg/day, respectively. These
doses are more than a 100-fold higher than
the usual intake ofzinc from a normal nat-
ural product diet.
In a very limited study in sheep (256),
high doses ofzinc sulfate, 2 g zinc/day for
13 days by intubation in solution or 0.8 g
zinc/day for 12 days incorporated into the
diet (2000 ppm), produced more than a
10-fold increase in the pancreatic content
of zinc. On gross inspection the pancreas
was altered in color. Histology revealed
changes in acinar cell structure including
decrease in basophilia, vacuolization of the
cytoplasm, some necrosis, as well as evi-
dence of neutrophil infiltration and inter-
stitial fibrosis. Atrophy and necrosis of
pancreatic acinar tissue was also observed
following high doses of zinc fed to veal
calves (706 pg/g milk replacer) for 1 month
(275).
Cats (3.5 kg) fed 0.25 to 0.5 g of zinc
oxide per day for 12 to 16 weeks accumu-
lated up to 480 jig/g zinc in the pancreas,
about seven times normal control values
(276). Pancreaticweight dropped, total in-
sulin content remained the same and no
changes were observed in islet cells. How-
ever, there were marked changes in histol-
ogy including fibrotic tissue replacing and
surrounding acinar cells. These findings
were consistent with results from earlier
studies by Drinker et al. (277) in three cats
receiving the highest doses, 680 to 1000
mg zinc oxide per day for 13 weeks. No
pancreatic changes were found in this study
in other cats or in dogs on slightly lower
doses.
Only limited studies have been carried
out in mammalian models to investigate
the mechanism ofincreased serum amylase
and lipase. One report indicates that zinc
stimulated the release ofamylase from iso-
lated rat pancreatic acini (278). The effect
of only one concentration of zinc was re-
ported; this study focused primarily on the
mechanism of copper-induced amylase re-
lease. Astudy in dogs indicated that the in-
crease in pancreatic output of protein
following intraduodenal administration of
zinc sulfate may be mediated in part
through stimulation ofcholecystokinin re-
lease (279)
It should be noted that levels ofanother
serum enzyme, alkaline phosphatase, also
change with zinc status, decreasing in zinc
deficiency and increasing with zinc*replen-
ishment or excess in both human and ani-
mal studies (3,175,187,280). A decrease in
the activity of serum alkaline phosphatase
with the induction of zinc deficiency and
its reversibility to normal levels following
zinc supplementation have been observed
in otherwise normal human subjects (175).
In zinc-deficient subjects reported from the
Middle East (3), serum alkaline phos-
phatase was observed to increase severalfold
following supplementation with zinc. A
consensus sequence for the transcription
factor Spl, which contains several zinc fin-
gers, has been found in the promoter re-
gion of the gene coding for the intestinal
form of serum alkaline phosphatase (281).
It is thus possible that the promoter region
of other alkaline phosphatase isoenzymes
also contains a sequence or metal-respon-
sive element similar to genes ofother met-
alloproteins such as metallothionein (282).
It is, therefore, probable that zinc induc-
tion ofserum alkaline phosphatase is a con-
tinuum in that zinc deficiency produces
below normal values, whereas zinc supple-
mentation produces higher than normal
levels. The major organ source, characteri-
zation ofthe isozymes affected by zinc sta-
tus, and the mechanism ofthis effect have,
however, not been determined.
In summary, zinc is required for normal
function of the pancreas, in part through
its critical role in enzymes like 7-glutamyl
hydrolase and carboxypeptidase, and also
in the stabilization ofinsulin. Studies in ex-
perimental animals indicate that zinc inges-
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tion of a 100- to a 1000-fold above normal
may produce degenerative abnormalities in
acinar cells with release of pancreatic en-
zymes into plasma. Clinical case reports fol-
lowing overdoses also suggest that marked
increases in zinc intake may elevate plasma
amylase and lipase. The mechanisms of
these effects have not been definitively es-
tablished.
Liver. There is limited reference to al-
tered structure or function of the liver in
the literature on zinc deficiency and zinc
excess. Studies in mice and rats fed diets
supplemented with 30,000 ppm zinc sul-
fate (more than a 1000-fold in excess ofthe
normal dietary intake) did not reveal
changes in the histology of the liver or
changes in the liver weight to body weight
ratio after 13 weeks (254). Plasma GOT
and GPT were not increased, indicating
that zinc did not produce plasma mem-
brane damage in the liver. In a study with
chicks fed zinc oxide (500 or 1000 mg/kg
purified diet containing a basal zinc level of
70 mg/kg), no significant change in PGPT
was found after 14 days; PGOT was signif-
icantly elevated in a dose-dependent man-
ner with a 33.3% elevation at the highest
dose which the authors considered of
doubtful physiological significance (273).
Limited study has been conducted on
effects of zinc on the activity of intracellu-
lar hepatic enzymes. Zinc deficiency in rats
impairs the biotransformation of certain
pharmacologic agents (283). In a clinical
study a significant correlation was observed
between the degree of zinc deficiency (as
assessed by leukocyte zinc content) and re-
duction ofthe total plasma clearance ofan-
tipyrine in subjects with hepatic cirrhosis
(284). Other investigators have demon-
strated a correlation between leukocyte zinc
content and degree of impaired "hepatic
functional reserve" as assessed by biochemi-
cal indices and clinical symptoms (285).
Whether zinc deficiency per se contributes
to impaired hepatic biotransformation of
xenobiotics is unclear.
An increase in zinc exposure has been
reported to enhance biotransformation me-
diated by hepatic mixed-function oxidases.
Specifically, Kadiiska et al. (286) found
that zinc sulfate (100 mg/kg/day for 30
days via the drinking water) decreased
hexobarbital-induced sleeping time in rats.
An increase in hepatic level of cytochrome
P450 was found in association with an in-
crease in the activity ofALA synthetase and
decrease in heme oxygenase. The activity of
several cytochrome P450 enzymes was in-
creased. The zinc content in the animals
was not determined and only one level of
zinc exposure was examined. In contrast,
Cho et al. (287) have reported that the he-
patic concentration ofcytochrome P450 was
decreased in a dose-dependent manner by
zinc (20 and 40 mg/kg once each day for 5
days by gastric intubation). In vitro studies
have demonstrated that addition of zinc
(17) (70 pM) to hepatic microsomes im-
paired NADPH-dependent monooxyge-
nase activity (288,289).
Limited studies have also suggested that
zinc status influences the hepatic activity of
glutathione S-transferases. Zinc deficiency
in rats is reported to decrease the activity of
this enzyme system in the liver (290). A
single dose ofzinc in mice (30 mg/kg sc, as
ZnSO4) was reported to significantly in-
crease the hepatic activity 5 hr later (291).
No change in glutathione levels were ob-
served. Parenthetically, Seagrave et al.
(292) have shown that in vitro exposure to
100 pM zinc chloride in certain cells such
as the Chinese hamster ovary (CHO) cell
line increases glutathione levels and possi-
bly increases glutathione S-transferase ac-
tivity. The authors speculate that these
reponses may play a role in the ability of
zinc to protect against the cytotoxic effect
ofthe alkylating agent melphalan in certain
cell lines. In none ofthese studies have the
individual isozymes ofglutathione S-trans-
ferase been examined.
Administration of zinc in animal mod-
els has also been shown to increase the syn-
thesis of metallothionein in the liver. In
rats, for example, a single ip injection of a
high dose of zinc chloride (10 mg Zn/kg)
produced about a 5-fold increase in metal-
lothionein concentration in the liver within
24 hr (293).
In 13 subjects treated with 600 mg zinc
sulfate per day for 18 weeks, no significant
changes were observed in liver-function
tests measured every 6 weeks; the nature of
the tests was not specified in the publica-
tion (294).
In summary, animal and clinical studies
indicate that increased intake of zinc, even
in extremely high doses, is not likely to be
hepatotoxic. Data on the effect ofincreased
zinc exposure on the activity ofenzyme sys-
tems such as the cytochrome P450s are con-
flicting and require further investigation.
Kidney. As with the liver, there is lim-
ited reference to the kidney in the literature
on zinc deficiency and zinc excess. Zinc
status is known to influence the expression
of metallothionein in the kidney (293).
Studies ofthis phenomenon have dealt pri-
marily with the role of zinc status on the
mechanism and magnitude of renal injury
from cadmium. In the clinical study re-
ferred to above (294), in which subjects re-
ceived 600 mg zinc sulfate per day, urinaly-
ses were carried out and the authors only
imply that no abnormalities were observed.
Studies in animals have been limited. A
small study using ferrets indicated that a diet
containing 18-fold higher levels ofzinc than
normal (500 ppm, added as zinc oxide to
"tinned dog food") fed for 48 to 191 days to
three animals produced no changes in renal
histology, serum urea nitrogen, or urinalysis
(Boehringer-Mannheim Combur eight test
strips) (255). Higher levels ofsupplementa-
tion in seven animals (54- and 108-fold
above normal) produced evidence of "dif-
fuse nephrosis" (evidence not provided)
and abnormalities in urinalyses. The ferrets
had marked anorexia, decrease in body
weight, and pronounced anemia with sig-
nificant intestinal hemorrhages. In three
sheep, 2 g of zinc per day for 13 days (as
zinc sulfate intubated in drinking water)
produced a 16-fold increase in kidney zinc
but no change in renal histology (256). In
two sheep fed 0.8 g per day for 12 days and
then 1.2 g for 44 or 72 days (about 2000
ppm zinc), renal zinc increased 14-fold and
a variety of abnormalites were observed. In
mice fed 30,000 ppm zinc for 13 weeks,
"regressive changes ofthe renal cortex" and
an increase in kidney weight was observed
in females (254). No changes in renal his-
tology were observed in male mice or male
or female rats treated with these levels of
zinc or in animals fed one-tenth or one-
hundredth these amounts. Blood urea ni-
trogen was unaltered in all groups at all
levels ofzinc.
In summary, unlike numerous nones-
sential metals, excess zinc exposure appears
not to cause significant nephrotoxicity ex-
cept with extremely high doses ingested by
experimental animals.
Cardiovascular System. CARDIOVAS-
CULAR FUNCTION. The literature on zinc
administration in humans, in doses above
dietary requirements, suggests that zinc
does not produce major changes in the
function of the cardiovascular system. Re-
ports of cases of acute overdoses do not
refer to alterations in blood pressure or car-
diac function. Detailed clinical studies ad-
dressing this issue are very limited.
Two recent prospective studies tested the
effects of zinc on cardiovascular function in
humans. One double-blind prospective
study involved 24-week administration of
placebo or zinc (220 mg ZnSO4 orally 3
times a day) (296). Subjects (14 placebo, 16
zinc) were institutionalized, over 65 years of
age and had senile dementia due to athero-
sclerosis. Blood pressure and heart rate were
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measured weekly, and EKGs performed at 0,
12, and 24 weeks. Zinc treatment increased
plasma zinc from 84 pg/dl to 124 pg/dl by 2
weeks with a plateau after 4 weeks at about
150 pg/dl. No significant changes were de-
tected in pulse rate, blood pressure, or EKG
characteristics (or in hematologic or chemical
evaluation ofblood samples).
A second prospective study examined
the effect of zinc (30 mg/day of ZnSO4
orally for 4 days followed by 600 mg/day
for 4 days more) on plasma renin actvity,
serum aldosterone, and diastolic and sys-
tolic blood pressure in normal subjects
(297). Zinc treatment produced a dose-de-
pendent rise in plasma renin and aldos-
terone but no significant changes in blood
pressure, or plasma and urinary sodium
and potassium. No tests of cardiac perfor-
mance were included in this study. The
data from this study are compromised be-
cause there were no placebo controls and
only six subjects.
In a retrospective study from Dunedin,
New Zealand of69 noninstitutionalized el-
derly subjects taking zinc supplements for
at least 1 year (20 to 150 mg/day), there
was no evidence that increased zinc intake
was associated with changes in the electro-
cardiogram or frequency of cardiovascular
disease based on questionnaire responses
(heart failure, heart attack, angina, claudi-
cation, hypertension, medication use)
(295). Among the deficiencies ofthis study
are a lack of verfication of reported zinc
supplementation, lack of information on
dietary zinc content, concomitant intake of
vitamins not matched in controls, and lack
ofdata on other cardiovascular risk factors
such as level ofexercise.
Analysis of data from the National
Health and Nutrition Examination Survey
II (NHANES II) has indicated that serum
zinc is inversely correlated with diastolic
and systolic blood pressure in both men
and women (298). This observation was
revealed through use ofa multiple stepwise
regression model, which adjusted blood
pressure values for known covariables (age,
race, body mass index). The range ofserum
zinc levels in this data base was not stated
in the report, which primarily focussed on
the hypertensive effects oflead.
Several recent studies have examined
the effect ofzinc on components ofthe car-
diovascular system under in vitro condi-
tions. Unlike other metals tested, zinc
chloride, even at cumulative concentrations
above 83 PM, did not change the tension
of vascular smooth muscle in vitro (en-
dothelium-free ring of ventral aorta from
the dogfish shark) (299). In physiologically
relevant concentrations (IC50 of 9-35 pM
but without protein in buffer) zinc has
been shown in vitro to selectively inhibit
the binding of platelet activating factor
(PAF) to human platelet membranes and
inhibit PAF-induced platelet secretion and
aggregation (300). Inhibition of aggrega-
tion by other stimulants such as collagen
and thrombin has been demonstrated with
platelets from dog and rabbit, respectively.
Whether zinc may attenuate thrombus for-
mation in vivo, or modify other effects of
PAF related to ovulation, implantation,
parturition or inflammation is not known.
A study with the isolated rat heart
preparation indicates several effects ofzinc,
administered in the perfusate as the histi-
dine complex (301). Decreases in cardiac
rate, contractile force, and peak systolic
pressure were observed; for each ofthese ef-
fects there was a significant dependence on
zinc concentration (12.5 pM in 2-fold in-
crements to 400 pM). Inspection of the
data suggests that for each of these end
points the maximum effect was achieved
with 100 pM zinc. Coronary flow was un-
altered. Negative inotropy and chronotropy
have been reported by other investigators
using isolated cardiac preparations exposed
to 1 to 5000 pM zinc (302,303). In the
study by Powell et al. (301) zinc was also
found to protect the heart during regional
ischemia as indicated by a decrease in ven-
tricular fibrillation during reperfusion and
a decrease in release of lactic dehydroge-
nase. The authors argue, not too convinc-
ingly, that the antiarrythmic effect of zinc
cannot be fully explained by the negative
inotropy and chronotropy (which decreases
myocardial oxygen demand and therefore
the degree ofinjury during coronary occlu-
sion) and suggest that zinc may inhibit free
radical formation during ischemia. They
noted the work of others, indicating that
zinc protects against catecholamine-in-
duced cardiotoxicity (304,305).
SERUM LIPIDS. There is evidence that
serum lipid concentrations can be altered
by both deficient and excess intake ofzinc.
Prasad (306) observed that total serum
cholesterol decreased following experimen-
tally induced zinc deficiency in two human
volunteers. To investigate the mechanisms
underlying impaired intestinal absorption
of lipids in zinc deficiency, Koo et al.
(307) measured the apo-B content and
chemical composition of chylomicrons for
marginally zinc-deficient rats fed 2.8 ppm
of dietary zinc, and the results were com-
pared with those for pair-fed and ad libi-
tum-fed control rats. The authors
concluded that the intestinal synthesis of
apo-B, essential for chylomicron forma-
tion, may be impaired in zinc deficient rats
which may account for the impaired in-
testinal absorption oflipids.
High levels ofzinc ingestion by rats are
associated with an increase in serum choles-
terol (195). Most studies suggest that this
effect is due to copper deficiency which
may be induced by excess zinc intake
(308,313).
Alterations in serum lipids with in-
creased oral intake ofzinc in humans have
been reported, but the results are not con-
sistent. Black et al. (314) conducted a
placebo-controlled trial with dietary restric-
tions and record keeping. They observed a
significant decrease in HDL cholesterol in
young men (19 to 29 years old) after 12
weeks of daily supplementation with 50
mg zinc (as the gluconate). A decrease in
HDL cholesterol occurred at 6 and 12
weeks in men receiving a slightly higher
dose, 75 mg zinc per day. These decreases
were based on comparisons to both a
placebo group and baseline values for each
subject. It should be noted, however, that
the magnitude of this effect was small; the
mean (± SE) values of HDL cholesterol at
week 12 in the 50- and 75-mg groups,
1.38 ± 0.05 and 1.39 ± 0.08 mM, were
similar to the baseline value in the placebo
group, 1.44 ± 0.09, and higher than the
placebo group at week 8, 1.31 ± 0.07. Fur-
thermore, in the 75-mg group although a
decrease was observed at 6 and 12 weeks,
no difference from placebo was found at
the 8- and 10-week samplings. No signifi-
cant changes in other lipid parameters, i.e.,
serum triglycerides or total, LDL, VLDL
cholesterol, occurred in the zinc-supple-
mented group. Freeland-Graves et al.
(315) observed only transient changes in
HDL cholesterol when she supplemented
women with 100 mg ofelemental zinc per
day.
Hooper et al. (11) administered higher
doses, 160 mg per day ofelemental zinc as
sulfate, to 12 healthy adult men for 35 days
and observed a decrease in HDL choles-
terol (from 40.5 mg/dl to 33.5 mg/dl, p <
0.001); total serum cholesterol showed no
change. These results were not observed in
a subsequent study by Samman and
Roberts (215) using a double-blind
crossover design. They studied the effect of
zinc supplementation (150 mg zinc per day
for 6 weeks) on plasma lipoproteins and
copper status in 26 healthy young females,
mean age 27 years, and 21 males, mean age
28 years. Plasma was analyzed only at the
beginning and end of the 6-week trials so
no time-dependent trend can be assessed
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from the study. Plasma zinc increased sig-
nificantly in both groups, as expected, with
a greater rise in females. Plasma total and
HDL cholesterol remained unchanged in
both sexes. In females the mean LDL cho-
lesterol decreased significantly (9%), thus
decreasing a major risk factor for cardiovas-
cular heart disease. There was a trend for
total HDL cholesterol to be redistributed
in that HDL2 increased and HDL3 fell
slightly in the females. Zinc supplementa-
tion altered copper status in females, but
not in males, as described earlier in this
text. Inasmuch as the females were lighter
than the males but received the same dose
ofzinc, a dose-response effect rather than a
sex difference could not be ruled out.
In a study with even higher doses, 300
mg zinc per day for 6 weeks in 11 healthy
men, an increase in LDL cholesterol and a
decrease in HDL cholesterol were ob-
served, although triglyceride and total cho-
lesterol concentrations did not vary
significantly (12); this study lacked a
placebo control.
Laitinen et al. (316) studied the associ-
ation between serum lipids (total choles-
terol, LDL cholesterol, HDL cholesterol,
and triglycerides) and levels of serum zinc,
serum copper, and their ratio in 3373 sub-
jects (3-, 6-, 9-, 12-, 15-, and 18-year-old
Finnish girls and boys). Serum zinc was
positively related to total cholesterol, HDL
cholesterol, and LDL cholesterol, whereas
serum copper related negatively to HDL
cholesterol. The results ofthis study, how-
ever, suggested only a weak relationship be-
tween serum lipids and serum levels ofzinc
and copper.
Shah et al. (317) conducted a con-
trolled study in order to evaluate the effect
ofzinc supplementation on serum lipids in
patients with ischemic heart disease. Ten
stabilized patients were given 200 mg of
zinc sulfate orally three times a day for 1
month. Ten other subjects received
placebo. The zinc-supplemented group
showed a significant decrease in serum cho-
lesterol P-lipoproteins, a significant increase
in a-lipoproteins, and no change in triglyc-
erides. Control subjects on placebo showed
no significant changes in any of the above
parameters. Inasmuch as serum ax-lipopro-
teins have a protective effect against athero-
sclerosis and serum lP-lipoproteins denote a
risk factor for cardiovascular heart disease,
these studies show a beneficial effect ofzinc
supplementation in patients with ischemic
heart disease.
Goodwin et al. (318) investigated the
relationship between zinc intake, physical
activity, and blood levels of HDL choles-
terol in a healthy elderly population. These
investigators observed that physical activity
was positively associated with HDL choles-
terol only for those subjects who were not
taking supplemental zinc. In those subjects
who were taking supplemental zinc (29.1 ±
11.8 mg/day), the effect of exercise on
HDL cholesterol was not observed. The
same group of investigators completed an
experimental trial of zinc supplementation
(50 mg of zinc/day for 8 weeks) in young
trained runners and found no change in
HDL cholesterol. It is not clear as to why
there is a difference between the elderly
and the younger subjects. It should also be
pointed out that although a significant in-
teraction between zinc intake and physical
activity with respect to the effects upon
HDL cholesterol was observed by using
multiple regression analysis, the level of
correlation was low, and it is not clear if
these effects are physiologically relevant to
the development ofcardiovascular disease.
Brewer et al. (319) have recently re-
ported the effect of zinc administration
(50 mg of elemental zinc as acetate three
times per day) on lipid profiles in 24 sub-
jects (11 females and 13 males) with Wil-
son's disease. In male patients receiving
zinc for an average ofalmost 2 years, both
total cholesterol level and HDL choles-
terol were significantly reduced by zinc.
The reduction in HDL cholesterol was
proportionally a little greater than total
cholesterol, resulting in a slight increase in
average cholesterol to HDL cholesterol
ratio from 3.9 to 4.6. This change was,
however, not significant statistically. In fe-
males, this ratio changed from 4.36 to
3.83 following zinc treatment for almost 2
years. As interpreted by the authors (based
primarily on the Framingham cardiovas-
cular studies), a ratio of total cholesterol
to HDL cholesterol of 5.0 will give a
coronary heart disease risk factor of 1.0,
i.e., an average risk for developing coro-
nary heart disease within 4 years. Thus,
the coronary heart disease risk factor was
not changed significantly by zinc therapy
in either sex and, further, it remained
below average in these patients after zinc
therapy for almost 2 years. The authors
have concluded that zinc therapy in Wil-
son's disease is not atherogenic (319).
In the Dunedin, New Zealand,
study (referred to earlier) elderly sub-
jects who consumed zinc supplements
(20 to 150 mg/day for more than 1
year) did not differ from controls in
laboratory. values commonly associated
with cardiovascular disease including
total cholesterol and triglycerides
(295). Thus, none of the indices exam-
ined provided any association of
increased risk of developing cardio-
vascular disease in participants who reg-
ularly took zinc supplements.
Kok et al. (320) performed a case-con-
trol analysis of data obtained in a Dutch
prospective follow-up study in order to in-
vestigate the association of serum copper
and zinc with mortality from cancer and
cardiovascular disease. Cancer (n = 64) and
cardiovascular disease (n = 62) deaths and
their matched controls were taken from a
cohort of 10,532 persons examined during
1975 to 1978. Trace elements were assayed
in baseline serum samples which had been
stored during the 6 to 9 years offollow up.
The adjusted risk ofdeath from cancer and
cardiovascular disease was 4 times higher
for subjects in the highest serum copper
quintile (serum copper >143 mg/dl) com-
pared with those with normal levels. An ex-
cess mortality was also observed in subjects
with low copper status, suggesting a U-
shaped relationship. A protective effect of
high zinc status on the risk of cancer and
cardiovascular disease was compatible with
their data (320).
Nervous System. DISTRIBUTION AND
FUNCTION OF ZINC IN THE BRAIN. A com-
prehensive review of the neurobiology of
zinc has recently been published by Freder-
ickson (110). The following information
concerning metabolism ofzinc in the brain
is from Frederickson's review, unless indi-
cated otherwise.
The zinc content ofbrain tissue is about
13 to 17 pg/g of tissue water. The zinc
content of gray matter on a dry weight
basis is about 2.5 times the level in white
matter because of the high fat content of
white matter. The zinc content of gray
matter from all regions of the brain is
about 50 to 80 pg/g with slightly higher
levels in the hippocampus.
In the brain, in addition to its general
functions as an 'essential component of
more than 50 functionally diverse metal-
loenzymes, and in the structure of macro-
molecules including DNA and RNA, zinc
appears involved in neurotransmission, the
formation ofmicrotubules, and is bound to
hormones such as insulin and 7-S-nerve
growth factor.
Intracellular zinc content is maintained
within a fairly narrow range in spite of in-
creases or decreases in extracellular zinc.
The mechanism of zinc uptake by brain is
incompletely understood. Ultrafilterable
zinc in plasma rapidly enters the cere-
brospinal fluid where its concentration is
similar to that of plasma (10 pg/l). Under
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usual conditions zinc in spinal fluid is
slowly taken up by brain cells against a
concentration gradient and bound to pro-
teins in the subcellular fractions. In rats the
half-time for whole brain zinc turnover is
about 22 days, and the zinc content of
most brain regions is little affected by zinc
deficiency (321,322). Exceptions are seen
in the hippocampal neuropil, a region
where zinc is concentrated in mossy fiber
boutons and olfactory bulbs (322). In liver
disease, a condition that can cause substan-
tial losses of zinc (323), decrements in
brain zinc may be substantial.
Certain neurons "sequester histochemi-
cally reactive zinc in their axonal boutons"
(110). For example, granular cells of the
hippocampus are considered "zinc neu-
rons" because their stimulation by im-
planted electrodes causes zinc to
accumulate in regions they innervate. This
accumulation ofzinc is greater in older rats
than young rats with incompletely devel-
oped mossy fiber systems. In addition,
mossy fiber boutons have lower stainable
zinc after electrophysiological activity. The
release of zinc from mossy fiber boutons
appears to occur by exocytosis of zinc-rich
vesicles. Mapping studies suggest that "vir-
tually all of the major zinc-containing sys-
tems of the brain are of limbic or
cerebrocortical origin." Zinc neurons have
also been identified in the thalamus, brain
stem and spinal cord. Though no neuroac-
tive substance has been identified uniquely
in association with zinc-containing neu-
rons, studies ofreceptors suggest that zinc-
containing neurons are a subclass of
glutamate-aspartate neurons (110).
The functions ofzinc in nerve terminals
are unclear (110). One putative function is
stabilization of secretary macromolecules.
Its stabilization ofthe hormones insulin, 7-
S-nerve growth factor, histamine-heparin,
and thymulin is consistent with such a
function. Another proposed function is
modulation ofsynaptic receptors. Research
on this hypothesis has produced mixed re-
sults. Zinc-deficient rats displayed lower
hippocampal electrophysiological responses
to stimuli (324). In vitro studies found in-
hibition ofthe uptake ofamino acid neuro-
transmitters and increased uptake of
monoamines by brain tissue. Low (10 pM
or less) and high (100 pM or more) con-
centrations ofzinc inhibited receptor bind-
ing ofcertain amino acids. In other studies
the activity ofglutamate decarboxylase was
inhibited by zinc, resulting in a decrease in
GABA.
IMPORTANCE OF ZINC TO BRAIN DEVEL-
OPMENT AND FUNCTION: ANIMAL STUDIES.
The essentiality of zinc for growth of rats
was described in the mid 1930s
(325-327). In vivo evidence of the essen-
tiality of zinc for maturation of the brain
was provided by studies in chicks
(328,329) and rats (330,331), which
demonstrated a variety ofmalformations in
brains of offspring that had been deprived
of zinc early in gestation. Inhibition of
DNA synthesis in neural crest cells is be-
lieved to be one ofthe causes ofthe malfor-
mations (332). In humans some studies
have shown an association between low
maternal plasma zinc in early gestation and
neural tube defects in infants (333).
Further evidence of the essentiality of
zinc for development of the brain was
found through studies of zinc-deprived
suckling rats. Incorporation of thymidine
into DNA was suppressed in 10-day-old
sucklings (334). Histologic examination of
the cerebellum on the 21st postnatal day
found retarded maturation (335) and im-
paired division and migration of external
granular cell neurons (336,337). In addi-
tion the arborization of Purkinje, stellate
and basket cell dendrites was decreased and
morphologically grossly abnormal; the
number ofboutons was decreased and their
shapes were strikingly abnormal
(336,337). Presumably similar abnormali-
ties occur in other regions of the brain
when zinc is deficient during the critical
time ofmaturation.
The long-term functional significance
ofzinc deficiency in the fetus and neonate
was studied in rats deprived ofzinc during
late gestation and/or suckling. Severe ma-
ternal zinc deprivation (<1 ppm Zn in the
diet) from days 14 through 20 ofgestation
caused stunting and a decrease in brain
cell number in fetuses (338). Active avoid-
ance of shock was impaired in nutrition-
ally rehabilitated male offspring while
littermate females performed as well as the
controls (339). When compared to con-
trols, rehabilitated offspring also showed
an increased aggressive response to shock
that was most evident in females
(340,341).
Severe maternal zinc deprivation
throughout nursing impaired growth of
suckling pups and subsequently increased
errors by nutritionally rehabilitated off-
spring on a relatively simple maze (342).
Food motivation of previously zinc-de-
prived offspring was increased compared
to ad libitum controls, but was less than
that offood-restricted controls (343). Ref-
erence or long-term memory, 40 days after
exposure to shock on days 18, 19, 20, and
21 of nursing, was also impaired (344).
Adult nutritionally rehabilitated offspring
also displayed impaired working memory
ofa 17-arm radial maze (345).
Experiments in mildly zinc-deprived
dams fed 10 ppm Zn throughout preg-
nancy and lactation, a level of intake that
did rot appear to impair pregnancy or lac-
tation and had only a small effect on
growth ofpups, found deficits in working
memory ofa 17-arm radial maze when the
offspring had been nutritionally rehabili-
tated and were 300 days of age (346).
These findings indicate the rat brain is
highly susceptible to injury from zinc defi-
ciency during its critical period ofdevelop-
ment, and that sequelae from the injury
include persistent abnormalities in behav-
ioral function.
Severe zinc deprivation in weanling rats
caused higher brain levels of cate-
cholamines, copper and manganese than
were present in pair-fed control rats
(321,322,347). The concentration ofzinc
was decreased in the olfactory bulb. Zinc
deprivation caused anorexia and cyclic pat-
tern of feeding. Food intake was inversely
related to the level of plasma zinc but not
to plasma amino acids, glucose, and fatty
acids (348). Brain tryptophan, tyrosine
(349), and serotonin (350) were increased
compared to pair-fed control animals.
Findings in chronically zinc-deprived
rats suggest that electrophysiological func-
tion is impaired. Responses recorded from
the mossy fiber region ofthe hippocampus
by electrodes were abnormal (324). Be-
havioral functions were also impaired
(351,352). Further evidence of the essen-
tiality of zinc for hippocampal function
was provided from acute zinc depletion
studies in which the zinc was removed by
perfusion of the hippocampus with zinc
binding chelators (DDC, Na2S) (110).
Immediate transitory impairment of spa-
tial memory function was produced. Func-
tion returned with clearance of the
chelator and precipitated zinc.
Research on a small number ofnonhu-
man primates (rhesus) has shown that se-
vere maternal zinc deprivation (<1 ppm
dietary zinc) throughout most ofthe third
trimester caused acrodermatitis in the dam
and a subsequent reduction ofexploration
and play in infants during weaning (353).
Later study of these animals found im-
paired ability to solve complex learning
sets at 300 and 700 days, but not at 1000
days (354). In other studies rhesus dams
fed about 4 ppm zinc throughout gesta-
tion and lactation displayed acrodermati-
tis, while their infants displayed abnormal
behaviors (355).
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IMPORTANCE OF ZINC TO BRAIN DEVEL-
OPMENT AND FUNCTION: HUMAN STUDIES.
In humans, evidence that zinc deficiency
can impair brain function is limited. The
most compelling evidence was provided by
an experimental depletion study in which
severe deficiency was induced by treating
the subjects with large amounts of histi-
dine, a potent chelator ofzinc (1). Follow-
ing massive zincuria, the subjects displayed
ataxia, dysgeusia, dysosmia, nyctalopia, and
disturbed mentation. Zinc repletion re-
stored function.
Effects of mild zinc deficiency are less
clear. A small study (356) of nine men
who were fed about 3.5 mg zinc daily
found an inverse relationship between ac-
curacy of backward recall of digits and
plasma zinc. Retention ofzinc measured by
balance technique was inversely related to
accuracy and speed of immediate recall of
verbal and visual information. These latter
findings disappeared during the repletion
ofzinc nutriture.
Further evidence that mild zinc deple-
tion can affect cognitive function was pro-
vided by two studies that were presented at
the 1991 meeting ofthe American Institute
of Nutrition. Fourteen men fed low zinc
diets displayed evidence of impaired func-
tion (7). The men were housed under
well-controlled conditions for 7 months
and fed diets that provided 1, 2, 3, 4, or 10
mg Zn daily, in random order, for intervals
of 35 days. Significant (p< 0.05) decreases
in function were found in two sensory-
motor tasks (pursuit and trials), two atten-
tion tasks (orienting and misdirection),
three perceptual tasks (search, time esti-
mate, and Sternberg), two memory tasks
(shape and cube recognition), and one spa-
tial task (maze). Abnormalities were evi-
dent at all levels of zinc deprivation,
although there were no decreases in plasma
or leukocyte zinc (DB Milne, personal
communication, 1991).
Supportive of the above findings were
results ofa study ofpremenopausal women,
aged 19 to 40 years (357,358). An 8-week
randomized controlled trial ofzinc treatment
(30 mg daily with a vitamin-mineral mix-
ture that was based on NRC guidelines)
found that zinc-treated women (n=11) dis-
played increases over baseline in scores on
tests of short-term recall of visual images
(17.5%, p< 0.004) and word pairs (11.4%,
p< 0.07), while women given vitamins and
minerals alone (n= 6) showed little or no
change in scores on these tests (part of the
Wechsler Memory Scale No.1 and 2).
The relation ofzinc nutriture to seizure
disorders, senile dementia, anorexia ner-
vosa, schizophrenia and other neurological
conditions is unclear (110). Clinical find-
ings do not distinguish whether low levels
of serum zinc or brain zinc reported are
primary, or secondary to complications of
the condition. Appropriately designed, ran-
domized, controlled zinc treatment trials
have not been reported.
NEUROLOGICAL FUNCTION AND EXCESS
ZINC. Clinical evidence suggests that neu-
rological abnormalities do not typically
occur in animals or humans exposed to
higher than usual levels ofzinc in air, water
or food. For example, neurological phe-
nomena, other than headache, are not con-
sidered a part of the zinc fume fever
syndrome (359) and workers chronically
exposed to zinc fumes and dust do not dis-
play characteristic neurological findings
(360). Neurological findings are not part
of the typical illness ofhumans exposed to
levels ofzinc in food or drink sufficient to
cause nausea, vomiting, and diarrhea (361).
Neurological abnormalities were not noted
in ruminants naturally or experimentally
exposed to amounts of zinc in feed suffi-
cient to cause pancreatic degeneration
(256).
Isolated reports have raised questions
about possible associations of excess zinc
with development of neurological diseases.
For example, Stein et al. (362) in 1987 de-
scribed a statistically significant increase in
the incidence of multiple sclerosis (MS)
(11 cases over 10 years) in workers in a
manufacturing plant where zinc was a pri-
mary raw material. However, plasma and
erythrocyte zinc levels in subjects with MS
did not differ from controls. Furthermore,
there was no relationship between the
length of employment at the site and the
time of onset of symptoms. There is thus
no convincing evidence that excess zinc
contributes to the known role of risk fac-
tors such as genetics, sex, and geography in
the etiology of this immunologically based
myelin disorder ofthe nervous system. Ani-
mal models with CNS pathology analogous
to MS are available (363), which might be
used to examine the effect ofincreased zinc
intake on disease progression.
Unlike the clinical data, neurological ef-
fects of excess zinc have been observed in
animal studies of CNS administration and
in cell culture. Injection of 10 pg zinc or
more into the ventricles ofthe brain ofrats
increased motor activity in a dose depen-
dent manner; activity of ATPase was re-
duced in the hippocampus (364). Other
investigators found that motor activity
caused by intraventricular injection of 0.3
pmole zinc could be prevented by adminis-
tration of 0.4 pmole GABA acid (365).
The phenomenon was associated with
lower activity of glutamic acid decarboxy-
lase in hippocampus, but not in other brain
regions that were assayed. A recent study,
consistent with these observations, has
demonstrated allosteric inhibition of the
GABA response of voltage clamp spinal
cord neurons by 10 to 100 EM zinc (102).
When zinc wires were placed in brain,
degenerative changes occurred in proxim-
itry to the wire. The inflammatory re-
sponse included astrocytic scarring,
lymphocyte cuffing of capillaries and de-
myelination (366). In addition, mitochon-
dria were enlarged, and swollen and
cytoskeletal changes were found in neu-
rons. Abnormalities also included loss of
neurotubules, the formation of structures
that were morphologically similar to zinc-
tubulin aggregates, accumulation of lipo-
fuscin inclusion bodies, and other
degenerative changes. Exposure to plat-
inum, nickel, cobalt, or magnesium did not
produce such changes.
Studies in tissue culture also indicate
that high concentrations of extracellular
zinc are neurotoxic. Exposure to 250 pM
zinc overnight caused death ofcortical neu-
rons (367,368). In contrast, 100 and 200
pM caused minimal injury. Yokoyama et
al. (367) speculated that these findings are
significant for human and animal health
because concentrations of zinc released
during neurotransmission are believed to
reach 250 pM at least temporarily. The va-
lidity ofthis speculation is unclear. In their
experiments exposures to high levels ofzinc
were prolonged. In vivo zinc is presumably
retrieved by neurons from the extracellular
space, and that not retrieved is soon diluted
by the extracellular fluid.
Duncan et al. (369) have also demon-
strated the toxicity of zinc chloride (100
pM) to cultured cerebellar granule and
ventral mesencephalic cells (with sparing
of astrocytes). Their study was designed
to identify neurotoxins in cycad-derived
flours, a putative environmental factor in
the etiology ofamyotrophic lateral sclero-
sis parkinsonism dementia. These investi-
gators provide evidence of high zinc
content in traditionally prepared flours
(possibly from soaking of seed in galva-
nized containers) and data to suggest that
the zinc was the causative factor for in
vitro neurotoxicity of extracts from these
flours. No in vivo studies were performed
to test whether oral intake of these flours
would produce neurological effects. Based
on the zinc content, the authors specu-
lated that consumption of zinc would in-
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crease to 100-fold the daily requirement.
Other studies described in this report
with zinc supplements ofthis level in ani-
mal models (e.g., 100 ppm dietary zinc
for 100 g rat consuming 20 g diet) have
not revealed neurological effects.
SUMMARY. Zinc is essential for on-
togeny ofthe brain and for brain function.
Among its normal roles are participation in
neurotransmission of mossy fiber neurons
of the hippocampus. Zinc deficiency im-
pairs development of the brain and has
been shown to cause long-term behavioral
sequelae in rats. In humans as well, severe
zinc deficiency causes abnormalities in neu-
rophysiological function. Recent research
suggests that mild zinc deficiency also can
impair neurophysiological function in hu-
mans. Clinical evidence does not support
the thesis that exposures to high concentra-
tions of zinc, such as occur in metal fume
fever, cause acute or persistent neurophysi-
ological abnormalities. However, experi-
mental studies in which zinc was injected
into brain ventricles, introduced as a wire,
or incubated at high levels with cultured
neurons have demonstrated neuronal in-
jury.
Lung. RESPIRATORY EFFECTS IN Hu-
MANS. There were no reports in the accessi-
ble literature of respiratory effects from
ingestion of zinc. On inhalation exposure
to zinc compounds adverse effects may
occur in situations where individuals are
exposed to relatively high concentrations
for long periods oftime, such as in mining
and smelting, or from exposure to very
high concentrations for short periods of
time, as with exposure to smoke bombs
(370-372). Thus, the response in cases of
human exposure to high levels of toxic
forms ofzinc is predictable and largely pre-
ventable by precluding excessive exposure
in such occupations as mining, smelting, or
welding, or exposure to smoke bombs
without protective gear.
Acute exposure to high concentrations
of zinc chloride or zinc oxide, e.g., 600
mg/m3 for 5 hr, results in "metal fume
fever," a well-recognized syndrome which
results from inhaling the compound,
largely zinc chloride, contained in smoke
bombs (373-375). The common army
smoke bomb contains a mixture of zinc
oxide or zinc chloride/hexachloroethane
and small quantities ofcalcium silicide and
potassium nitrate (376). This type of ex-
posure results from release ofzinc oxide or
zinc chloride and hexachloroethane in
closed spaces or where little ventilation is
available. The resulting irritation to the
lungs, often referred to as smoke bomb
pneumonitis (377), is readily reversible ex-
cept under extreme conditions ofexposure.
The reaction between zinc oxide and hexa-
chloroethane, in the presence of other
agents, produces zinc chloride particles
small enough to reach the deeper airways of
the lung. Zinc chloride is relatively caustic
when in contact with moist areas of the
body, particularly the deeper recesses ofthe
lung (371), which further enhances the
toxic effects ofthese compounds.
Typically, the syndrome of metal fume
fever begins 4 to 12 hr after the initiating
exposure (373). The response is manifested
initially by a metallic taste in the mouth,
accompanied by dryness and irritation of
the throat. The attacks have been described
as a flulike illness accompanied by shaking
chills, muscle and joint aches, weakness,
sweating, and a high fever (374). Cough-
ing, fatigue, and shortness ofbreath may be
present and the entire process, when un-
complicated, runs its course in 24 to 48 hr
(375).
Respiratory tract irritation occurs in
both human and experimental animals fol-
lowing exposure to zincoxideorzincchloride.
Experimental studies have demonstrated ef-
fects ofexposure to inhaled zinc oxide/hexa-
chloroethane (11,580 mg/min/m3) or to
intratracheally instilled zinc chloride (2.5
mg/kg bodywt). Most laboratoryanimals and
humans exhibited pulmonary congestion,
peribronchial leukocytic infiltration, respira-
torydistress andpneumonitis (370,371,378).
Evans (376) reported on casualties fol-
lowing exposure to smoke bombs in 1945.
During World War II on the Island of
Malta, smoke generators stored near the
entrance to Corradino tunnel were ignited,
and the smoke generated filled the tunnel
in a short time. Over 100 people were in
the tunnel at the time, and most of them
were exposed to high levels of the zinc
chloride generated by the smoke bombs.
Ten ofthe 34 treated patients died. This is
an extreme case in which individuals were
exposed to an unusually large amount of
zinc compound in a closed space. It was es-
timated that exposure was about 0.2
lb/cubic yard near the generators. While as
noted this was a most unusual case, it illus-
trates the potential for significant numbers
of people to be exposed to the adverse ef-
fects of zinc oxide and zinc chloride in
combination with other compounds and
under unusual conditions.
Most reports in the literature describe
metal fume fever in individual cases where
the clinical history of the exposure and its
sequelae may be of interest. Pare and San-
dler (377) described the case of a soldier
who was exposed to a cannister smoke
bomb for about 10 min, without a respira-
tor. The patient had an undulating course
over a period of several weeks with severe
clinical symptoms including shortness of
breath, high temperature, epistaxis, pain in
chest and side, rales in right lung and
patchy consolidation ofmany areas ofboth
lungs. Within about 6 weeks the patient
had effectively recovered with no residual
signs of the exposure. The case described
here is not unusual in its clinical course, ei-
ther in individuals exposed to smoke
bombs or in welders (noted below) exposed
to fumes generated during the welding
process (371,377). The salient feature, de-
spite the rather severe symptoms, is the
pneumonitis which in a large majority of
exposed individuals is reversible with or
without treatment.
In some cases assumed to be metal
fume fever, there are additional signs and
symptoms which diverge from the norm.
For example, Farrell (379) described ana-
phylactoid reactions wherein the patient
developed rales and angioedema after
working in a zinc smelting plant for 12
years. Although the patient was an engi-
neering technician and his office was sepa-
rated by a considerable distance from the
smelting mill, he entered the mill about
once weekly. In addition, he occasionally
helped in the use of a oxygen-acetylene
torch to cut metal and also did limited
electric welding on zinc-coated items.
Thus, there was a long history ofon-going
exposure.
There are many reports in the literature
regarding metal fume fever all of which
play on a central theme with some usually
modest variation on either the conditions
of exposure or the parameters) examined.
Brown (359) described the radiologic ap-
pearance of the chest cavity of an individ-
ual following exposure to zinc fumes in a
shipyard job. There were multiple nodules
in both lung fields measuring 3 to 4 mm,
following a few days ofexposure. Based on
clinical features of headache, dyspnea,
arthralgia, lymphocytosis, and the lung le-
sions, a diagnosis of zinc fume fever was
made. After 3 days of hospitalization the
symptoms had cleared, and a day later the
chest fields had cleared.
Others have measured lung function
and found generally minimal to moderate
declines in function which returned to nor-
mal within 2 to 3 days after cessation ofex-
posure to the metal fume. Blanc et al.
(380) designed a human model of metal
fume fever using volunteer welders re-
cruited through public advertisements. The
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exposures to zinc oxide fume from welding
over a 15- to 30-min period (in a specially
designed 512 ft3 exposure chamber with a
ventilation rate of 273 ft3/min) were de-
signed to exceed 10 mg/m3 over 15 min.
Actual exposure to zinc oxide was mea-
sured using personal sampling pumps. The
mean cumulative exposure to zinc oxide
for the 14 participants was reported as 2.3
± 1.7 g min/m3 (range 0.6-5.1) for 15 to
30 min ofwelding. Dividing this value by
the shortest (15 min) and longest (30 min)
exposure times indicates a mean ex osure
level ranging from 77 to 153 mg/in and a
minimum exposure of 20 to 40 mg/m3.
Data for individual exposures were not re-
ported. Based on bronchioalveolar wash-
ings and measurements oflung volume, air
flow, and diffusion capacity for carbon
monoxide, these investigators demon-
strated minimal to mild changes which
were transitory and returned to normal
within two days. Results of another study
in which welders were exposed to fumes
from zinc-coated steel indicate no effects
on lung function (372). Many additional
reports in the literature confirm that, ex-
cept for the most extreme exposures, zinc
metal fumes produce a generally mild pul-
monary response that is self-limiting.
A recent experimental study examined
pulmonary function in four subjects who
inhaled ultrafine zinc oxide particles for 2
hr at the current 8-hr threshold limit value
(TLV, 5 mg/m3) (386). All subjects expe-
rienced clinical symptoms of metal fume
fever such as fever and chest tightness;
however, no changes occurred in the 24-hr
observation period in specific airway resis-
tance, diffusion capacity ofcarbon monox-
ide, forced vital capacity, or maximal
forced expiratory volume.
Nemery (381) has published an excel-
lent, extensive review on metal toxicity
and the respiratory tract, documenting
that other metals, including cadmium,
manganese, mercury, copper, vanadium,
chromium, and nickel can also cause metal
fume lung disease. The consequences of
exposure to these metals are often more se-
rious than the syndrome associated with
zinc metal fume fever. For example, cad-
mium, chromium, and nickel are docu-
mented human carcinogens (382-384);
manganese and mercury cause serious
CNS disturbances which can be irre-
versible.
Studies in Experimental Animals.
There are numerous reported studies on
pulmonary toxicity ofzinc based on animal
experimentation. Since a majority of them
describe similar results, only a few of the
more recent and typical ones will be sum-
marized here.
Amdur et al. (385) have examined ef-
fects in guinea pigs ofzinc oxide fumes at a
concentration ofabout 1 mg/in3 for 1 hr, a
relatively low exposure. The degree of irri-
tant response was evaluated by measuring
pulmonary mechanics in unanesthetized
guinea pigs, including intrapleural pressure,
tidal volume and rate offlow ofgas in and
out ofthe respiratory system. The exposure
produced a slight but statistically signifi-
cant decrease in compliance 1-hr postexpo-
sure. In a second group of guinea pigs,
observed 2 hr after exposure, there was a
progressive decrease in compliance between
the 1- and 2-hr periods, indicating an esca-
lating effect with time ofzinc oxide fumes
on lung distensibility. There were no
changes observed in tidal volume.
The most recent work by Amdurs
group (386) examined pulmonary lavage
fluid at 0, 4, and 24 hr after 3 hr inhalation
of ultrafine zinc oxide particles by guinea
pigs, rats, and rabbits. Zinc oxide concen-
trations were 2.5 and 5.0 mg/m3 (TLV for
8-hr exposures in the industrial setting). At
both exposure levels, changes in lavage
fluid from guinea pigs and rats, but not
rabbits, were consistent with development
ofan acute inflammatory response.
Marrs et al. (387) exposed female mice,
rats and guinea pigs to smoke produced by
ignition of a zinc oxide/hexachloroethane
pyrotechnic composition for 1 hr/day, 5
days/week at three different dose levels.
Mice and rats received 100 daily exposures
but guinea pigs were exposed to only 15
doses because of high mortality during
early exposures. The exposure concentra-
tions in the three species were the same and
ranged from a low of 1.3 mg/m3 to a
medium of 12.8 mg/m3 to a high ofabout
120 mg/m3 as zinc. Following exposure to
the smoke, the animals were held for up to
18 months for observations. Mortality at
the high dose was significant in all three
species with mice sustaining the greatest
losses (Table 10). Table 11 lists results of
observations, mainly histological, recorded
at the end of the study. The most signifi-
cant observation in mice was the increase
in alveologenic carcinoma in the high dose
group. Other lesions have been reported
previously, and since there was no signifi-
cant chronic injury reported, only lympho-
cytic infiltration is shown for each of the
three species. There were no lung tumors
in either rats or guinea pigs. Lung lesions,
i.e., macrophages and other signs of
chronic injury, were not remarkable and
were similar to those described in other
studies (388,389). Lymphocytic infiltra-
tion in the lung as shown in this study can
be associated with age, as well as with expo-
sure to zinc oxide smoke.
The results ofthe study by Marrs et al.
(387) deserve further comment. First, the
design and conduct ofthe studywere excel-
lent examples oftoxicological investigations
which provide reliable results in a difficult
area ofresearch. Second, despite the exten-
sive and intensive nature of the multi-
species, chronic investigation, essentially
nothing new was revealed. Aside from the
increased incidence of lung tumors in a
susceptible strain of mice, the results were
less severe than might be expected based on
knowledge of human exposure and experi-
mental animal data. The only significant
observation was the increased incidence of
lung tumors in the high-dose group of
mice. There are a number of problems in
attempting to relate zinc toxicity to the
lung tumors observed as follows:
*The increase occurred only at the high-
dose, not in the medium or low dose.
*Only one sex (female) of mouse was
used.
*The high dose of smoke caused a mor-
tality ofabout 50%, much higher than is
usual for such a study.
*The alveologenic lung tumors in the
mouse strain studied are not generally re-
garded as a reliable end point for lung
cancer studies by many carcinogenesis
experts because of the high incidence
and variability of this type of tumor in
control untreated animals.
These points illustrate the question of
the significance of the observed increase in
tumor incidence in the treated mice and
relative difficulty in interpretation of such
observations. The extreme treatment, con-
firmed by high mortality, undoubtedly
contributed to lung damage, and this effect
may have contributed to an indigenous
process already extant in the mouse lung.
This observation cannot be used to ascribe
a carcinogenic role for zinc.
Two other studies warrant mention
here. One study (378) exposed rats to in-
haled zinc oxide/hexachloroethane smoke
(11,580 mg/min/m3) or to intratracheally
instilled zinc chloride (2.5 mg/kg/body
weight). Both the smoke and the instilled
zinc chloride produced similar responses
including pulmonary edema, alveolitis,
and, in some, a late stage fibrosis. The ad-
ditional imposition ofoxygen had little ef-
fect on the development or progression of
the pathological changes.
Another study used sheep as the test an-
imal, exposed either to a single bolus dose
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of welding fume solution or to 5 weeks
daily exposure by inhalation (390). The
metals in the fume from the welding elec-
trode included by percentage: iron 14.1;
manganese, 4.0; titanium, 0.56; magne-
sium 0.17; zinc, 0.02; copper, 0.02; and
aluminum, 0.50. In the acutely exposed,
sheep were anesthetized, a bronchoscope
inserted into the trachea and a suspension
ofwelding fume, 0.5 g suspended in 50 ml
normal saline, was instilled into the right
main bronchus. The 0.5 g was calculated
from a welding fume exposure of 5 to 10
mg/m3 for 3 effective working hours, an
average welder's exposure to welding fume.
For the long-term exposure (25 to 33 days,
174 to 181 min per day, 31 to 51 mg/m3),
sheep were exposed via tracheal tubes to
welding fumes, sucked from a bench where
welding was performed in a mixing cham-
ber. Particle size, determined by an optical
particle counter in combination with a par-
ticle meter and scanning electron mi-
croscopy, averaged less than 1.0 microns
(range 0.5-10).
In both acute and chronic exposures
fume metal particles accumulated, as deter-
mined histologically, and in the chronic ex-
posure there was fibrosing pneumonitis. In
the acutely exposed sheep there was accu-
mulation of iron, magnesium and man-
ganese in the lungs as well as elevated
pulmonary arterial pressure. In the animals
exposed daily for 5 weeks, there were in-
creases in iron and, particularly, in man-
ganese which was retained at high
concentrations (40 times more than in un-
exposed sheep) following exposure. The
concentration of zinc in the lungs of ex-
posed sheep was about the same as the un-
treated controls. Metals are found in
organs and tissues of welders with disease
symptoms (390,391); the observations in
sheep correlated with those in welders
with chronic diseases and suggested that
accumulation and retention ofmanganese
and iron can result in negative health ef-
fects. Zinc, however, was not implicated.
Skin. Zinc accumulates in skin, 3- to
7-fold relative to plasma (392), and is re-
quired for normal function of this tissue.
Zinc deficiency is characterized by rash,
alopecia, hyperkeratosis, parakeratosis,
and hypopigmentation (393). These
symptoms are observed in acrodermatitis
enteropathica (AE), a hereditary hypo-
zincemia (392), and in dietary zinc insuf-
ficiency in humans as well as in animal
models (267). In four patients with AE,
levels ofzinc in the skin were about one-
third to one-half normal levels (392).
The reasons for development of skin le-
sions from zinc deficiency are not known.
As reviewed by Bettger and O'Dell
(109), in animal models the development
of these lesions can be retarded by high
dietary levels ofantioxidants such as vita-
min E. This observation and others sup-
port the concept that enhanced lipid
peroxidation contributes to development
ofdermal symptoms.
Dermal effects of increased zinc in the
skin in response to elevated plasma levels
have not been examined. Thereis literature
on dermal effects oftopical exposure to zinc
salts. Studies purporting to demonstrate en-
hanced wound healing following application
of zinc in humans are controversial; the
weight ofevidence suggests that in man and
animals zinc accelerates wound healing only
in the zinc deficient (267,394).
Certain of the zinc salts have irritant
properties when applied in sufficiently
high concentrations (395). For a series of
zinc compounds tested in a single concen-
tration, the degree of dermal irritation
based on macroscopic observations was
similar in a variety of mammals (rabbit,
mouse, and guinea pig). In this study the
zinc compounds in a 0.5 ml volume were
applied to shaved skin on dorsal sites once
a day for 5 days. Twenty-four hours after
the last application, mice were adminis-
tered vincristine (0.1 mg, ip) to arrest mi-
toses; after 4 hr the mitotic index was
determined by assessment of the number
of cells in mitosis per 1000 cells in the
stratum germinativium and first layer of
the stratum spinosum. In all species zinc
chloride (1% w/v in deionized water) con-
sistently produced irritant effects, includ-
ing ulceration, acanthosis, parakeratosis,
hyperkeratosis, and inflammatory re-
sponses. In mice the epidermal mitotic
index was significantly elevated. Zinc ac-
etate induced similar effects, somewhat
less in magnitude, when tested at a 20-
fold higher concentration than ZnCl2.
Other compounds tested, 1% zinc sulfate,
20% zinc oxide suspension, 20% zinc un-
decylenate suspension, and 20% zinc
pyrithione suspension, did not alter the
mitotic index and did not definitively
alter the epithelial histology.
In summary, alterations in epidermal
structure are an important component of
zinc deficiency, although the biochemical
mechanism is not understood. Zinc com-
pounds, applied topically in high enough
concentration to the skin, may also induce
pathology. This effect is highly dependent
on the specific form of the zinc com-
pound with the chloride salt being the
most potent. Zinc oxide in contrast is
used therapeutically for its topically pro-
tective effect on the skin.
Effects OnImmunological Function
Immunopathology ofZincDeficiency. Clin-
icians have frequently noted that subopti-
mal nutriture predisposed their patients to
increased risk of infection and disease
(396). Further, the severity of the disease
was enhanced in malnourished patients
such that recovery and even survival were
threatened. Indeed, the mortality rate of
undernourished children in Third World
countries to ordinary childhood diseases is
50 to 100 times that of well-fed children
(396). Suboptimal intake ofdietary zinc is
one ofthe most common worldwide nutri-
tional problems and has been shown to
exist in low-income, institutionalized, preg-
nant teenagers and elderly Americans as
well (397,398).
However, poor quality diet and insuffi-
cient amounts of food are not the only
causes ofnutritionally acquired immunod-
eficiency states. A number ofWestern dis-
eases, including various cancers, AIDS,
gastrointestinal disorders, renal disease,
sickle cell anemia, and chronic alcoholism,
alter the intake and assimilation of nutri-
ents. Suboptimal zinc is also noted in all of
these diseases (398). Reduced food intake
andweight loss accompany these diseases as
Table 11. Histological changes in lungsofmice, rats, and guinea pigs exposedtozincoxide/hexachloroethane smoke.
Dose group
Control Low Medium High
Alveologenic carcinoma
Mice 6/78 7/74 8/76 15/50
Rats 0/43 0/44 0/48 0/44
Guinea pigs 0/45 0/39 0/46 0/39
Lymphocytic infiltration
Mice 26/78 26/74 17/76 17/50
Rats 27/43 32/44 10/48 7/44
Guinea pigs 44/45 38/39 44/46 39/39
aLow, 1.3mg/m3; medium, 12.8mg/m3; high, 120mg/M3aszinc; 1 hr/day, 5days/weekfor20weeks(mice and rats) or3
weeks(guinea pigs). Abridged from Brown et al. (378).
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well as heightened susceptibility to respira-
tory illness, sepsis and other secondary in-
fections. All indicate that malnutrition and
impaired immunity are significant factors
in the morbidity ofthese diseases.
There is little question that the effect of
dietary zinc deficiency on immune func-
tion of rodents represents the best devel-
oped paradigm regarding the effects of a
nutritional deficiency on host defense sys-
tems. The ubiquitous nature of zinc defi-
ciency (398) and the high reliability ofthe
mouse as an immunological model for hu-
mans makes these in-depth studies of sub-
stantial interest to those interested in
malnutrition and its effects on immunity.
Furthermore, they indicate that zinc is es-
sential to maintaining integrity of the im-
mune system. Information gathered to date
indicate that a 30-day period ofsuboptimal
intake of zinc in the young adult mouse,
which produced a 20 to 25% weight loss,
reduced the thymus to a quarter normal
size and depleted the lymphocytes and
macrophages in the spleen 50 to 70%
(399-401). Thymic atrophy, which is a
benchmark of both zinc deficiency and
protein-calorie deficiency, was also accom-
panied by loss in activity of thymulin, a
thymic hormone dependent on zinc for
function (402). Antibody-mediated re-
sponses to both T-cell dependent and T-
cell independent antigens were reduced 50
to 70% as demonstrated by several labs
(399-401). Antibody-mediated responses
are key to immune defense against a variety
ofpathogens and tumors, thus, such reduc-
tions explain the increased incidence of
disease and infection observed in zinc-defi-
cient subjects. Delayed-type hypersensitiv-
ity skin reactions, cell-mediated responses
to tumors, and the function of natural
killer cells were significantly reduced in
zinc-deficient mice (399,401). Recent work
indicates, nevertheless, that the residual
splenocytes of zinc-deficient mice are nor-
mally distributed. In other words, the pro-
portion of T-cells to B-cells and subsets
thereof remained normal, although the ab-
solute number of lymphocytes declined
(403). Likewise, the functional capacity of
these residual lymphocytes appeared to be
normal. The ability oflymphocytes to pro-
liferate and produce interleukins and anti-
body in response to mitogenic stimuli was
normal. This remained the case even when
care was taken to avoid possible repair of
function by avoiding the high levels ofzinc
present in conventional culture media
(404). The overall picture which emerges
suggests that much of the loss of host de-
fense capacity created by suboptimal zinc is
due to the overall loss in the total numbers
ofleukocytes ofthe peripheral immune sys-
tem. The underlying mechanism for this
loss in cellularity appears to involve the in-
ability ofthe bone marrow to produce ade-
quate numbers ofnew lymphocytes.
Since substantial characterization of ef-
fects of zinc deficiency on the rodent im-
mune system are in place, it is appropriate
to begin to compare these results with
those obtained with zinc-deficient humans.
Unfortunately, the data collected to date
for zinc-deficient humans are diverse with
regard to disease state, age, overall nutri-
tional status, etc. Further, almost no data
are available on effects ofzinc deficiency on
the number and types ofleukocytes present
in the peripheral blood of the murine sys-
tem, whereas a great deal ofthe human im-
munologic data have come from studies of
the blood. Nevertheless, some encouraging
commonality can be found between the ro-
dent studies and patients suffering from
acrodermatitis enteropathica, a genetic de-
fect in the assimilation of zinc (405).
These patients have increased incidence of
secondary infections, lymphopenia, and re-
duced natural killer and delayed type hy-
persensitivity responses. Prasad's group has
noted similar changes in patients with
sickle cell anemia and other subjects who
were zinc deficient (398,401). An increase
in T101-, sIg-cells, and decreases in
T4+/T8+ ratio, in serum thymulin activity,
and in IL-2 production by mononuclear
cells were observed in an experimental
human model during specific, mild zinc
depletion, induced by dietary means;
changes were corrected after zinc repletion
(86). A patient primarily zinc-deficient
due to prolonged artificial feeding of an
oral supplement containing insufficient
zinc exhibited decreased delayed type hy-
persensitivity reaction and reduced lym-
phocytic response to phytohemagglutinin,
a T-cell mitogen (406). Both functions
were rapidly restored by zinc repletion. An-
other group studying patients receiving
total parenteral solutions without sufficient
zinc observed lymphopenia and reduced
natural killer function, but elevated mono-
cyte activity (407). For the most part these
observations match the findings for the
murine model. However, human data
which conflict with the murine model can
be found for the reasons already discussed
(401).
PotentialModulation ofImmune Func-
tion by Excess Zinc. As is evident from
other sections of this report, the average
US citizen is at far greater risk ofbecoming
zinc deficient than experiencing adverse
health effects as a result ofexposure to high
zinc. Further, data collected from both
human and various animal models clearly
indicate that the integrity of all aspects of
the immune system is highly dependent on
the availability of adequate levels of zinc.
What effects excess zinc has on immune in-
tegrity is more problematic because expo-
sure of subjects to high zinc is infrequent
and the available literature is limited.
When considering potential effects of
excess zinc on immune function, the route
ofexposure ofthe subject to this metal will
control how the host defense system may
be altered. For example, inhalation of zinc
compounds could adversely affect the mu-
cosa where responses ofmacrophages, neu-
trophils, mast cells and other components
of the secretary immune system might be
altered. Skin contact would involve phago-
cytic cells and the T-helperlike cells in-
volved in delayed contact sensitivity and
perhaps mast cells. Oral intake ofhigh zinc
via water or diet would have a more sys-
temic effect that might alter circulating
leukocytes and immune cells found in the
primary and secondary lymph nodes. In
addition, considerable variation in the ob-
served immune defects would be expected
depending on exposure duration.
In this regard, a set of related practical
questions must also be addressed to prop-
erly evaluate the current literature as well as
design meaningful future experiments.
Under what circumstances, how fre-
quently, and for what durations of time
might industrial workers be exposed to zinc
inhalation? It is these individuals who are
at greatest risk of experiencing immuno-
toxic effects as a result ofexposure to zinc.
In what situations would individuals re-
ceive milligrams of zinc in water and/or
diet as a result of"pollution" and for what
lengths of time? Which animal species are
good predictors of potential immunotoxic
effects of zinc for the human population
and which are poor models? These impor-
tant variables, given little consideration in
reports concerned with potential immuno-
toxic effects of zinc, must be addressed, if
future research in this area is to provide
meaningful data.
Effects ofHigh Intake ofOral Zinc on
HostDefense. The 1984 study of Chandra
(12) is frequently cited as evidence that
zinc is toxic to the immune system. In this
case, 11 adult men were given 300 mg of
elemental zinc once a day for 6 weeks. This
constituted pharmacological levels of zinc,
being 20 times above the RDA. Because
high levels of intake ofzinc can cause cop-
per deficiency (398), a major flaw in this
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study was the failure to monitor serum
copper levels of the subjects. There is a
high probability that the subjects were
moderately deficient in copper with this
prolonged regime of high intake of zinc.
Thus were observed changes in immune
function (and rising HDL levels) noted in
this study due to high zinc or low copper?
The seriousness ofthis flaw alone precludes
the usefulness ofthe results ofthis study in
assessing the effect of excess zinc on im-
munocompetence.
A second major flaw concerns the mea-
sures of immune status, most of which
were performed in vitro over a period of 2
to 4 days, using culture medium which
contained normal levels of zinc. It is un-
clear how these responses, tested in a nor-
mal zinc environment, relate to those in
the host environment with a 2-fold eleva-
tion in serum zinc. Possible metabolic or
physiological aberrations resulting from el-
evated zinc in the host environment were
obviously not mimicked in tissue culture.
Thus, the cells of the immune system
might have repaired or performed better in
the in vitro test environment than in vivo.
Mitogens mimic antigens and cause certain
resting lymphocytes to become activated
and proliferate. The degree ofproliferation
can be measured by quantitating the
amounts of 3H thymidine incorporated
into the DNA ofthe actively dividing cells.
In this study one mitogen (phytohemag-
glutinin) at a single dosage was used as a
test oflymphocyte immune function. This
assessment is too restrictive; proper im-
munology necessitates that a dose-response
curve be determined. Proliferative re-
sponses thought to be suboptimal may
have been normal at different doses of mi-
togen. Nonetheless, a depressed prolifera-
tive response was observed 4 weeks into the
study that was presumed to be due to the
high level oforal zinc.
Zinc itself is a well-known mitogen
when present at high levels (408). The
background response of the supplemented
individuals might well have been high as a
result of exposure to high zinc. If so, this
would give a false negative because of the
way the data were expressed. In this study,
the data were reported only as a stimula-
tion index (SI) rather than absolute counts
(SI = absolute counts ofstimulated cells di-
vided by background counts of unstimu-
lated cells). Thus, a high background in
cells from zinc-treated subjects causing a
lower SI would have been interpreted as a
reduced mitogen-induced proliferative re-
sponse when that was not really the case.
Direct addition ofzinc to culture medium
in this study as an additional means of
looking at "zinc toxicity" simply confirmed
results noted in earlier studies which
showed that high levels of zinc can, in
some cases, activate lymphocytes (408).
The subsequent observed influx of Ca"+
into lymphocytes, which was reported, is
also a common event noted early in the ac-
tivation process ofthese cells.
A reduction in chemotaxis and ability
to engulf or phagocytose bacteria was also
noted in these studies. However, these as-
sessments were also performed in vitro so
all of the aforementioned concerns about
in vitro studies apply to these data as well.
The absolute number of lymphocytes and
proportion of T- and B-cells were not al-
tered in these subjects. It is interesting that
there was no change in this important para-
meter that is often greatly altered in other
nutritionally related immunodeficiency dis-
eases (396).
The immunological data are further
confounded by the fact that there were no
placebo controls. Baseline assessments were
made ofthe subjects prior to supplementa-
tion. However, the various immune assess-
ments made are all subject to a great deal
of biological variation giving different ab-
solute values on different test days. Thus,
there was no control for the experimental
variation that can occur over time.
Since more than 50% of adults would
find the doses of zinc used in the above
study to be highly irritating to the stomach
and would generally stop taking zinc, it is
interesting that all 11 subjects apparently
tolerated this zinc preparation. This well-
known side effect ofhigh zinc was not dis-
cussed. Indeed, few discussions of
problems associated with oral intake of
truly high levels ofzinc consider that stom-
ach disorders would be an early indicator
of excess zinc and would probably cause
subjects to seek alternate water and food
sources (61). Zinc at 15 mg/1 produces an
undesirable taste in water, so it is doubtful
that its presence would go unnoticed (61).
The elderly represent a subset of the
population that may be more sensitive to
the effects of certain toxic substances. A
plethora ofdata indicates that many ofthe
elderly (>70 years of age) may be margin-
ally zinc deficient (397,409). As a result, a
number of studies examined the effects of
zinc supplementation on zinc status and
degree of immunocompetence of the el-
derly. These studies are of interest because
they are in conflict with the findings of
Chandra (12). In each ofthe studies ofthe
elderly which will be discussed, they were
supplemented for substantial periods of
time with doses of zinc well above the
RDA. In one case, modest improvement in
immune function was noted, while in an-
other very well-controlled study, no change
was noted.
In the first study, Duchateau et al.
(410) gave elderly subjects doses of zinc
for 1 month which were clearly pharmaco-
logical (440 mg zinc sulfate per day). Un-
fortunately, there were only 15
supplemented and 15 unsupplemented
subjects. Furthermore, their zinc status was
not assessed at the outset of the study.
Nevertheless, seven of the subjects showed
some increase in responsivity to delayed
type hypersensitivity antigens and immu-
nization with tetanus toxoid after zinc sup-
plementation. However, the latter are
recall responses which are easier to rejuve-
nate than virgin immune responses. Never-
theless, they indicate that high dietary zinc
may have some enhancement capacity for
certain human populations. Whether these
subjects became marginally copper defi-
cient as a result ofthis regime was not de-
termined.
Bogden's laboratory initiated more
careful studies of the elderly. Degrees of
mild zinc deficiency were noted in 100 el-
derly subjects (397). Some 40% of these
individuals gave poor delayed type hyper-
sensitivity skin responses. Subsequently,
some of these subjects were given 100 mg
ofzinc for 3 months (411). These individ-
uals exhibited a modest increase in serum
zinc from 13.1 to 16.8 pmole/l with no
change in plasma copper. Although no en-
hancement of immune function was noted
by these investigators, the number of tests
made was necessarily limited. Further, no
attempt was made to stratify subjects ac-
cording to zinc status and compare the im-
munological responses of zinc
supplementation between the two groups.
What is clear is that levels ofzinc about 6
times above the RDA had no adverse ef-
fect. Interestingly, Winchurch et al. (412)
found that he could substantially increase
the antibody mediated responses ofspleno-
cytes (lymphocytes from spleens) from old
mice by simply incubating them with high
quantities of zinc (0.15 mM ZnCI2) in
vitro. Many nutritionists as well as scien-
tists at the US Food and DrugAdministra-
tion feel that further investigation of
possible efficacious effects of high quanti-
ties oforal zinc supplementation ofthe el-
derly are needed. In sum, prolonged
exposure to oral intake of high levels of
zinc had no adverse immunological or
physiological effects on the elderly in these
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studies, which further detracts from the va-
lidity ofthe 1984 study ofChandra (12).
Effects ofZinc Inhalation on Immune
Defense Systems ofthe Lung. The small
concentration of zinc routinely found in
the air suggests that the average American
citizen is at little risk ofadverse pulmonary
effects from zinc. However, inadvertent ex-
posure to high levels of zinc either on an
acute or a chronic basis in the industrial
arena appears to have the potential for
damaging immune defense systems in the
lung. This supposition is based on litera-
ture containing less-than-desirable experi-
mental protocols. Those at risk appear to
be industrial workers, involved in welding
galvanized steel or processing zinc from
ore, who could become victims of metal
fume fever (413).
At the onset, it must be recognized that
understanding of pulmonary immunology
is quite limited. Lavage of the lung reveals
the presence of extensive numbers of
macrophages, some neutrophils and com-
ponents of the secretary immune system
vital to host defense in the mucosa. Some
lymphocytes and various classes of im-
munoglobulin are also present in the lung.
The lung is continuously exposed to a vari-
ety of air- and bloodborne agents that
might trigger inflammation, activate vari-
ous immune processes, or enhance the
probability of infection. For example, it is
known that exposure to organic dusts can
induce hypersensitivity pneumonitis; so it
is possible that metals such as particulate
zinc may do the same. Indeed the symp-
toms of metal fume fever parallel those of
hypersensitivity pneumonitis (413). In
the acute phase of pneumonitis, symp-
toms appear 4 to 6 hr after exposure and
include a nonproductive cough, dyspnea,
fever, chills, malaise, etc. These symptoms
along with increased numbers of neu-
trophils and immune complexes are often
noted in the lungs of patients with metal
fume fever (413). In more delayed reac-
tions of pneumonitis, mononuclear cells,
granulomas and other signs ofongoing in-
flammation of the lung become apparent.
Wheezing, cough, respiratory rales, etc.
and general malaise can accompany this
phase. Thus, it is important to keep in
mind that this well-known disease or in-
flammatory lung response and metal fume
fever have the same general characteristics.
At a very early date numerous studies
of fume fever noted the rise in body tem-
perature and increased leukocytosis in the
lung among welders and those involved in
smelting operations (414). One of the
earliest attempts to further document im-
mune inhalation effects of zinc oxide was
an animal study conducted by Drinker
and Drinker in 1928 (415), which gave
mixed results. These investigators exposed
cats, rats, and rabbits in a gas cabinet to
zinc oxide in concentrations ranging from
110 to 600 mg/m3 for several hours. The
cats exhibited excessive lung secretions
and "varying degrees" ofinfiltration ofthe
lungs with neutrophils, but surprisingly,
no rise in temperature was noted for the
subsequent 29 hr. The lungs of rats and
rabbits subjected to the same treatment
appeared normal. The dichotomy in ef-
fects among these species was an early
warning that there are significant species
variations in responsivity to inhalation of
zinc oxide. As a result, animal experimen-
tal models appropriate to humans should
be selected with extreme care. In a later
related study, it should be noted that
guinea pigs exhibited a resistance to re-
peated inhalation exposure to zinc sulfate
but not to zinc oxide (385). The latter
data help make the point that it would in-
deed be important to know ifhumans be-
come more sensitive or more resistant
upon repeated exposure to zinc oxide in the
air.
More recent studies of fume fever in
humans affirm the already well-known at-
tributes of the phenomenon, but unfortu-
nately they do not provide much further
illumination on the condition. Vogelmeier
and colleagues (416) monitored a 26-year-
old individual who experienced metal fume
fever as a result of welding in improper
conditions. He exhibited the usual fever,
sweating, and shortness of breath within a
few hours of the accident with no observ-
able signs of illness after a few days time.
Six months later the investigator had him
weld for 1 hr again under conditions that
purposefully reexposed him to high zinc.
One day later the subject was free of overt
symptoms of fume fever; however, a lung
lavage indicated the presence of 10 times as
many leukocytes as normal. Many of the
additional cells appeared to be neutrophils.
Nevertheless, cell and differential counts in
the lung were normal when checked 7
weeks later. It would have been helpful if
additional time points had been taken to
see ifthe neutrophils continued to rise sev-
eral days after inhalation ofzinc. Neverthe-
less, this and other studies suggest that the
effects of inhalation of zinc on the lung
may be transient. The 10-fold increase in
cellularity of the lung upon reexposure to
zinc also suggests the possibility of a
heightened response upon reexposure to
zinc among humans.
The most current study available re-
garding metal fume fever was published re-
cently by Blanc et al. (380). Though part
of this study was well-controlled, the im-
munological analyses have weaknesses.
Fourteen welders were placed in a special
chamber and asked to weld without neces-
sary respiratory protection for a 15- to 30-
min period such that they were exposed to
2.3 g zinc oxide min/m3. Bronchial respira-
tory rates were measured 6 and 20 hr later.
Changes in immune components of the
lung were measured 8 and 22 hr later using
bronchoalveolar ravages. In the 8- to 22-hr
span, the cells found in the lung ravages in-
creased 3-fold with the proportion of neu-
trophils increasing from 9 to 37%. No
increase in the production of cytokines by
infiltrating leukocytes was noted in the
lung fluids. These studies reaffirm that
fume fever markedly increases the neu-
trophils in the lung, but the duration of
these increases is not known. Too much re-
liance was placed on commercial kits for
measuring the cytokines which could initi-
ate fever and inflammation. What controls,
ifany, the investigators used to test the effi-
cacy of these kits was not provided. Func-
tional assays of the various cytokines were
not carried out and could have been infor-
mative. Further, 22 hr might have been too
soon to examine lung fluids for these par-
ticular substances. Worse, these investiga-
tors apparently never tested for signs of
fever in the subjects which was a major
oversight. Indeed, the subjects were pro-
vided with acetaminophen to use. As a re-
sult only two subjects reportedly exhibited
fever. It is not clear to what extent the low
incidence of fever was a result of the sub-
jects taking acetaminophen. This unfortu-
nate variable introduced into the study
may well have altered the investigators'
ability to measure the actual degree of in-
flammation created by zinc oxide. Thus,
the immunology regarding effects of zinc
oxide on host defense systems of the lung
remains wanting and in need offurther ex-
perimentation.
AdditionalStudies ofEffects ofZinc In-
halation. In 1987, Farrell (379) demon-
strated that it is also possible to develop
dermal hypersensitivity responses after in-
halation ofhigh amounts ofzinc in the air.
A subject experienced some signs of fume
fever (e.g., malaise and fever) a few hours
after welding. The next day hives and itch-
ing ofthe face, lips, and throat were appar-
ent. These observations suggest a delayed
allergic response to zinc was in operation.
Since the dermal sensitivity of some indi-
viduals to the metals found in jewelry, es-
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pecially earrings, watches, etc. has been rec-
ognized for some time, it may be possible
that this individual had a dermal allergic
response to zinc. This report is interesting
only in that it documents that a hypersensi-
tive dermal response might be expected
among a small fraction of those suffering
from metal fume fever. Stated another way,
the types of hypersensitive states induced
by exposure to high quantities of airborne
zinc may vary among individuals and may
not be limited to the lung.
There are also studies which document
lung injury among those exposed to smoke
bombs containing zinc chloride. Because of
the presence ofother highly toxic chemicals
such as phosgene in such smoke bombs, it
is not clear that all observed symptoms can
be ascribed to zinc. Further, it would seem
that the number of individuals at risk to
such exposure today are minuscule. Never-
theless, a study by Matarese and Mathews
(417) of a 20-year-old male exposed to a
smoke bomb for at least 5 min in a con-
fined area noted that he suffered acute res-
piratory distress. Four months later there
was little residual evidence ofthe accident.
Once again, these studies point out that
the degree and duration ofchanges in pul-
monary immunity are key to whether or
not zinc inhalation causes significant and
prolonged impairment of defense systems
in the lung.
Summary ofEffects ofZinc Inhalation
on Pulmonary Immunology. The febrile
response associated with metal fume fever
(413) certainly indicates probable involve-
ment of cells of the immune system and
synthesis of immune cytokines known to
induce inflammation and fever such as in-
terleukin 1 (IL-1) and tumor necrosis fac-
tor (TNF). Infiltration of the lung with
neutrophils and other leukocytes after ex-
posure to zinc oxide has frequently been
noted in humans and some animal species
as discussed. Macrophages, in particular,
can produce high quantities of IL-1 and
TNF that would induce fever and cause
malaise and loss of appetite. They may
well be released into the fluid of the lung
as a result ofexposure to zinc. In addition,
the phagocytic cells can release
prostaglandins, thromboxanes, and
leukotrienes that initiate inflammation,
cause tissue injury, and facilitate edema.
Depending on the nature of the interac-
tion of phagocytic cells with particles of
zinc, the oxygen burst might also be initi-
ated which causes the release of toxic oxy-
gen radicals such as the superoxide anion,
peroxide, and hydroxyl radical into the
surrounding environment, causing tissue
injury and inflammation. Complement
factors are known to be chemotactic, en-
hancing infiltration of neutrophils and
macrophages into the lung after such an
insult. Quantitation of the extent of pro-
duction of cytokines, inflammatory fac-
tors, complement factors, etc., would
reveal the degree ofinflammation and dis-
ease process initiated by fume fever and
also serve as hallmarks to determine the
duration of damage and injury caused by
fume fever. Unfortunately, examination of
lungs for the presence of these important
biological products has yet to be done in a
satisfactory way subsequent to inhalation
ofzinc.
Effects on Reproduction
Role ofZinc in Reproduction. Zinc nutrit-
ure affects specific processes that control
and facilitate genetic expression, DNA
replication, and RNA and protein synthe-
sis; the efficient utilization of food; the
metabolism of carbohydrates and lipids;
and processes that mediate metabolism of
some vitamins, including retinol, pyridox-
ine, and folate. Therefore, it is not surpris-
ing that severe zinc deficiency is either
lethal or injures the embryo and fetus of
experimental animals (418).
A review of research from the 1975 to
1985 by Apgar (418) found the evidence
of adverse effects from zinc deficiency in
human pregnancy incomplete. In contrast,
evidence from animal experiments conclu-
sively showed zinc essential for conception
(419), blastula development and implanta-
tion (420), organogenesis (328-330), fetal
growth (338,421), prenatal survival (330),
and parturition (422).
An extensive 1987 review of the topic
by Swanson and King (333) found associa-
tions between maternal zinc deficiency and
adverse outcomes, but noted that under-
standing of the phenomenon was incom-
plete. They attributed the lack of
understanding in part to the lack ofa sensi-
tive and generally available method for as-
sessment ofzinc status.
An important contribution of Swanson
and King (333) was their factorial estima-
tion of zinc requirements during preg-
nancy. Using published data on zinc
concentrations of tissues, they estimated
that an average daily retention of zinc of
1.2, 3.7, 8.1, and 11.2 pmole/day during
successive quarters of pregnancy was suffi-
cient to satisfy the added needs of preg-
nancy. They also estimated about 9.2
pmole (about 600 pg) was needed daily
during the last halfofpregnancy. This was
lower than a previous estimate of 11.5
pmole (about 750 pg) daily (63). Swanson
and King (333) estimated the mean dietary
requirement for zinc is 10.5 mg zinc daily
at 25% bioavailability. Assuming a 15%
coefficient of variation, this suggests that
13.6 mg daily will meet the needs of most
normal women who consume diets from
which zinc is 25% bioavailable (74). It also
indicates that 50% of women who con-
sume 10.5 mg zinc daily are at risk ofzinc
deficiency, unless homeostatic adjustments
increase the amount of zinc they retain.
Relevant to this interpretation, Apgar
(418) found published dietary zinc intakes
ofpregnant women were 8 to 11 mg daily
in eight studies and 12 to 14 mg daily in
two studies. Thus it appears the occurrence
of zinc deficiency in human pregnancy is
probably far greater than is currently recog-
nized clinically.
The first comprehensive study to show
an association between an index ofzinc nu-
triture and human pregnancy outcome was
published by Jameson (423,424). He
found that low serum zinc at about the
14th week of gestation was predictive of
outcome. Women with low plasma zinc
were found to have a significantly increased
incidence of complications of pregnancy,
including teratology. Others cited byApgar
(418) and Swanson and King (333) also
reported an association between low in-
dices ofmaternal zinc status and malforma-
tions, including neural tube defects in
babies.
Supportive ofJameson's (423) findings
was a study (425) from Ohio that found a
highly significant increase in pregnancy
complications, including fetal distress and
maternal infections, among women with
low plasma zinc during the latter half of
pregnancy. More recently Neggers et al.
(426) confirmed Jameson's finding that
plasma zinc levels in early pregnancy are
predictive of outcome. They studied low-
income women from Alabama and found
lowest quartile plasma zinc at about 16
weeks gestation associated with an 8 times
greater likelihood ofdelivery ofa low birth
weight infant compared to highest quartile
plasma zinc. Supportive ofthis finding was
the report of Meadows et al. (427) of an
association of low maternal leukocyte and
muscle zinc at term with low birth weight,
and a report by Campbell-Brown et al.
(238) ofthe association oflow zinc intakes
in Hindu women with low birth weight.
Some zinc treatment trials found evi-
dence that improved zinc nutriture was
beneficial for pregnancy outcome in some
women. A double-blind, randomized con-
trolled trial of 30 mg zinc daily given to
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poor teenagers found zinc eliminated the
need for assisted respiration in the new-
born infants and reduced the incidence of
premature delivery among mothers who
were of normal weight (78). Another
study found that 20 mg zinc daily lowered
the overall incidence of pregnancy-in-
duced hypertension (428). Related to
these observations are Jameson's (429)
findings that zinc treatment reduced the
perinatal mortality in 598 women to 2,
compared to 13 in 633 control women
(p<0.001). In addition, delivery before 33
weeks of gestation was decreased to 2/598
as compared to 14/633 (p<0.001). Spon-
taneous abortions were less frequent
among women who received zinc supple-
ments before the 22nd week of gestation
compared to women who were untreated
before the 22nd week (p< 0.05). Consis-
tent with the reported benefits ofzinc sup-
plements were results of an incompletely
controlled study by Kynast and Saling
(430) which found improved pregnancy
outcome in women given zinc. In contrast
a randomized controlled intervention trial
from Britain was "negative" (431).
Excess Zinc and Reproduction. Re-
ported evidence that high intakes of zinc
cause harm to the embryo and fetus is lim-
ited. Studies in hamsters found intra-
venous injection of 25 mg zinc sulfate/kg
caused about 12% fetal resorptions and
6% malformations, including exencephaly
and rib malformations (432). In contrast,
2 mg cadmium/kg caused a nearly 60%
rate of malformations which were pre-
vented by dosing with 2 mg zinc/kg simul-
taneously. In contrast to the observations
in animals, there is essentially no inter-
pretable data indicating that zinc can im-
pair human pregnancy outcome. This is
probably because very high exposures to
zinc are unusual in human pregnancy. The
only evidence of possible harm from zinc
supplements is an unpublished report
from the Indian National Nutrition Insti-
tute (433) that found administration of
300 mg daily during the third trimester
was associated with the occurrence of
three premature births and one stillbirth,
which caused the research project to be
discontinued.
Summary. In animal species, zinc defi-
ciency during gestation causes a variety of
adverse effects in the fetus, including abor-
tion, malformations and growth failure.
Evidence in humans is consistent with the
animal data. Current evidence in animals
suggests there is a wide range between re-
quired doses of zinc and toxic doses in
pregnancy. Clear evidence of zinc toxicity
in human pregnancy has not been re-
ported.
Genotoxicity
There were no reports in the accessible lit-
erature on genotoxic effects of zinc com-
pounds in human populations.
Zinc salts do not appear to be genotoxic
when administered to animals, even at very
high doses. Zinc sulfate was negative in a
sex-linked lethal assay in Drosophila. This
form of zinc was also negative in a mouse
bone marrow micronucleus assay (434).
Other studies (435) have shown that zinc
chloride induced chromosomal aberrations
in bone marrow cells of calcium-deficient
mice but not in normal calcium-supple-
mented mice. These investigators adminis-
tered high doses (5000 ppm) of zinc
chloride for 1 month in the diet without
observable genotoxic effects in calcium-re-
plete animals.
A single report (436) on chromosomal
aberrations in mice exposed to zinc oxide
by inhalation is difficult to interpret and
not considered significant; the reported cy-
togenetic effects of inorganic and acetate
compounds of tungsten, zinc, cadmium,
and cobalt in animal and human somatic
cells are not convincing.
The results of mutagenicity studies of
zinc, based on in vitro genotoxicity tests,
are mixed. In an extensive survey of metal
mutagenicity, Nishioka (437) reported
moderately positive recombinant-deficient
(rec) effects for arsenic and cadmium, but
cobalt, magnesium, nickel, lead, and zinc
chloride were negative. The assay used by
these investigators compared differential
growth inhibition by the various chemicals
in wild and recombination-deficient (rec)
strains of Bacillus subtilus. In contrast to
cadmium, nickel, and transplatinum (II)
diaminedichloride, which significantly in-
creased the absolute number of trifluo-
rothymidine-resistant mutants, zinc chloride
did not. The mutagenicity of the metals
generallyparalleled their carcinogenicity.
Others have also failed to find that zinc
salts are mutagenic. Marzin and Vo (438)
observed that zinc sulfate in water at doses
of 10 to 3000 nmole/plate, the latter the
threshold toxic dose, was negative in the
Salmonella typhimurium TA102 assay.
Doses were in logarithmic progression up
to insolubility or toxicity. Zinc chloride has
been reported to be capable of disrupting
or breaking chromosomes in lymphocytes
(439). However, Amacher and Paillet
(440) found that zinc chloride did not in-
duce mutations at the thymidine kinase
locus in L5178Y/TK mouse lymphoma
cells.
In another study of the genotoxicity of
zinc in four short-term mutagenicity as-
says, Thompson et al. (441) observed that
the result depended on the assay used to
evaluate genotoxicity. Zinc acetate pro-
duced dose-related positive responses in
the L5178Y mouse lymphoma assay and in
an in vitro cytogenetic assay using Chinese
hamster ovary cells (CHO), but was nega-
tive in the Salmonella mutation assay and
did not induce unscheduled DNA synthe-
sis in primary cultures of rat hepatocytes.
Zinc-2,4-pentanedione produced frame-
shift mutations in Salmonella tester strains
TA1538 and TA98, but did not induce
unscheduled DNA synthesis in primary
cultures ofrat hepatocytes.
The cytotoxicity of zinc in vitro has
been examined by Borovansky and Riley
(442). These investigators tested effects of
zinc acetate on three mammalian cell lines
and found that growth was inhibited in all
three by zinc in concentrations ranging
from 0.125 to 0.15 mM Zn2+. This
growth inhibition could be suppressed by
either iron or calcium ions. There appears
to be at least two routes ofzinc entry into
the cell, one of which can be blocked by
iron, the other by calcium. The authors
suggest that the toxic action of zinc re-
quires entry into the cell and that zinc
shares cell entry channels with iron and
calcium ions.
In summary, these observations, similar
to those reported by Hansen and Stern
(443), indicate that in vitro and in vivo
genotoxicity test results vary widely and
that the weight of evidence supports the
conclusion that zinc is not genotoxic in
the systems examined. However, zinc salts
can be cytotoxic at high concentrations, as
noted in numerous studies.
Carcinogenicity
Epidemiological Studies
There are very few references in the litera-
ture relative to the risk for cancer from zinc
exposure in human populations. Stocks
and Davies (444) correlated cancer mortal-
ity with the zinc and copper content ofsoil
in 12 districts of England and Wales.
These investigators found higher zinc levels
and higher ratios of zinc to copper in the
soil ofvegetable gardens near houses where
a resident had died from gastric cancer
compared to houses where a death had oc-
curred from other causes. A combined
study in France and Italy (445) on the role
of zinc and copper in breast cancer inci-
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dence, using hospital-based case-controls as
subjects, showed that blood zinc levels were
consistently higher in cancer patients than
in controls. Dietary intake of zinc was re-
ported to be equivalent in all subjects.
Schrauzer et al. (446,447) evaluated
food intake in several countries and re-
ported a direct correlation between esti-
mated zinc intake and age-adjusted
mortality from leukemia and cancers ofthe
skin, breast, prostate, and intestine. The
authors speculated that increased dietary
zinc interfered with absorption or utiliza-
tion of dietary selenium, producing a rela-
tive deficiency of this latter essential trace
element. A relative deficiency of selenium
produced in this manner may have con-
tributed to the increased cancer incidence,
but the data provided by these investigators
did not support this hypothesis.
In contrast to the interpretation of
Schrauzer et al., Van Rensburg (448) ob-
served that in many countries where wheat
and corn are primary staples there is a high
risk for esophageal cancer. After examining
the correlations between dietary intake of
selected nutrients, this investigator pro-
posed that diets low in micronutrients, par-
ticularly zinc, magnesium, and nicotinic
acid, might be etiologically related to can-
cer of the esophagus. While there were no
data to support such an assumption, the di-
etary deficiencies may have modified the
metabolism of carcinogens in the environ-
ment by changing the activity of cy-
tochrome P450 enzymes which activate or
detoxify the chemicals; such inferences
have been drawn from zinc deficiency stud-
ies in animals (449).
Strain et al. (450) compared zinc and
copper levels in serum of patients with
bronchogenic carcinoma to levels of these
elements in serum of controls. Zinc levels
were comparable, but copper levels were
lower in controls, resulting in higher ratios
ofzinc to copper in the bronchogenic can-
cer patients. In contrast to the observations
by Strain et al. (450), Davies et al. (451)
had reported earlier that zinc levels in
plasma of bronchogenic patients were
lower than in patients with other types of
cancer and lower than normal laboratory
reference values. Similar results were re-
ported byGyorkey et al. (452).
Lin et al. (453) examined serum, hair
and other tissues from Chinese men in
Hong Kong for zinc and copper concentra-
tion. These investigators found that zinc
concentrations in serum, hair and appar-
ently tumor-free esophageal tissues from
esophageal cancer patients were signifi-
cantly lower than concentrations in pa-
tients with other types of cancer or in pa-
tients dying from other causes. Analyses of
esophageal tumors and apparently tumor-
free esophagi showed that the zinc concen-
trations (jig/g dry weight) in the tumors
from 72 to 111 (mean 95) were much
lower than those in healthy tissues from
114 to 159 (mean 148). Esophageal tissues
in normal adults contained 150 to 197
(mean 178) pg zinc/g. Caution is recom-
mended, however, in the interpretation of
results from serum concentrations of zinc,
since many factors including infectious dis-
ease can influence these levels.
Logue et al. (454) studied workers in
nine electrolytic zinc and copper refining
plants. In two of the plants the employees
were exposed to zinc or zinc and copper.
There were no correlations between zinc
exposure and any form ofcancer; however,
the numbers of people dying of cancer
were small. Similar observations were re-
ported by Newberger and Hallowell (455)
with respect to lung cancer mortality in a
subpopulation living in an area where an
old lead/zinc mining and smelting opera-
tion had previously existed. Lung cancer
incidence was elevated in the area but it
could not be traced to the smelting opera-
tion and consequent exposure to environ-
mental contamination byzinc or lead.
Studies inExperimentalAnimals
A number of reliable reports associate zinc
status with susceptibility to cancer. Most of
these studies examine zinc deficiency as op-
posed to zinc excess. In studies of zinc ex-
cess, exposure has primarily been by
inhalation (387,388). For example, rats,
mice, and guinea pigs were exposed to a
zinc oxide/hexachloroethane smoke mix-
ture in concentrations up to approximately
125 mg zinc/m3. Exposure was 1 hr/day, 5
days/week for 18 months. There was a sta-
tistically significant increase in frequency of
alveologenic carcinoma in mice exposed to
the concentration of 125 mg zinc/m3, but
no tumorigenic effect was noted in either
rats or guinea pigs subjected to similar ex-
posure protocols. However as pointed out
above, lung tumors are common in many
strains of mice and an increased incidence
of this type tumor in one strain, one sex
and at the highest dose ofexposure cannot
be taken as evidence for carcinogenicity of
zinc. Moreover, as noted, this study used
only female animals, and the exposure was
to a mixture ofchemicals, not to zinc only;
the contribution of other chemicals to the
end result is unknown.
A number ofreports from experimental
animal studies suggest that zinc deficiency
inhibits growth of transplanted tumors in
animals as well as prolonging survival time.
Petering et al. (456) and DeWys et al.
(457) showed that growth of transplanted
Walker 256 carcinoma in rats was signifi-
cantly inhibited by zinc deficiency. Other
studies have demonstrated an effect ofzinc
deficiency on leukemias and lung carci-
noma (458), Ehrlich ascites tumor (459),
and plasmacytoma (460) in rats and mice.
The inhibitory effects ofzinc deficiency on
these tumors can be explained in part by
the well-known influence ofzinc on tumor
cells: rapidly growing tumor cells require
relatively large amounts ofzinc for mainte-
nance ofgrowth.
The reports ofother investigators seem-
ingly contradict the results of studies al-
luded to above. Fong et al. (461) observed
that the incidence ofesophageal tumors in-
duced by methylbenzylnitrosamine (MBN)
was significantly higher in rats maintained
on diets low in zinc (3 ppm) compared to
normal, zinc-supplemented (60 ppm) ani-
mals. It is likely that the dramatic effect of
zinc deficiency on the esophageal epithe-
lium (462) contributes to enhanced sus-
ceptibility to cancer. The epithelium is
severely damage by the deficiency alone,
leaving it more sensitive to the carcinogen
or its activated metabolite. There is also
some evidence that metabolism of the car-
cinogen (MBN) is modified by zinc defi-
ciency (463).
Others have shown that zinc intake
greatly exceeding nutritional requirements
(more than 10 times) suppressed carcino-
genesis induced by dimethylbenzanthracene
(DMBA) in Syrian golden hamsters (464).
Duncan and Dreosti (465) have observed
similar effects in rats exposed to azo dye
which induces liver cancer in rats.
The contradictory nature of the two
types ofexperiments described above would
appear to result in part from different sys-
tems and approaches to studies in carcino-
genesis. The studies wherein zinc deficiency
inhibited tumors used transplantable tu-
mors or tumor cells introduced into the
zinc-deficient animal. The host, serving es-
sentially as a graft recipient, simply could
not support the growth oftumor cells since
immediately after transplant of the tumor
or cell lines they require a source ofzinc in
relatively large amounts. In the case where
zinc deficiency enhanced the chemical in-
duction oftumors, the host provided a lim-
ited supply ofzinc which was sufficient for
development ofthe tumor but not enough
zinc to permit resistance to tumor develop-
ment, perhaps via immune mechanisms.
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Other investigators have shown that
zinc offers a protective effect against such
carcinogens as nickel (466) and cadmium
(467). These investigators gave zinc in
doses of 1.0 mmole zinc acetate/kg sc, 6 hr
before, simultaneously, and 18 hr after cad-
mium injection, or 100 ppm zinc acetate in
drinking water throughout the 100 week
study. Diplock (468) has discussed mineral
insufficiency, including zinc, and a possible
relationship between minerals and cancer.
The impression gained from results of
genotoxic studies as well as epidemiologic
and experimental cancer studies is that,
while there may be some conflicting and
contradictory results, the weight of evi-
dence is that zinc, although potentially
toxic at high levels ofexposure, is clearly es-
sential for optimum resistance to cancer, es-
pecially in mounting an immune defense
against developing tumors. Furthermore,
there is no evidence for enhanced cancer
risk by higher than normal dietary zinc.
Summary of Health Effects
In summary, this review supports the con-
sensus statement from the NAS/NRC re-
port (9) on "Drinking Water and Health"
which stated that: "In view ofpossible defi-
ciency in United States diets, it is prudent
to maintain all dietary sources of zinc...
The possibility ofdetrimental health effects
arising from zinc consumed in food and
drinking water is extremely remote." The
evidence for significant toxic effects ofzinc
in human subjects is restricted almost en-
tirely to accidental exposure to high con-
centrations of zinc compounds, such as
those in smoke bombs, or from accidental
or intended overdosage ofzinc in therapeu-
tic forms. Notably, these kinds ofexposures
are acute sudden exposures to high concen-
trations. Even so, these effects are almost al-
ways reversible.
There are unequivocal results from both
human and animal observations, which
document that acute, high level exposure to
zinc compounds can produce respiratory
and gastrointestinal toxicity. However,
these effects are largely self-limiting and re-
quire only modest medical attention. Expo-
sure to smoke from bombs containing zinc
compounds can cause illness, generally
transient, as can acute or chronic exposure
to fumes from acetylene or electric welding
of zinc-containing metals. Exposure to ex-
cess zinc in tablets intended for human
consumption, controllable for the most
part, can also result in clinical changes,
such as decreased activity oferythrocyte su-
peroxide dismutase and increased activity of
serum alkaline phosphatase and pancreatic
enzymes. Other reported effects such as
changes in serum lipoproteins and im-
munological status are controversial and re-
quire more definitive assessment. There is
no compelling evidence supporting a cause
for concern about zinc in the environment
as a putative toxic agent.
Research Priorities for the
1990s
Identification ofSubjects at Risk of
Altered Zinc Status
Environmental Studies. Nutritional studies
have confirmed that inadequate zinc intake
occurs in subsets ofthe United States pop-
ulation and can lead to adverse health ef-
fects. Toxicity from increased intake ofzinc
has been documented following acute in-
halation by industrial workers, overdose of
oral supplement preparations and excessive
levels in total parenteral nutrition fluids.
Currently, there is not good evidence that a
subset ofthe population is at risk ofadverse
health effects from increased zinc intake as
a result of local environmental contamina-
tion at waste sites or from industrial dis-
charges. A first priority is to establish that
drinking water levels or dietary content of
zinc are increased in populations adjacent
to environmental sites with unusually high
zinc content. This rationale is based on
concern that research dollars should not be
devoted to study ofthe high end ofthe zinc
dose-response curve without clear evidence
of its relevance. Reasons for considering
that there is unwarranted concern about in-
creased intake of zinc include the well-
known aversive taste ofdrinking water with
elevated zinc levels and uncertainty that
crops and other dietary sources would accu-
mulate zinc in significantly greater levels
from leaching ofthe metal from waste sites.
Research is needed to identify populations
suspected of increased intake of zinc from
contamination ofdrinking water and foods,
before further work is justified to evaluate
the effects ofelevated zinc intake in experi-
mental studies. Environmental studies
should entail sampling of ground water,
drinking water, and the diet. Care must be
taken to evaluate the contribution to tap
water of zinc from water-supply piping, as
opposed to environmental waste sites.
EpidemiologicalStudies. Ifenvironmen-
tal studies reveal that segments ofthe popu-
lation are indeed at risk of zinc ingestion
significantly above the RDA, epidemiologi-
cal studies may prove useful in determining
whether there are associated health effects.
These types ofanalyses would not necessar-
ily reveal effects of zinc alone, since under
environmental conditions contaminations
might potentially include multiple metal
and organic pollutants and require exten-
sive data collection to account for con-
founding variables. The difficulty arises in
that although zinc at certain dose levels
may produce symptomalogy, it may also be
protective against effects of other agents.
Questionnaire-based surveys of popula-
tions in areas of unusually high or altered
distribution of zinc, in comparison to a
well-chosen control group, might consider
end points such as reproductive history, in-
fection rates, behavioral assessments, and
cardiovascular morbidity and mortality.
Such a study obviously would require care-
ful attention to dietary histories for assess-
ment ofzinc intake and ofcourse would be
most productive with some measure ofzinc
status in individuals (see below).
Development ofMethods forAssess-
ing Zinc Status in Humans
Research should be supported to develop
improved methodology for determining
zinc status in individual subjects. More
practical, inexpensive, sensitive and physio-
logically valid methods are needed to per-
mit estimating the total body burden of
zinc and its compartmental distribution
within the body. This methodology is
needed to improve research on the dose-re-
sponse relationship between zinc levels in
the body and effects at various target sites.
Since plasma zinc concentrations have been
criticized as a relatively insensitive indicator
of zinc status, other approaches including
reliable biomarkers must be developed, es-
pecially for large-scale screening studies.
Possibilities that deserve expanded consid-
eration include: zinc in sampling sites such
as hair and nails, shed teeth from children,
and urine. A more sophisticated approach
for clinical studies that warrants further val-
idation is the determination ofthe turnover
rate ofthe readily mobilizable pool ofzinc,
about 10% of total body burden. There is
evidence that this parameter is inversely
correlated with zinc status. This relation-
ship should be more clearly established by
determination of turnover rates in subjects
with controlled or estimated zinc intakes.
Turnover rate appears to be most accurately
estimated by iv administration ofthe stable
isotope 67Zn, followed by measurements of
30- to 60-min plasma levels using plasma
emission mass spectrometry. The most
well-controlled, albeit expensive, study
would entail placing subjects in a metabolic
ward and sequentially providing diets vary-
ing in zinc content below, at, and above the
RDA. A less well-controlled approach
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would be to study subjects whose dietary
history permitted classification as marginal,
normal, or zinc-supplemented. Another
posssible indicator of total body burden of
zinc may be provided by in vivo neutron
activation analysis of zinc in bone, a con-
cept that also deserves research develop-
ment.
In addition to zinc measurements for as-
sessing zinc status, research should be di-
rected, as noted above, to the development
ofvalid biomarkers. Among possible candi-
dates are erythrocyte superoxide dismutase,
metallothionein, serum alkaline phos-
phatase, and serum amylase or lipase, al-
though none of these alone would be
sufficient. Research in this area must in-
clude studies that further elucidate the
mechanisms of zinc-induced changes in
these parameters, especially in relation to
alterations secondary to changes in other
essential metals such as copper.
Studies ofthe HealthEffects ofZinc
Status: Interactionswith OtherTrace
Elements
Rationale. Further research on the health
effects of zinc should primarily address
questions related to the critical role of this
metal in physiological processes. Studies
should therefore encompass the dose-re-
sponse relationship ranging from mild defi-
ciency to mild excess. Research is
encouraged in areas ofimmunology, repro-
duction, multigenerational studies, neurol-
ogy, and lipoproteins and cardiovascular
function. Studies should address the role of
zinc-induced perturbations in other essen-
tial metals, especially copper and iron, in
the production ofbiological effects. In vivo
dose-response experiments with zinc
should therefore include the monitoring of
copper and iron status by measures ofthese
metals in serum and tissues and ofrelevant
biomarkers such as erythrocyte superoxide
dismutase and serum ceruloplasmin for
copper and serum ferritin for iron. The ef-
fect of increased copper or iron intake on
zinc dose-response curves should be deter-
mined.
Interactions of zinc and toxic heavy
metals are also fertile fields for investiga-
tion, especially because of the likely multi-
ple components of environmental waste
sites. The well-known toxicity ofboth lead
and cadmium seem to be, under some cir-
cumstances, ameliorated by zinc. The in
teractions of zinc, lead, and cadmium on
biological systems appear to be poorly un-
derstood. As a minimum, end points that
should be examined include immunocom-
petence and reproduction.
Studies feeding massive doses such as
100 and 1000 times the RDA, as in some
work described earlier in this text, do not
warrant support. Long-term carcinogenesis
studies with high doses in rodents also are
not recommended, primarily because ofthe
negative results in earlier studies.
Immunological Function. CAUSES OF
IMMUNE DEFECTS IN ZINC DEFICIENCY.
The average American is at far greater risk
of experiencing immune defects due to
suboptimal intake of zinc rather than de-
fects induced by high zinc. There is a defi-
nite need for more extensive human
research to elucidate further the nature
and degree ofchange that suboptimal zinc
status makes in host defense. Additional
studies ofthe immune defects using rodent
models are also necessary to identify the
underlying mechanism(s) that cause the
rapid demise of the immune system by
zinc deficiency. Animal models have not
been used to good advantage to elucidate
how cytokines, nutritional repletion, etc.,
might be used to help rejuvenate immune
systems impaired by inadequate zinc. Ro-
dent models (since extensive in vivo assess-
ments can be performed) would be vital to
these studies as well.
It is now clear that deficiencies in zinc
alter endocrine function and lymphopoi-
etic processes in the mouse. More studies
are needed regarding the nature and extent
of induction of glucocorticoids and the
stress-endocrine axis by suboptimal zinc.
Likewise, it is now clear that the glucocor-
ticoids induce programmed cell death or
apoptosis in the immature cells of the im-
mune system. This induction of cell sui-
cide and its role in the rapid atrophy ofthe
thymus and decline in lymphopoiesis and
production of new lymphocytes in the
bone marrow need to be further character-
ized for the zinc-deficient mouse, since it
appears to be a seminal mechanism.
The elderly appear to be mildly defi-
cient in zinc. Whether this is a normal and
acceptable outcome ofaging or a deviation
that should be addressed by supplementa-
tion is a topic ofkey current interest. The
studies of Bogden et al. (397) indicate
that extensive zinc supplementation ofthe
elderly may have little effect on immune
competence. However, this is an impor-
tant problem that might well be addressed
again with better attention given to the
immune tests used and appropriate con-
trols. It is well documented that T-helper
function and production of IL-2 decline
with age. This might be exacerbated by
mild zinc deficiency and might also be
quite sensitive to the beneficial effects of
supplementation. There has been virtually
no examination of the capacity of mono-
cytes and neutrophils to carry out phago-
cytosis and microbicidal killing in the
elderly. These cells, the first line of im-
mune defense, may be impaired by zinc
deficiency (398). Vaccinations of the el-
derly and subsequent analysis of antibody
titers (e.g. influenza) would be an excellent
way ofcomparing host defense capacity in
zinc-supplemented and unsupplemented
groups.
CHARACTERIZATION OF IMMUNE EF-
FECTS FROM ZINC INHALATION. Purpose-
ful, oral supplementation of various
subjects, including the elderly, with levels
of zinc significantly in excess of the RDA
have provided no substantive evidence of
immune toxicity. However, the repeated
observation that the lungs of welders ex-
posed to metal fume fever are infiltrated
with PMNs provides evidence that expo-
sure to high levels of zinc in the air may
have possible adverse immune effects. Ad-
ditional experimentation in this area
would be ofvalue providing the following
caveats are considered.
Human Studies. a) Experiments should
closely mimic the amounts and extent to
which workers are exposed to zinc oxide
and use well controlled conditions and ap-
propriate inhalation chambers. Obviously
smokers, asthmatics and other individuals
with respiratory diseases should be elimi-
nated from such studies.
b) Future studies should take greater
care to examine the duration ofthe changes
in immune parameters oflungs after expo-
sure to zinc inhalation. It is undoubtedly
important to monitor pulmonary immuno-
logical changes for at least several days after
signs ofmetal fume fever have subsided, to
determine if effects are transient or poten-
tiallylong lasting.
c) Examination of lung fluids, post in-
halation ofzinc should include: 1) total and
differential counts of all major leukocytic
cell groups; 2) flow cytometric quantitation
of changes in the phenotypic distribution
ofsubsets ofthe major classes ofleukocytes
ifthe proportions are markedly changed; 3)
test of lung fluids for proteins and other
molecules indicative of initiation of fever,
inflammation, etc. (e.g., IL-1, TNF, im-
mune complexes, complement factors,
leukotrienes, prostaglandins); 4) the capac-
ity of PMNs and macrophages prepared
from such lungs to carry out phagocytosis
and/or initiate an oxygen burst should also
be determined since these functions are
vital to protection of the lung. It is not
enough to simply determine the number of
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PMNs, or macrophages present in the lung.
Rather it must be ascertained whether they
can still carry out vital functions.
d) Whether or not repeat exposure to
inhalation of zinc oxide increases or de-
creases the sensitivity ofthe lung is also im-
portant to ascertain. For example, if
sensitivity increases markedly, the effect of
sequential exposure on pulmonary immune
function could prove to be far more serious
than results from a single exposure would
suggest.
Animal Studies. Inhalation studies
should be conducted in several animal
species until definitive assessment is made
ofthe most appropriate model for mimick-
ing the human response to zinc inhalation.
Because the mouse has served as a highly
reliable immunological model for humans,
it should serve well for predicting immuno-
logical effects ofexcess exposure to oral in-
take of zinc. The optimum experimental
facsimile for oral intake would seem to be
to provide excess zinc to mice via their
water supply rather than adding it to their
diet, in order to mimic the most likely
source in man ofincreased zinc from envi-
ronmental contamination.
To ascertain the effects ofexcess intake
ofzinc on immune function, care must be
taken to measure host defense response in
vivo. This approach will avoid the artificial-
ity ofthe in vitro or tissue culture environ-
ment that contains normal levels of zinc,
metabolites, hormones, etc., and which can
facilitate repair of defective functions. For
this purpose mice provided normal and ex-
cess amounts ofzinc should be periodically
challenged by in vivo immunization with
T-cell dependent and independent antigens
using a standard Jerne plaque assay to eval-
uate the proportion ofsplenocytes respond-
ing in the two treatment groups. In this
manner, actual differences in antibody-me-
diated response capacity can be readily de-
tected. In addition, mice should be
challenged with subacute levels of live
pathogens to determine if immune defense
systems are indeed intact.
To ascertain the status of cell-mediated
responses, mice should also be challenged
in vivo with small numbers ofsolid tumor
cells and evaluated for their ability to elimi-
nate the tumor. Balb/c mice inoculated
with myeloma cells are especially useful for
such studies. Finally, since leukopenia and
altered distribution of leukocytes accom-
pany many changes in nutritional status,
the peripheral blood, spleen, thymus
lymph nodes, and bone marrow should be
evaluated for the absolute numbers of the
major classes ofleukocytes. The proportion
ofthe major classes and subclasses ofleuko-
cytes should be determined by flow cytom-
etry. These evaluations would provide a
solid preliminary determination ofwhether
or not excess intake ofzinc significantly al-
tered antibody or cell-mediated responses,
key to host defense.
Reproduction and Teratology. Multigen-
erational studies to assess possible effects of
zinc on fertility and reproduction should
be carried out in a rodent model. These
studies should emphasize analysis of doses
ranging from mild deficiency to moderate
excess. The highest priority is determina-
tion of effects of doses above the RDA,
since effects of deficiency are better stud-
ied. Zinc should be administered in the
diet or drinking water but only at levels
that do not alter food or water intake. The
protocol for these studies should follow
EPA guidelines. End points should include,
as a minimum, number of conceptions,
percent live births, teratologic assessment,
and birth and growth weights of pups.
Studies should include analysis of both
male and female fertility. Attention should
be directed to potential effects secondary to
induced deficiency of other essential met-
als, such as the reduction in litter size and
increased neonatal mortality associated
with copper deficiency (469).
Neurological Function. ANIMAL MOD-
ELS. Further research is important to char-
acterize the role of zinc in neurological
function, especially development and
function of the brain. Mechanistic studies
of the mediators of release of zinc from
nerve terminals and receptor modulation
are critical to understanding the normal
role ofendogenous zinc. Ofhigher priority
with respect to effects ofzinc excess are in
vivo experiments in rodent models. These
studies should entail dose-response analy-
ses ofoffspring from pregnant rats fed in-
creased levels of zinc before, through and
after gestation. Offspring should be inves-
tigated for zinc concentrations in brain re-
gions, histological assessment of neural
architecture and myelination, and long-
term behavioral effects. Because of the
known effects of copper deficiency on
neural development, especially reduced
myelination (470), copper status in off-
spring should be assessed as well. Studies
of adult rats fed excess zinc are of lesser
priority because the literature suggests that
behavioral effects are not likely to be ob-
served.
STUDIES OF ZINC NUTRITURE AND
COGNITION IN HUMANS. Premenopausal
Women. Premenopausal women are at risk
of zinc deficiency from food selection and
menstrual loss. A pilot, randomized con-
trolled trial in women with low serum fer-
ritin and lower serum zinc than women
with normal ferritin found that zinc reple-
tion was associated with improved short-
term recall of visual design compared to
baseline, while control women showed no
improvement. Findings from this pilot
study are consistent with experimental
findings in zinc depleted men and in ex-
perimental animals. Studies are needed to
validate and expand on these pilot observa-
tions. Three groups should be included in
this study: women with documented zinc
deficiency, women with adequate zinc sta-
tus, and women supplementing with zinc
at 50 mg or more daily. In each group as-
sessments of cognitive function should be
carried out before and after treatment with
zinc, 50 mg/day orally.
Offipring of Women Supplemented with
Zinc during Pregnancy. The long-term ef-
fects of zinc status during gestation on
neurological function in children is not
known. Animal studies clearly indicate
that zinc deficiency during pregnancy ad-
versely affects fetal development and cog-
nitive function of offspring. Studies in
women indicate fetal growth failure and
increased incidence of complications of
pregnancy. A two-center study, which ex-
amined the relation between the nutri-
tional status of low-income teenagers and
pregnancy outcome, included a random-
ized controlled trial of zinc (30 mg/day)
from the middle to end ofpregnancy. Zinc
reduced the incidence of pregnancy com-
plications. The maternal records from this
study are available. Follow-up studies of
the offspring offer a pilot approach for de-
termining the effect of zinc supplementa-
tion during pregnancy on long-term
cognitive function in offspring. Critical
data on children would include estimates
ofnutritional status after birth and indices
of cognition that test short and long-term
memory, problem-solving and motor
skills.
Serum Lipoproteins and Cardiovascu-
lar Effects. The dose-response relationship
between zinc intake and serum lipopro-
teins should be further explored. Primary
emphasis should be on a) definitive deter-
mination ofthe effect ofincreased oral in-
take of zinc on lipoprotein particles of
significance to atherosclerosis, b) where
changes are found, mechanisms should be
evaluated by studies of clearance and syn-
thesis of the particles and the major rele-
vant apoproteins, c) the effects of zinc on
serum lipoproteins and induction rates of
atherosclerosis in animal models ofhyperc-
Environmental Health Perspectives 36HEALTH EFFECTS OFZINC
holesterolemia such as the Watanabe rab-
bit. Careful evaluation of the role of zinc-
induced changes in copper status should
be included in these studies because ofthe
documented relationship between mild
copper deficiency and hypercholes-
terolemia.
There is no evidence that excess zinc
impairs cardiovascular function. However,
copper deficiency has been shown to pro-
duce cardiac arrythmias, impair ATP for-
mation in the heart and increase aortic
fragility secondary to reduced lysyl oxidase
activity (471). Studies of the effect of ex-
cess zinc intake on these parameters should
be explored in relation to copper intake.
Hematologic Effects: Sideroblastic Ane-
mia. Excess intake ofzinc has been shown
in humans to induce sideroblastic anemia.
In this condition ferric iron accumulates in
mitochondria of erythrocytes. The mecha-
nism of this effect is unknown. One hy-
pothesis is that the symptoms result from
zinc-induced copper deficiency. The
pathogenesis of this effect should be stud-
ied, which may facilitate understanding of
mechanisms of sideroblastic anemias and
possibly management strategies, both of
which are lacking at present.
Mechanistic Studies
FACTORS INFLUENCING ZINC STATUS. Reg-
ulation ofAbsorption and Excretion. Re-
search should be directed to enhance
understanding of the molecular mecha-
nisms ofzinc absorption and excretion and
their homeostatic regulation under condi-
tions of mild deficiency and moderate
excess. The transport process of zinc
through the brush border membrane of
gut mucosal cells and its interaction with
intracellular ligands that influence the ex-
tent of absorption needs better definition.
Pancreaticobiliary secretion is known to be
a major excretory route ofzinc. Research is
needed to improve understanding of the
regulation ofthese secretary pathways, the
form of zinc in these fluids e.g., "packag-
ing," the extent of intestinal reabsorption
from this source and the of altered secre-
tion by this route in homeostatic regula-
tion.
CLONING OF GENES THAT INFLUENCE
ZINC TRANSPORT. Study of the molecular
mechanisms of the known genetic disor-
ders which affect zinc status should pro-
vide critical knowledge about zinc
transport under normal conditions. These
disorders include acrodermatitis entero-
pathica in humans, characterized by im-
paired zinc absorption, and lethal milk
syndrome in mice, characterized by de-
creased zinc transport into milk. Research
should be directed to determination ofthe
altered genes, cloning of these genes and
identification ofthe normal gene products.
Functional Significance ofZinc-in-
duced Metallothionein Expression. Fur-
ther research should be supported to
determine the significance of zinc-in-
duced expression of metallothionein
isozymes, especially in relation to zinc
disposition, hydroxy radical scavenger ac-
tivity and metal donor function for met-
alloenzyme activation.
Zinc Status and the Function of
Ezymes and DNA-binding Proteins. The
molecular mechanism for the essential
role of zinc in biological processes has
been facilitated by basic studies on the in-
teraction of zinc with enzymes and more
recently with DNA-binding proteins.
Further work in this area is likely to be
highly fruitful. Studies should be sup-
ported to determine dose-response rela-
tionships between zinc status and
function at the molecular level, such as
the activity of critical regulatory tran-
scription activators.
Mechanism ofZinc-induced Copper
Deficiency: Regulation of Ceruloplasmin
Expression. The molecular mechanisms
underlying the interactions of zinc with
other trace elements requires better defini-
tion. As indicated above, the inverse rela-
tionship between zinc and copper levels in
the body appears significant to understand-
ing the health effects ofzinc status. Studies
should be supported to determine the basis
for the effect ofzinc on copper status. The
competition between these metals demon-
strated in intestinal mucosal cells is likely
to explain the reciprocal relationship be-
tween zinc status and copper bioavailabil-
ity. Other interaction sites should be
determined. For example, ceruloplasmin,
the major copper-binding protein in
plasma which is synthesized in the liver,
also exhibits an inverse relationship to zinc
status. Factors which decrease plasma zinc
such as stress and acute infection, mediated
in part by IL-1, also increase plasma ceru-
loplasmin. Studies should be carried out to
determine whether zinc is a negative or
positive regulator of the hepatic synthesis
ofthis protein.
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